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Zusammenfassung 
 
 
 
 
Trotz effizienter Impfungen stellt Hepatitis B Virus (HBV) immer noch ein weltweites 
Gesundheitsproblem dar. Insbesondere in struktur- und entwicklungsschwachen 
Regionen, wie zum Beispiel in Subsahara-Afrika oder Südost-Asien, ist HBV hoch 
prävalent. In diesen Regionen ist die Übertragung während der Geburt oder in früher 
Kindheit der wichtigste Infektionsweg für HBV und führt häufig zu chronischer HBV 
Infektion. 
Auf Grund genetischer Unterschiede wird HBV in acht klassifizierte Genotypen A-H 
und einen möglichen Genotyp I eingeteilt. Zusätzlich dazu wurde Genotyp J 
vorgeschlagen. Mit Ausnahme von E, G, H und J, werden die Genotypen in 
Subgenotypen unterteilt. In Gebieten mit hoher HBV Prävalenz in denen 
verschiedene Genotypen und Subgenotypen zirkulieren, sind Infektionen mit 
mehreren Genotypen und Rekombinationen zwischen Genotypen häufig. 
Im ersten Teil der vorliegenden Dissertation wird Genotyp E in Afrika charakterisiert. 
Dieser Genotyp ist in weiten Teilen West-Afrikas verbreitet und ist hoch prävalent, 
jedoch wurden identische virale Sequenzen tausende Kilometer entfernt 
voneinander gefunden. Wir zeigen, dass Genotypen E trotz seiner weiten Verbreitung 
und Dominanz in weiten Teilen West-Afrikas eine überraschend niedrige genetische 
Diversität hat. Dies deutet darauf hin, dass dieser Genotyp nur eine kurze 
Evolutionszeit hat. Im Gegensatz dazu ist Genotyp A, der in dieser Region in der 
Minderheit ist, hoch divers und hat eine lange Evolution durchlaufen. Die weite 
Ausbreitung, hohe Prävalenz und niedrige genetische Diversität des Genotyp E ist ein 
derzeit ungelöstes Rätsel, das wir hier in mehreren Studien untersuchen. 
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Die Ausbreitung von Pathogenen ist eng mit der ihrer natürlichen Wirte vernetzt. 
Daher ist anzunehmen, dass auch afrikanische Sklaven, die zwischen dem 17. und 19. 
Jahrhundert von Afrika nach Süd- und Mittel-Amerika deportiert wurden, die 
afrikanischen HBV Varianten in der Neuen Welt verbreitet hätten. Wir zeigen jedoch, 
dass Genotyp E dort nur sporadisch auftritt und bestätigen somit das rezente 
Erscheinen dieses Genotyps. Auch in Haiti, wo mehr als 90% der Bevölkerung 
Nachfahren afrikanischer Sklaven sind, wurden mehr als 40% der HBV Infektionen 
durch Subgenotyp A1 verursacht, der sonst hauptsächlich in Ost-Afrika zu finden ist. 
Weitere 20% der Infektionen sind auf den seltenen Subgenotyp A5 zurückzuführen, 
der zuvor nur in der Bucht von Benin, einem Dreh- und Angelpunkt des 
transatlantischen Sklavenhandels, gefunden wurde. Unsere Ergebnisse zeigen 
weiterhin, dass sich die haitischen HBV A Subgenotypen früh unabhängig von den 
afrikanischen weiterentwickelt haben, während die heute in West-Afrika dominanten 
Sub-/Genotypen (E und A3) in Haiti selten sind. Diese Ergebnisse untermauern, dass 
die dominanten Sub-/Genotypen des heutigen West-Afrikas sich nur nach dem Ende 
des transatlantischen Sklavenhandels ausgebreitet haben können, und zwar 
innerhalb der letzten 100 bis 200 Jahre. Dies erklärt auch die niedrige genetische 
Diversität von Genotyp E. Die hohe Prävalenz dieses Genotyps in weiten Teilen Afrikas 
lässt weiterhin darauf schließen, dass die HBV Hyperendemie ein relativ neuer 
Zustand ist und vermutlich auf kontaminierte Injektionsnadeln in wohlgemeinten 
Massen-Injektionskampagnen der französischen und belgischen Kolonialmächte 
zurückzuführen ist. 
Des Weiteren zeigen unsere phylogenetischen Analysen, dass Genotyp E eine 
niedrigere genetische Diversität in den südlichen Ländern des Ausbreitungsgebietes 
besitzt als in den nördlichen. Dies deutet darauf hin, dass Genotyp E zuerst im Norden 
aufgetreten ist und von dort in die südlichen Länder verbreitet wurde. Wir bestätigen 
dies durch phylogeografische Analysen, die auf einen Ursprung von Genotyp E in der 
Gegend von Nigeria hindeuten, von wo aus sich dieser dann rasant durch das 
westliche Afrika südlich der Sahara ausbreitete. 
Weiterhin finden wir eine Substitutionsrate von 1.9x10-4 Substitutionen pro Nukleotid 
und Jahr und demonstrieren, dass Genotyp E erst kürzlich und sehr wahrscheinlich vor 
130 Jahren verbreitet wurde. Auch modellieren unsere Analysen einen starken 
Anstieg der Genotyp E Infektionszahlen und untermauern so das gehäufte rezente 
Auftreten. Interessanterweise scheinen die Genotyp E Varianten in Haiti das Ergebnis 
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mehrerer Einschleppungen in der zweiten Hälfte des 20. Jahrhunderts zu sein, was 
unsere Hypothese unterstützt, dass Genotyp E zur Zeit des Sklavenhandels noch nicht 
hochprävalent war. Im Ganzen zeigen unsere Ergebnisse, dass die Hyperendemie 
von HBV und Genotyp E im heutigen Afrika ein überraschend rezentes Phänomen ist 
und sehr wahrscheinlich das Ergebnis dramatischer Änderungen der viralen 
Übertragungswege. 
In einer weiteren Studie in Subsahara-Afrika charakterisieren wir Hepatitis D Virus 
(HDV), ein Satelliten-Virus von Hepatitis B Virus, anhand von Proben aus Burkina Faso, 
der Zentralafrikanischen Republik, dem Tschad und Nigeria. Wir demonstrieren, dass 
bis zu 50% der HBV Infizierten, nachgewiesen durch Detektion des HBsAg, auch mit 
Hepatitis D Virus infiziert sind. Die Prävalenzen variierten jedoch in den verschiedenen 
Kohorten und Ländern. So hatten Kinder aus Burkina Faso mit 20,5% eine 
überraschend hohe HDV Prävalenz, die fast 10-mal höher war als die ihrer Mütter. 
Diese Kinder unterliegen einem hohen Risiko, schwere fulminante Hepatitis oder 
chronische Hepatitis zu entwickeln. Weiterhin waren 50% der Leberpatienten aus der 
Zentralafrikanischen Republik HDV Antikörper positiv, im Gegensatz zu 1,3% und 6,8% 
nigerianischer Leberpatienten. Dies deutet darauf hin, dass HDV Superinfektion in der 
Zentralafrikanischen Republik eine wichtige Ursache chronischer Hepatitis mit 
möglicherweise schwerem Verlauf ist.  
In der untersuchten geografischen Region konnten wir von den acht 
charakterisierten viralen Typen (sogenannten clades), Typ 1, 5, und 6 detektieren, 
wobei jedoch HDV-1 dominierte. Interessanterweise waren mehr als 50% der 
genotypisierbaren HDV und HBV Paare mit HDV-1 und HBV/E infiziert. Während 
unsere Analysen darauf hinweisen, dass HDV seinen Ursprung in Afrika hat, zeigen wir, 
dass eine enge Koevolution von HDV-1 und HBV/E unwahrscheinlich ist. 
In weiteren Studien charakterisieren wir HBV in Serumproben aus Laos. Dort sind circa 
9% der Bevölkerung chronische Träger von HBsAg, dem primären Marker einer 
Infektion mit Hepatitis B Virus. Weiterhin ko-zirkulieren in Laos verschiedene 
Subgenotypen der Genotypen B, C und I. 
Wir zeigen, dass fast 6% der HBsAg positiven abgelehnten Blutspender mit einer 
Vielzahl an Sub-/Genotypen infiziert sind. Weiterhin erbringen wir den Nachweis, dass 
circa 65% der HBV misch-infizierten virale Varianten mit Rekombinationen im 
Oberflächengen in sich tragen. Diese hatten überraschend diverse Rekombinations-
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Stellen und beinhalteten die vorherrschenden Genotypen B und C. Wir 
demonstrieren, dass die Rekombinanten weitestgehend unterschiedlich sind und 
sowohl zwischen Spendern als auch innerhalb einzelner Personen variieren. Auch 
deuten unsere Analysen darauf hin, dass rekombinante virale Varianten zu Lebzeiten 
der Spender evolviert sind. Weiterhin schlagen wir auf Basis der Analyse viraler 
Quasispezies eine Substitutionsrate von 1.58x10-4 Substitutionen pro Nukleotid und 
Jahr für HBV in Laos vor. Zusammengenommen zeigen unsere Ergebnisse, dass, 
zumindest in Laos, ein großer Anteil der Hepatitis B Virus Misch-Infektionen zu 
Rekombinationen führt, die jedoch noch nicht zu neuen dominanten viralen 
Varianten in der Bevölkerung geführt haben. 
Abschließend demonstrieren wir in serologischen und phylogenetischen Analysen in 
zufällig ausgewählten Blutspendern, dass 45,5% positiv für mindesten einen Hepatitis B 
Virus Marker sind. Dies zeigt, dass circa die Hälfte der laotischen Bevölkerung in ihrem 
Leben in Kontakt mit HBV war. Weiterhin erbringen wir den Nachweis, dass die in Laos 
verwendeten Screening-Methoden überdacht werden sollten. Wie unsere Ergebnisse 
zeigen, birgt die Analyse von Blutspenden die nur auf HBsAg limitiert ist, ein 
beträchtliches Restrisiko durch HBsAg-negative okkulte Infektionen in mindestens 
3,9% aller Blutspender. Diese sind potentiell DNA positiv und können Hepatitis B Virus 
übertragen. 
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Despite efficient vaccines, hepatitis B virus (HBV) continues to be a global public 
health problem. Especially in low income regions, such as sub-Saharan Africa or 
South-East Asia, HBV is highly endemic. In these regions perinatal or early childhood 
transmission is considered the most important route of infection for HBV, frequently 
leading to chronic HBV carriage. 
Based on the genetic variability of the DNA genome, hepatitis B virus has evolved 
into at least eight classified genotypes A–H and a tentative genotype I. Recently a 
tenth genotype J has been proposed. With the exception of genotypes E, G, H and 
J, HBV genotypes are divided into subgenotypes with more or less distinct 
geographic distributions. In highly endemic regions where different HBV genotypes 
and subgenotypes co-circulate, mixed infections and recombinations are frequent.  
In the first parts of the present dissertation, genotype E is further characterized. This 
genotype has an extensive spread throughout a vast West African crescent where it 
is highly prevalent. Nevertheless, identical sequences have been found several 
thousand kilometres apart. We show that genotype E has a surprisingly low genetic 
diversity, despite its wide spread and dominance in most countries in sub-Saharan 
Africa. These results indicate an only short time of evolution for genotype E, while 
genotype A, the minority genotype in this region, is highly divers and has a long time 
of evolution. Due to its wide spread, high prevalence and low genetic diversity, 
genotype E represents an unsolved puzzle that we investigated in multiple studies.  
As the spread of pathogens is closely linked to their natural hosts, African slaves that 
were force-migrated to the Americas from the 17th to the early 19th century during 
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the transatlantic slave trade would have disseminated African HBV strains in the New 
World. Nevertheless, we show that genotype E is only sporadically found in the 
Americas, corroborating an only recent emergence of this genotype. We 
furthermore demonstrate that in Haiti, where >90% of the population are 
descendants of African slaves, more than 40% of hepatitis B virus infections were 
caused by subgenotype A1, which today is found mainly in eastern Africa. Another 
20% belong to a rare subgenotype, A5, which has been found only in the former 
Bight of Benin, a former primary slave trading post. Haitian A subgenotypes appear 
to have separated early from the African subgenotypes, while the most prevalent 
genotype and subgenotype in West Africa today (E and A3, respectively) are rare in 
Haiti. These results provide evidence that the dominant sub/-genotypes in West-
Africa emerged in the general population only after the end of the transatlantic 
slave trade, within the last 100 to 200 years, and explain the low genetic diversity of 
genotype E. The high prevalence of genotype E in much of Africa further suggests 
that HBV hyperendemicity is a recent phenomenon, probably resulting from well-
intended injection mass campaigns using unsafe needles, performed by the French 
and Belgian colonial powers.  
Our phylogenetic analyses also provide evidence that genotype E may have 
emerged in the Northern part of the genotype E crescent before spreading to the 
South, as the Southern countries of the genotype E crescent exhibit lower genetic 
distances than the Northern countries. We confirm this by phylogeographic analyses 
that suggest an origin of genotype E in the area of Nigeria, before rapidly spreading 
throughout sub-Saharan Africa. 
We find a substitution rate of 1.9x10-4 substitutions per site and year and demonstrate 
that genotype E emerged only recently, most likely within the last 130 years. Together 
with the strong increase in the effective number of genotype E infections over time, 
our results corroborate the recent introduction in sub-Saharan Africa. Interestingly, 
genotype E strains found in Haiti seem to be the result of multiple introductions only in 
the second half of the 20th century, corroborating an absence of a significant 
number of genotype E strains in West Africa when and where the slaves were 
rounded up. Taken together, the results provide strong evidence that the 
hyperendemicity of HBV and genotype E in today`s Africa is a surprisingly recent 
phenomenon and likely the result of dramatic changes in the routes of viral 
transmission. 
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In an additional study in sub-Saharan Africa we characterize hepatitis delta virus 
(HDV), a satellite virus of hepatitis B, in samples from Burkina Faso, the Central African 
Republic, Chad and Nigeria. We demonstrate that up to 50% of hepatitis B surface 
antigen positive carriers were infected with HDV, with prevalences varying between 
cohorts and countries. Children from Burkina Faso had a surprisingly high prevalence 
of HDV, with 20.5% being infected. This prevalence is almost 10-times higher than the 
one observed in their mothers and these children are at high risk to develop severe 
fulminant or chronic hepatitis. We furthermore found 50% of liver patients in the 
Central African Republic to be HDV-antibody positive, indicating that in the Central 
African Republic, in contrast to Nigeria with only 1.3% and 6.8% prevalences in liver 
patients, HDV super-infection might be an important cause of chronic hepatitis with 
possibly frequent severe liver conditions. 
Of the eight characterized hepatitis delta clades, we detect clades 1, 5 and 6 in this 
region, with a predominance of HDV-1. Interestingly, more than 50% of genotypable 
HDV and HBV pairs revealed both HDV-1 and HBV/E. However, while our results 
indicate that HDV might have originated in Africa, we demonstrate that a close co-
evolution of HDV clade 1 and HBV genotype E seems unlikely. 
In additional studies, we analysed sera from Lao PDR, were about 9% of the 
population are chronic carriers of HBsAg, the primary marker of hepatitis B virus 
infection. Additionally, multiple subgenotypes of genotypes B, C and I co-circulate in 
this country.  
We demonstrate that about 6% of HBsAg positive rejected blood donors are infected 
with multiple sub-/genotypes. We furthermore provide evidence, that about 65% of 
the mixed infected donors showed recombinations in the surface gene that had 
surprisingly diverse recombination breakpoints and involved the predominant 
genotypes B and C. We show that recombinant virus strains were largely distinct and 
varied between donors and within individuals. In addition, our analyses indicate that 
recombinant strains largely evolved within the lifetime of the donor. In addition, 
based on the analyses of viral quasipecies, we propose a substitution rate of 1.58x10-4 
substitutions per site and year for strains in Lao PDR. Thus, our results provide evidence 
that, at least in Laos, hepatitis B virus mixed infections lead to frequent 
recombinations that so far have not led to new dominant strains in the population. 
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Finally, in serologic and phylogenetic analyses on sera from randomly selected blood 
donors in Lao PDR, we show that 45.5% of the blood donors were positive for at least 
one of the hepatitis B virus markers. Our results indicate that about half of the Laotian 
population has been in contact with this virus at one point during their lives. We 
furthermore provide evidence, that blood screening procedures in Lao PDR need to 
be reconsidered. We show that the screening of donations solely for HBsAg leaves a 
sizable risk of hepatitis B virus transmission by HBsAg-negative occult infected donors 
in at least 3.9% of blood donations. These are potentially DNA positive and could 
transmit hepatitis B virus.  
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1 Hepatitis B virus 
Hepatitis B virus (HBV) had first been described in an Australian Aborigine in 1967 (35). 
A specific serum antigen had been observed and designated the Australia antigen, 
which is now known as the hepatitis B surface antigen (HBsAg). This antigen was 
linked in 1970 to the presence of the so called Dane particle (70), which was later 
found to be the complete infectious HBV virion (Figure 1) (131, 244, 245). 
Today, HBV is the prototype of the virus family Hepadnaviridae. Due to similarities in 
the DNA sequence and the genome organization, Hepadnaviruses are grouped in 
the genera Orthohepadnavirus, with viruses infecting mammals, and 
Avihepadnavirus, infecting birds (252). 
By accumulating mutations during its natural history, the human HBV has evolved into 
at least eight recognised genotypes A–H (145, 146, 209-211, 217, 252, 270) and a 
putative genotype I (106, 125, 219, 294). Furthermore, a potential genotype J has 
recently been proposed (284). With the exception of E, G and H, genotypes are 
divided into subgenotypes with more or less distinct geographic distributions (6, 75, 
107, 116, 117, 119, 120, 133, 142, 145-147, 150, 152, 202, 209, 220, 221, 223, 273, 274, 
294). In addition, genetically close variants of HBV were also found in nonhuman 
primates, including chimpanzees (ChHBV), orangutans (OuHBV) and gibbons 
(GiHBV), each with its own distinct genotype (101, 179, 209, 249, 252). While cross-
species transmission of HBV from humans to baboons (139) and gibbons (19, 258) was 
shown experimentally, there is no evidence of systematic natural transmission of HBV 
from non-human primates to humans (249). 
1.1 Hepatitis B virus structure 
Three different structures associated with HBV are found in the blood of infected 
individuals (Figure 1, Figure 2). Only the larger structure, the Dane particle, with a size 
of 42 nm is a functional viral particle (131, 244, 245). The small spheres (22 nm) and 
filaments (variable length), although usually found in 10,000 to 1,000,000-fold excess 
over the Dane particles, do not contain genomic material and are not infectious 
(306). The outer envelope of the virus, as well as the spheres and filaments consist of 
hepatitis B surface protein (HBs), also known as hepatitis B surface antigen (HBsAg). 
The HBs protein consists of three different forms: the small HBs protein (SHBs), the 
middle HBs protein (MHBs) and the large HBs protein (LHBs) (see chapter 1.2, p.3) 
(108). Depending on the size, the HBs protein consists of different domains. While the 
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SHBs solely contains the S domain, the MHBs and LHBs include the preS2 or preS1 and 
preS2 domains, respectively (Figure 2) (98). In addition, the virus particle harbours an 
inner capsid that is formed by 240 HBV core (HBc) protein units (66). The capsid 
surrounds the 3.2kb partially double stranded DNA genome that is covalently linked 
to the viral polymerase. Furthermore, each viral particle contains a protein kinase 
and the heat shock proteins hsp70 and hsp90 (Figure 2) (128).  
1.2 Hepatitis B virus genome and gene products 
The HBV genome is a partially double stranded, relaxed-circular DNA molecule of 
approximately 3.2kb (Figure 3), which replicates its genome via an RNA intermediate 
(108). Its circularity is maintained by the 5’ cohesive ends of both the negative and 
positive strand and two short (10 or 11 nucleotides) direct repeats (DRs) in the viral 
DNA, a region that is suspected to also be important for integration into the hepatic 
genome (72, 306). The 5’ end of the minus-strand is located in the DR1, while the plus 
strand starts at the DR2. The repeats are involved in priming the synthesis of the 
respective DNA strands (108, 306).  
The minus strand is unit length, with the primase domain of the polymerase 
covalently linked to its 5’ end, while the plus strand is less than unit length, with a 
capped oligoribonucleotide molecule at its 5’ end (24, 155, 259).  
Figure 1: Electron-microscopy images of HBV particles. 
Dane particles, filaments and small spheres can be observed in the serum of infected 
individuals (Figure adapted from (128)).  
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The complex structure of the HBV genome is furthermore increased by its small size 
and compact organisation, with four overlapping open reading frames (ORFs), 
polymerase (P), surface (S), X and core (C), coding for seven proteins. The starting 
point of the genome is defined as the EcoRI restriction site that is located on the S 
and polymerase ORF (Figure 3). 
1.2.1 The polymerase (P) ORF 
The polymerase (P) ORF is the longest HBV ORF and overlaps, at least partially, with 
all other HBV ORFs (Figure 3). The polymerase has at least four domains, with the N-
terminal primase domain linked to the 5’ end of the negative DNA strand (24, 25, 
204). It is separated by a spacer domain from the RNA-dependent DNA polymerase, 
which has similarities to the reverse transcriptase of retroviruses (25, 26, 204, 291). The 
C-terminal domain encodes an RnaseH activity that cleaves the RNA of the DNA-
RNA hybrid in the assembled viral capsids (100, 204).  
 
Figure 2: Schematic representation of HBV particles. 
Empty spheres and filaments are secreted in the blood stream of infected donors in 
addition to the virus particle. The HBV virion consists of a HBs protein envelope and a 
HBc protein capsid. The encapsidated 3.2 kb DNA genome is covalently linked to the 
primase domain (Pr) of the DNA polymerase. Protein kinase (PK) and heat shock 
protein hsp90 are also encapsidated, while hsp70 is associated with internal preS 
domains of the LHBs. The figure is adapted from (128). 
  
Introduction 
5 
1.2.2 The surface (S) ORF 
The surface (S) ORF codes for three different surface proteins, the small SHBs, the 
middle MHBs and the large LHBs, depending on the usage of one of the three in-
frame translational start codons (Figure 3). For all three proteins, translation is 
terminated at a common stop codon. While the SHBs solely contains the S domain, 
the MHBs and LHBs include the preS2 or preS1 and preS2 domains, respectively 
(Figure 2, Figure 3). Consequently, the proteins share a common C-terminal region of 
226 amino acids (AA). The MHBs contains an additional 55 AA at the N-terminus, 
while the LHBs is further extended N-terminally by 108 AA.  
The common S-domain is generally referred to as HBV surface antigen (HBsAg) and is 
the main target of the host immune response during acute HBV infection. Anti-HBs-
antibodies against important epitopes of the HBsAg, especially against the major 
antigenic determinant ‘a’ (amino acids 124–147), are critical for protection (330). 
 
Figure 3: Organisation of the HBV genome. 
The HBV genome is a partially double stranded DNA molecule of 3.2 kb size with four 
overlapping open reading frames, encoding seven transcripts (Figure adapted from 
(46)).  
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1.2.3 The core (C) ORF 
The core ORF codes for two proteins, using two different translational start codons 
(69). The HBc protein or HBV core antigen (HBcAg) is 183 to 185 AA in length, 
depending on the viral genotype (123). The HBc protein assembles into the viral 
capsid of the infectious virion (69).  
The HBe protein (HBeAg) is encoded by the same ORF, albeit from a different RNA 
species (see1.3 Life cycle of hepatitis B virus, p.7), using an alternative upstream start 
codon, thus including the N-terminal preC domain into the protein (69). The preC 
domain is of 29 AA length of which the first 19 AA encode a hydrophobic alpha helix 
that allows for translocation of the HBe protein into the lumen of the endoplasmic 
reticulum (ER), where the 19 AA are cleaved off by a signal peptidase (45, 269). The 
remaining ten residues are sufficient to prevent assembly of this protein. Following the 
transport through the ER and the Golgi apparatus, parts of the HBe protein undergo 
additional cleavage, and a heterogeneous population of HBeAg proteins, with a size 
of 15 to 18 kDa, is secreted (269). 
1.2.4 The X ORF 
The X ORF is only found in the genome of the Orthohepadnaviridae and codes for 
the X protein. It has a length of 154 AA (305). The function of the HBV X protein is not 
well understood, but it seems to be essential for the infection and replication of HBV. 
Indeed, studies in the woodchuck model (56, 328) or in mouse models (137, 138, 313) 
indicate that HBx is needed for productive infection. In addition, cell culture models 
were used to understand the function of HBx. While HBx deficiency had only a little 
effect when using Huh7 hepatoma cells, a key position of HBx in the initiation and 
maintenance of HBV replication was observed in HepG2 and HepaRG cells, as well 
as in primary human hepatocytes (34, 137, 138, 161, 175, 305). Furthermore, HBx was 
found to be a transactivator of multiple cellular and viral promoters (305), while some 
studies suggested that HBx activates viral transcription (40, 161, 326), or enhances 
encapsidation (190). However, mutational studies also suggest, that the X protein is 
not of relevance for the HBV life cycle (34). In addition, multiple studies observed 
tumorigenicity in model systems and truncated forms of HBx were observed in 
chronically infected individuals and suspected to play a role in HBV-related liver 
oncogenesis (236, 253, 271). Thus, despite the large number of studies performed, the 
function of HBx in HBV replication is not yet completely clear. 
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1.3 Life cycle of hepatitis B virus 
During the last two decades the use of various hepatoma cell lines has profoundly 
increased the knowledge of the life cycle of HBV. However, especially the study of 
viral attachment has been hampered, as available in vitro systems such as HepG2 or 
HuH7 cell lines were dependent on transfection with the virus (98). Consequently, 
primary human hepatocytes (PHH) and those of chimpanzees, which were both 
limited in availability, were used for HBV infectivity studies (98). Recently, additional 
model systems have become available for the study of viral entry: primary 
hepatocytes from tree shrews (Tupaia belangeri) are used to substitute PHH and a 
new human hepatoma cell line (HepaRG) can be infected with hepatitis B virus (97, 
102). A large number of studies on the life cycle of HBV were furthermore performed 
using two HBV-related animal viruses, the duck hepatitis B virus (DHBV), infecting 
Peking ducks and the woodchuck hepatitis virus (WHV), infecting the woodchuck 
Marmota monax (94, 183, 191, 255, 276). 
Despite the limitations of the model systems, a large number of studies have been 
performed to understand the life cycle of HBV. Briefly, it can be divided into a 
number of steps (Figure 4) (128): (1) attachment of the infectious virion to the host 
cell membrane, (2) virus entry into the cell, (3) release of the viral core, (4) release of 
the viral genome into the nucleus, (5) transcription and translation of HBV genes, (6) 
genome replication, (7) virion assembly, (8) release of the virus. A schematic view of 
the HBV life cycle is presented in Figure 4. 
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Figure 4: Schematic view of the HBV life cycle. 
After attachment, HBV enters the hepatocyte, possibly by endocytosis. As soon as 
the nucleocapsid is released, it is transported to the nuclear pore, where the relaxed-
circular (rc) DNA genome is converted into covalently closed circular (ccc) DNA. 
cccDNA is transcribed into three viral mRNAs of 2.4, 2.1 and 0.7 kb size and 
pregenomic (pg) RNA of about 3.5 kb size. The synthesis of the non-essential HBe and 
HBx are omitted in this figure. The core and polymerase transcripts are assembled in 
the cytosol, forming core particles with the pgRNA. The transcripts of the surface 
proteins are translated through the rough ER. The surface proteins are inserted in the 
ER membrane and bud into the ER lumen, with a subset of these enveloping the core 
particles. The HBV and HBs particles are then secreted constitutively. The figure is 
from (128) and is still speculative in many details.  
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The first step of HBV infection is the viral attachment to the cell surface, which 
appears to involve a multistep process (257). A cell type unspecific primary 
attachment to heparan sulfate proteoglycan is followed by a highly specific 
attachment step, involving the HBV surface proteins (257). Numerous studies 
reported a variety of interaction partners for all three HBV surface proteins, although 
recent studies point towards the preS1 domain as a key factor in mediating 
hepatocyte binding (98, 188, 207, 254, 257). In addition, both the differention status of 
the hepatocytes and the cell polarisation seem to have a large impact on the 
infection process (98, 256). Upon binding to the membrane, entry occurs probably 
via endocytosis, but the mechanism remains unclear (98). After the release into the 
cytoplasm, the nucleocapsid is transported to the nuclear pore and the partially 
double stranded relaxed-circular DNA genome (rcDNA) is released into the 
nucleoplasm and converted into a stable, covalently closed circular form (cccDNA) 
(128, 204). The episomal cccDNA then serves as the central transcriptional template 
to produce various subgenomic RNAs encoding the HBV proteins (Figure 4, Figure 5). 
Figure 5: HBV genome and associated viral RNAs.  
The inner circle represents the HBV DNA. The outermost lines depict viral RNAs 
present in infected cells. The three mRNAs are of 0.7 kb (encoding the X protein), 2.1 
kb (middle and small HBs) and 2.4 kb (large HBs) size. The greater than genome 
length pgRNA encodes the HBc, HBe and polymerase and serves as template for 
HBV replication. The packaging signal (ε) is depicted as a hairpin structure. Figure 
adapted from (204).  
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The three viral mRNAs function as template for the viral proteins, using the cellular 
RNA polymerase II, with the 2.4 kb and 2.1 kb encoding the large or middle and small 
HBs protein, respectively, while the 0.7 kb mRNA encodes the X protein (128, 204, 
243).  
Two greater than genome length pregenomic (pg) RNAs of about 3.5kb encode the 
HBc, HBe and polymerase and serve as template for HBV replication (204). From the 
longer pre-core mRNA an extended non-assembling version of the core protein is 
translated that has an N-terminal extension with a hydrophobic alpha helix, allowing 
for the processing and secretion of the HBeAg via the ER (see 1.2.3 The core (C) ORF, 
p. 6). Another, slightly shorter, pgRNA serves as mRNA for the core protein and the 
polymerase (204). The newly translated polymerase then binds to the packaging 
signal ε at the 5’end of the pgRNA, preferentially to the molecule from which it was 
translated, and initiates the assembly with the core proteins to form a new 
nucleocapsid, in which the RNA is reverse transcribed into rcDNA (23, 204). The 
progeny capsids can then re-deliver their genomes into the nucleus to establish a 
pool of 10 to 100 copies of cccDNA or they bud into the ER to acquire their HBs 
envelope. Enveloped virions are then secreted through the constitutive pathway (44, 
128, 154, 204, 295, 304, 325). 
2 Clinical features of hepatitis B virus infection  
HBV infection patterns vary in different subpopulations worldwide. This is largely 
influenced by the age at which infection occurs. HBV infections tend to be mild or 
asymptomatic in children, but 90% of infants and 30–50% of toddlers become chronic 
carriers (82, 110, 306). In contrast, acute hepatitis B infection is cleared from the 
bloodstream in more than 90% of adult cases (306). The clinical manifestations vary in 
both the acute and the chronic disease. The acute phase can range from a 
subclinical to an icteric hepatitis and even to fulminant hepatitis in some cases. Also 
chronic carrier state ranges from asymptomatic to cirrhosis and hepatocellular 
carcinoma (HCC). 
2.1 Acute infections 
After HBV transmission, the incubation period ranges from 1 to 4 months, but may be 
shorter if exposed to higher viral loads (22, 36). Symptoms of HBV infection are 
typically arthralgia and arthritis, i.e. pains and inflammation of joints in hands, arms 
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and shoulders, as well as skin rash and fever. These symptoms usually cease with 
hepatitis onset (36). The majority of infections continue without additional symptoms, 
while only subsets of them are accompanied by jaundice or unspecific symptoms.  
The diagnosis of acute HBV is usually dependent on the presence of HBsAg and anti-
HBc IgM in the serum of the patient. The viral HBsAg is the hallmark of HBV infection 
and the first serological marker to appear in the serum, followed by HBeAg, HBV 
DNA, and anti-HBc (Figure 6). IgM anti-HBc antibodies appear early in infection and 
are detectable for about 6 months, while IgG anti-HBc antibodies appear later and 
can persist for many years. Furthermore, levels of serum liver enzymes ALT (alanine 
amino transferase) and AST (aspartate amino transferase) increase, varying from a 
moderate increase of 3- to 10-fold to more than 100-fold (306). In acute, self-limiting 
hepatitis seroconversion of HBeAg and HBsAg to anti-HBe and anti-HBs and loss of 
HBV DNA from the serum occur within about six months following exposure. 
 
Figure 6: Serological profile of acute (A) and chronic (B) hepatitis B. 
In acute, resolving infections HBV clearance is marked by the disappearance of HBV 
DNA and all HBV antigens and the presence of corresponding antibodies within 6 
months after infection. Chronic infection is characterized by persistence of infection 
over a longer period of time. Figure adapted from (108). 
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Until recently, it was assumed that after recovery from acute hepatitis B, the virus 
would be cleared from the body. However, recent evidence suggests, that HBV 
persists as cccDNA in the hepatocytes of infected individuals, indicating that 
immunosuppression could lead to reactivation of the virus (36). 
2.2 Chronic infections 
In a large number of infants and toddlers, as well as 5–10% of adults, replicative HBV 
infection persists for more than 6 month, thus progressing to a chronic carrier state 
(90, 187, 306). Chronic carriers are characterized by the continuous presence of 
HBsAg, HBeAg and anti-HBc, which can persist throughout infection (Figure 6). HBeAg 
is an important marker of the replicative activity of the virus and seroconversion from 
HBeAg to anti-HBe indicates disease remission. Although the course of chronic 
infection can be highly variable between individuals, it can generally be divided into 
three phases: “immune-tolerant”, “immune-clearance” and “inactive carrier” (166).  
The immune-tolerant phase is characterized by HBeAg seropositivity, high levels of 
HBV DNA (>107-108 copies/ml) and normal ALT levels. Histological changes are rare 
during this stage, probably as a consequence of the host immune tolerance to HBV. 
This phase is more frequent and prolonged in patients infected perinatally or in the 
first years of life (81). Furthermore, transplacental transfer of maternal HBeAg is 
suspected to induce helper T-cell unresponsiveness in neonates (60). Thus, especially 
in high endemic countries with a late seroconversion of HBeAg to its antibody anti-
HBe, patients in the immune-tolerant phase are usually young (166). 
Transition from immune-tolerance to immune-clearance in patients infected 
perinatally or during early childhood varies in different geographical regions, where 
different genotypes prevail. While HBeAg seroconversion in Africa where genotypes E 
and A prevail, occurs before the age of 15 or 16, seroconversion in Asian carriers of 
genotype B and C occurs much later in life, approximately at the age of 30 and 40, 
respectively (60, 130, 319). The immune-clearance phase may last from several 
weeks to years and is characterized by decreased levels of HBV DNA (<107-108 
copies/ml), abnormal and fluctuating ALT levels and increased histological changes 
(81). 
HBeAg seroconversion is followed by the inactive HBV carrier phase with low or 
undetectable levels of HBV DNA (<104-105 copies/ml) and normal ALT. While patients 
are usually asymptomatic during this phase, periodic reactivation with fluctuating 
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levels of HBV DNA and ALT occurs in some patients. Also HBsAg seroclearance was 
found to increase with age, approximately from the age of 30 and substantially 
increasing after age 50 (61). Generally, low-level HBV replication persists in the liver 
with undetectable HBV DNA in the serum, while anti-HBc antibodies, with or without 
anti-HBs antibodies, remain detectable.  
2.3 Occult infections 
After the loss of HBsAg (i.e. a lack of detection with currently available assays), low-
level HBV replication may still occur in a subset of chronically infected individuals, 
with detectable HBV DNA in the liver or blood, usually <1000 copies/ml or <200 IU/ml 
(242). The patho-physiological basis of occult hepatitis B infection (OBI) is still poorly 
understood but is probably due to an incomplete immune control of the infection. 
Most individuals with OBI have antibodies against HBV core antigen (anti-HBc), 
possibly reflecting an ongoing chronic infection with HBsAg below detection limits. 
This is particularly common in endemic countries where individuals are infected 
perinatally or during early childhood. OBI with antibodies against HBV surface 
antigen (anti-HBs), with or without anti-HBc antibodies, sometimes occurs during the 
recovery phase of the infection. Rare seronegative cases of OBI occur in individuals 
with no markers of HBV infection other than HBV DNA. Individuals with chronic 
hepatitis who have mutated HBsAg that is not detected by diagnostic assays also 
contribute to OBI (242).  
3 Epidemiology 
Worldwide, more than 2 billion people are or have been infected with hepatitis B 
virus at some time during their lives (308), accounting for approximately 600,000 
deaths per year, most of which occur in the developing world (147, 197, 308). About 
360 million people are estimated to be chronically infected and are at risk of liver 
cirrhosis and death due to liver failure (308). Furthermore, HBV is the major cause of 
hepatocellular carcinoma (HCC) worldwide (156), with the highest prevalences of 
HCC observed in regions with high HBV prevalence (30, 39, 43, 299, 317). 
3.1 Global distribution of HBV infection 
The prevalence of HBsAg, the primary marker of HBV infection, varies widely in 
different populations worldwide (Figure 7). Low prevalences (<2%) are found in North, 
West and Central Europe, North America and Australia (Figure 7) with prevalences 
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even below 0.5% in most regions (108). Intermediate prevalences of 2-7% are 
reported from the Mediterranean, Eastern Europe, Russia, Central and South 
America, and Southwest Asia, while high prevalences of ≥8% were largely observed 
in sub-Saharan Africa, Southeast Asia and parts of South America (Figure 7). In high 
risk populations the prevalence can be much higher, e.g. 55% in medical students in 
Mali (197) or more than 90% in HIV carriers in Cameroon (197). Also, the prevalence 
of anti-HBc antibodies is high and can reach over 85% in highly endemic regions 
(147).  
3.2 HBV serotypes and genotypes 
As the viral polymerase lacks proofreading capability, HBV shows a substantial 
genetic variability. Prior to the definition of genotypes, viral strains were classified by 
the four serotypes or HBsAg subtypes adw, ayw, adr and ayr. Classifications were 
based on the two mutually exclusive pairs d/y and w/r. The presence of lysine or 
arginine at AA 122 of the HBsAg indicates d or y, respectively, while lysine or arginine 
at AA 160 confer w or r. Furthermore, AA 113, 134, 144 and 145 sub-determine d/y 
specificity (52).  
 
Figure 7: HBsAg prevalence worldwide.  
Figure adapted from http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-
infectious-diseases-related-to-travel/hepatitis-b.  
Introduction 
15 
In addition, restriction fragment length polymorphism (RFLP) was, and still is, used in 
settings where no access to sample sequencing is available. Restriction enzyme 
digestion of HBsAg PCR products and separation of digested fragments allow a 
determination of the serotypes and genotypes A-H (103, 321). 
Today, amplification and sequencing has become the major tool for the analysis of 
HBV variants worldwide and to reconstruct the phylogenetic history of the virus. While 
genotypes were first defined based on a 8% nucleotide divergence of the complete 
genome or 4% on the S gene (217), the nucleotide divergence of the full-length 
genome was recently revised to 7.5% (145, 146, 209, 217). Additionally, subgenotypes 
are defined on a nucleotide divergence of 4% over the complete genome. 
Based on the nucleotide divergence, HBV is classified into at least 8 recognised 
genotypes (146, 209). In addition, a putative genotype I was described, while a tenth 
genotype J has recently been proposed for a virus isolated from a Japanese patient 
(106, 220, 284, 294) (Figure 8). With the exception of genotypes E, G, H and J, 
genotypes are divided into subgenotypes with more or less distinct geographic 
distributions (Figure 8). 
 
 
Figure 8: Worldwide distribution of HBV genotypes and subgenotypes. 
Figure modified from (323).   
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For genotype A seven subgenotypes have been reported so far. A1 is prevalent in 
South and East Africa, Asia, India and Indonesia, but also in Brazil and Argentina (6, 
21, 42, 107, 148, 150, 196, 199). A2 is mostly reported from Northwest Europe, but has 
also been detected in Africa, especially South Africa (142, 187, 209, 224, 252, 272). A3 
was mainly found in West African countries, such as Cameroon and Gabon and The 
Gambia, but also in Rwanda (107, 116, 117, 152, 197). Of subgenotype A4 only a few 
strains were found in Mali and The Gambia (107, 221). A5 strains were first reported 
from Nigeria, a region that was a former slave trading post, but has subsequently 
been reported from Haiti and Cameroon (8, 116, 221). The recently proposed 
subgenotype A6 strains originate from African–Belgian patients originating from 
Congo and Rwanda (235), while subgenotype A7 was proposed for strains from 
Cameroon and Rwanda (117). 
Genotypes B and C largely dominate in Asia and are divided into a number of 
subgenotypes. While B1 (formerly Bj) is mainly found in Japan and represents the non-
recombined B subgenotype (274), subgenotypes B2 to B4 (formerly Ba) largely 
originate from mainland Asia and are recombinants with genotype C. B2 is mainly 
found in China and Southeast Asia, B3 mainly in Indonesia and B4 in Laos, Vietnam, 
Cambodia and China (51, 209, 220). The subgenotypes B5 and B6 have been 
isolated in the Philippines and from the Canadian Inuit populations, respectively, and 
subgenotypes B7, B8 and B9 have been proposed in Indonesia (199, 212, 287). Also 
genotype C strains group into several subgenotypes. According to the nomenclature 
from Huy et al. (119), subgenotype C1 represents predominantly strains from 
mainland Asia (Laos, Vietnam, Thailand and Myanmar), while C2 is prevalent in 
Japan, Hong Kong, China and Korea (55, 119, 145, 209). Subgenotype C3 consists of 
strains from Oceania, C4 of strains exclusively from Australia and subgenotype C5 
strains have been reported from the Philippines, Indonesia, Vietnam and Laos (54, 
106, 220, 250). Additionally, subgenotypes C6 to C16 have been proposed recently 
for strains from the Philippines and Indonesia (54, 198, 200, 201, 220).  
Of the eight recognised genotype D subgenotypes, D1 is highly prevalent in the 
Mediterranean and the Middle East, and was also found in India and Pakistan (17, 
21, 209, 252). D2 and D3 prevail in East Europe, including Russia and the Baltic States, 
while D3 is also present in India, Pakistan, South Africa and Rwanda (17, 117, 209, 
281). D4 was observed in South Africa, Rwanda, Somalia and Oceania (117, 209). D5 
strains were reported from East India and from Morocco (15, 21, 227), while 
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subgenotype D6 was observed in Indonesia (176, 198, 200, 201). In addition, two 
HBV/D subgenotypes were observed in Africa. While D7 was observed in Tunisia 
subgenotype D8, resulting from recombination between genotypes D and E, was 
reported from Niger (1, 189). 
In contrast, genotype E has been found only in Africa, with some rare exceptions on 
other continents in persons with a link to Africa. Genotype E is found almost 
exclusively throughout the vast expanses of a crescent, spanning some 6000 km from 
Senegal in the West to the Central African Republic in the East and Namibia in the 
South (27, 48, 147, 177, 197, 278, 301). With about 70–140 million chronic carriers in this 
region, genotype E may well be the most important HBV genotype worldwide (197).  
Genotype G has been observed in the USA and in France (270, 300). HBV/F 
subgenotype F1 was found in Alaska, Mexico, Central America, Peru and Argentina, 
while F2 to F4 were solely observed in South America (74, 187, 209). In addition, 
genotype H was found exclusively in Central and South America (11-13).  
The putative genotype I, with its subgenotypes I1 and I2, was found in Laos, Vietnam, 
Northwest China and India (9, 106, 220, 248, 294, 316), while a tenth genotype J has 
recently been proposed in a virus isolated from a Japanese patient (284) (Figure 8). 
3.3 Mixed infections and recombinations 
In highly endemic countries, particularly in Asia where different HBV genotypes and 
subgenotypes co-circulate, mixed infections of different HBV variants (18, 114, 162, 
168) and recombinations have been described (38, 41, 67, 195, 220, 265, 303, 314). 
For example, mixed infections have been reported from Thailand (124) and in China 
almost 50% of infections were found to be mixed (114).  
Recombination events do not seem to be negligible artefacts of HBV co-infections, 
as recombinant strains have become the dominant variant in certain regions. 
Interestingly, most genotypes seem to be the result of recombination events (37, 265, 
279). For example subgenotype Ba, a B/C recombinant, prevails in major parts of 
mainland Asia, and a recombinant between genotypes C and D has become the 
predominant variant in Tibet (67). Furthermore, genotype I seems to be a 
recombinant between genotypes G, C and A, while genotype E has been 
suggested to be a recombinant between genotype D and another unknown 
genotype (41, 220). 
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3.4 Transmission of HBV 
HBV has been detected in a variety of body fluids. However, only serum, sperm and 
saliva have been demonstrated to be infectious, while transmission via breast milk, 
urine, tears and other body fluids remains controversial (4, 19, 33, 263). 
WHO considers perinatal and early childhood transmission to be the most important 
routes of transmission for HBV worldwide [9]. The capacity to produce HBeAg and 
seroconversion to anti-HBe antibody is thought to play an important role in the 
transmission and outcome of perinatally acquired HBV infections (48, 140). The risk of 
perinatal infection increases if the mothers are HBeAg positive and 80% of their 
infants become chronic carriers (140). In Asia, where genotypes B and C prevail, 
HBeAg seroconversion occurs later in life (see 2.2 Chronic infections, p.12). Thus 
women of childbearing age are likely to be HBeAg positive and to transmit the virus 
to the offspring (60, 130, 260, 306, 319). In sub-Saharan Africa on the other hand, a 
region where genotypes E and A prevail, HBeAg seroconversion occurs before the 
age of 15 or 16 (48, 88, 260, 306). Thus horizontal infection in early infancy is estimated 
to be as low as 1–8% in sub-Saharan Africa (48, 140, 246). Nevertheless, early vertical 
childhood transmission is thought to be the most important infectious route in Africa 
with most children being infected by the age of 5 years (48). 
Furthermore, horizontal transmission remains an important route of infection. Sexual 
contacts as well as percutaneous exposures e.g. due to contaminated medical 
equipment or contaminated blood donations, as well as injection drug use or 
tattooing are important routes of HBV transmission (87, 99, 127, 156, 208, 266, 308). 
However, transmission might also occur during household contacts (156). In addition, 
arthropod vectors, such as bedbugs and kissing bugs, have been implicated in the 
spread of HBV, but transmission has never been proven (31, 264). 
3.5 Prevention of HBV infection 
Infection with hepatitis B virus can be prevented by vaccination. The major response 
of individuals vaccinated against HBV is against the common ‘a’ determinant (see 
1.2.2 The surface (S) ORF, p. 5) of the HBsAg, protecting against all known HBV 
genotypes (108). 
First generation vaccines are plasma-derived vaccines consisting of purified and 
inactivated subviral HBsAg particles. They are derived from HBsAg positive donors, 
which are free of detectable HBV DNA (108, 306, 329). While these vaccines are still 
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produced in Asia they have been replaced by recombinant vaccines in many 
countries (306). Recombinant vaccines are produced by expressing the cloned HBV 
surface proteins (S, preS1, preS2) in yeast or mammalian cells (306, 329). 
WHO recommends an inclusion of HBV vaccination into routine immunization 
services worldwide to prevent chronic HBV infections (306). In regions with high 
endemicity, administration of the first vaccine dose occurs immediately after birth, 
preventing transmission from HBeAg positive mothers in up to 70%. This is even 
increased to 90% by simultaneously administering the hepatitis B immunoglobulin 
(HBIG) that confers passive immunity for several months (108, 329). 
The minimum protective level is generally considered to be 10 IU/l and booster doses 
are given to maintain a protective immunity. Nevertheless, 5 to 10% of healthy, 
immunocompetent individuals do not produce anti-HBs antibodies (nonresponders) 
or remain below the minimum threshold (hyporesponders) (108, 329). The 
nonresponders remain susceptible to infection with HBV (329). 
3.6 Treatment of chronic HBV infection 
The treatment of chronic HBV infection aims at the sustained depression of HBV 
replication in order to improve life quality and prevent the progression of disease. 
Nevertheless, HBV infection cannot be eradicated completely, as viral genomes 
persist in the hepatocytes as cccDNA (81). 
Depending on the response to treatment, different endpoints of therapy are 
considered (81). While the ideal endpoint of therapy is a sustained loss of HBsAg, 
which is associated with a complete HBV remission and favourable long term 
outcome, this is not possible in all infected individuals. As HBeAg seroconversion is 
associated with improved prognosis, this is considered a satisfactory endpoint in 
HBeAg positive donors. However, in HBeAg positive individuals who do not achieve 
seroconversion and HBeAg negative patients, therapy aims at suppressing the HBV 
replication and depressing serum DNA to undetectable levels by sustained 
treatment (81). 
Two different types of drugs can be used to reduce HBV DNA and viral replication: 
(pegylated) interferon alpha and nucleotide/nucleoside analogues (NUCs) (81). As 
(pegylated) interferon induces an antiviral state by inhibiting immunomodulation 
and cellular proliferation, no viral resistance is observed (108). However, side effects 
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are frequent and the drug has to be administered subcutaneously (76, 81). 
Furthermore, in patients with decompensated, HBV-related cirrhosis, autoimmune 
disease and those with uncontrolled severe depression or psychosis, interferon is 
contraindicated (81). 
Multiple NUCs are available, such as entecavir, tenofovir, adefovir and telbivudine 
(81, 108). As these NUCs directly target steps of the HBV replication process, fewer 
side effects are reported than when using interferon, even after extended use (76, 
81, 108, 165). However, the main disadvantage of NUCs is the development of drug 
resistances and cross-resistances, although in different rates for the individual drugs 
(76, 81). As this may result in treatment failure or HBV breakthrough during therapy, 
drugs have to be considered carefully for individual patients and patients should be 
monitored.  
4 Concurrent infection with other viruses 
As hepatitis B virus, hepatitis D virus (HDV), hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) share similar routes of transmission, concurrent 
infections occur. These were found to be clinically and virologically important, 
especially in areas with high prevalences, and complicate the course of disease, 
generally resulting in more severe and progressive liver disease than HBV infection 
alone. Infection with multiple viruses may occur as co-infection (i.e. simultaneous 
acute infection with different viruses) and super-infection (i.e. successive infection 
with different viruses). If the infection date of one or multiple viruses cannot be 
determined, the infection is referred to as concurrent (57).  
4.1 Hepatitis Delta (D) virus 
Hepatitis D virus (HDV) is a satellite virus that is dependent on HBV for its propagation. 
Worldwide, about 15 million HBsAg carriers are estimated to be also infected with 
HDV (285). The co-infection with these two viruses results in fulminant hepatitis more 
frequently than HBV infection alone, whereas super-infection of HBV with HDV is 
associated with chronicity of HDV in up to 80% of carriers (310). 
HDV is a spherical particle of 36 nm size. It consists of an outer envelope containing 
the three HBV surface proteins SHBs, MHBs and LHBs (see 1.2.2 The surface (S) ORF, p. 
5) and a nucleocapsid of hepatitis D antigen (HDAg) molecules, surrounding the 
approximately 1.7kb negative-stranded circular RNA genome (277). 
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Like HBV, HDV is transmitted through exposure to infected blood or body fluids as well 
as sexually (247, 310, 311). Perinatal transmission is however uncommon (310). HDV 
prevalences vary throughout the world, with regions of high endemicity in sub-
Saharan Africa, East Europe, the Middle East, parts of Asia and certain South Pacific 
islands (Figure 9). The HDV prevalence is generally highest in regions with high HBV 
prevalence. However, in some regions with high HBsAg prevalence, e.g. in South East 
Asia, infection with HDV is uncommon (199, 206).  
The HDV RNA genome is highly variable and strains are assigned to eight major 
clades, with divergence up to 18% within and up to 36% between clades (158). HDV 
clade 1 is the most prevalent clade worldwide and prevails in Africa, the 
Mediterranean basin, the Middle East as well as in Central and Northern Asia (73, 86, 
118, 157). Clades 2 and 4 have so far been described in East and North-East Asia, 
with Clade 2 also present in the Yakutia region in Russia (121, 122, 312). Clade 3 has 
only been detected in South America (53). Clades 5 to 8 on the other hand have 
recently been described in West Africa and individuals that migrated to West Europe 
from this region (158, 178, 241). In this region HBV is highly endemic (6, 104, 147, 178, 
197) and early childhood transmission is thought to be the most important route of 
infection (48). While this results in a high proportion of chronic HBV carriers, high rates 
of subsequent HDV super-infections add considerably to the burden of chronic liver 
disease (307). 
 
Figure 9: HDV prevalence worldwide and distribution of HDV clades.  
Figure adapted from (118)  
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While HDV depends on the HBsAg for propagation, treatment regimens against HBV 
do not necessarily affect HDV replication. Today, (pegylated) interferon alpha is the 
only drug impairing HDV replication (81). Thus the prevention of infection is of utmost 
importance. While no specific HDV vaccine exists, vaccination of individuals who are 
not chronic HBV carriers against HBV provides protection against HDV infection (310). 
4.2 Hepatitis C virus 
In countries with high prevalences of perinatal or early childhood infection, the 
presence of both HCV and HBV is largely due to HCV super-infection of chronic HBV 
carriers. Worldwide, more than 10% of chronic HBsAg carriers are also infected with 
HCV (163). While super-infection with HCV in HBeAg and HBsAg positive carriers 
usually results in transient HCV infection, acute infection in HBeAg-negative, HBsAg-
positive individuals advances to a persistent HCV infection. In addition, infection with 
both HBV and HCV seems to induce higher HBsAg seroconversion rates (63). 
Nevertheless, HCV super-infection is associated with earlier and more frequent 
progression to liver cirrhosis (164).  
4.3 Human immunodeficiency virus 
Human immunodeficiency virus (HIV) infection is prevalent in 10-15% of individuals 
chronically infected with HBV and is generally associated with increased levels of 
HBV DNA and decreased rates of spontaneous HBeAg clearance (62). Super-
infection is furthermore associated with higher risk of liver related mortality than 
infection with HBV or HIV alone and chronic HBV carriers with HIV are at increased risk 
of liver cirrhosis (81, 289). 
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5 State of the art und objectives 
Despite efficient vaccines, hepatitis B virus (HBV) continues to be a global public 
health problem. Especially in low income regions, such as sub-Saharan Africa and 
South-East Asia, HBV is highly prevalent, with prevalences reaching e.g. 55% in 
medical students in Mali (197) or more than 90% in HIV carriers in Cameroon (197).  
In Asia, where HBV genotypes B and C prevail, HBeAg seroconversion occurs later in 
life and women of childbearing age are likely to be HBeAg positive and to transmit 
the virus to the offspring (60, 130, 260, 306, 319). Thus, perinatal transmission from the 
mother to the child is considered to be the most important route of infection in Asia, 
leading to 80% chronicity in infants (81, 140). In sub-Saharan Africa on the other 
hand, a region where genotypes E and A prevail, HBeAg seroconversion occurs 
largely before childbearing age, before the age of 15 or 16 (48, 88, 260, 306). Thus, 
vertical perinatal transmission and infection in early infancy is estimated to be as low 
as 1–8% in sub-Saharan Africa (48, 140, 246). Nevertheless, horizontal transmission 
during early childhood is thought to be the most important infectious route in Africa, 
with most children being infected by the age of 5 years (48). 
In sub-Saharan Africa HBV is highly endemic. One of the two genotypes A and E 
dominates in most countries and only rare studies reported donors mixed infected 
with these genotypes. While genotype A is highly diverse with long evolutionary 
histories on the African continent, HBV/E, has a conspicuously low genetic diversity 
and seems to have a short evolutionary history. This, however, seems to be in contrast 
with its excessively high prevalence and its extensive spread throughout the vast 
West African genotype E crescent spanning from Senegal in the West to Namibia 
and the Democratic Republic of Congo in the South and East and including Ivory 
Coast, Ghana, Mali, Burkina Faso, Togo, Benin, Nigeria and Democratic Republic of 
the Congo, except for Cameroon where genotypes A and E co-circulate (27, 48, 
147, 152, 177, 197, 221, 278, 301). With the exception of single sporadic cases with 
links to Africa (184, 267), HBV/E has not been found outside of Africa. It had been 
proposed that HBV/E evolved within the last 200 years (197). This would be 
compatible with the conspicuous absence of this genotype in Afro-Americans, 
despite the forced migration of slaves from West Africa to the New World during the 
transatlantic slave trade. Nevertheless, a recent study proposed a co-evolution of 
HBV with humans within the last 34,000 years and a time of evolution of HBV/E in 
Africa of 6000 years (229). However, if HBV/E has evolved from a single virus or a small 
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pool of viruses, it seems unlikely that the genetic diversity of about 1.7% would have 
taken such a long time to develop.  
Furthermore, it is not known from where genotype E may originate and how it might 
have been introduced. While cross-species infections from humans to primates have 
been shown experimentally there is no evidence of natural HBV transmission. HBV/E 
has been found once in a chimpanzee, but the direction of transmission could not 
be established (280). Also arthropod vectors have been implicated in the spread of 
HBV, but transmission has not been proven (31, 264). 
The wide spread and high prevalence of genotype E in Africa, despite its surprisingly 
low genetic diversity, represents an unsolved puzzle that is addressed in the first part 
of the present dissertation. First, molecular and phylogenetic analyses of genotype E 
and A strains from Africa and the Americas give a comprehensive picture of the 
spread and routes of transmission of HBV/E. The low genetic diversity of genotype E 
and its absence from the Americas is confirmed and implications on the time of 
evolution of genotype E are discussed (Chapter IV, Part 1). Additional analyses of the 
African HBV/E strains give valuable insights into the regional origin of this genotype in 
sub-Saharan Africa (Chapter IV, Part 2). Furthermore, phylogenetic analyses of HBV 
strains from Haiti, where more than 90% of the population descends from African 
slaves, and the inclusion of historical data further increase the understanding of the 
timeframe of evolution of genotype E and other West African HBV strains (Chapter IV, 
Part 3). In addition, extensive phylogeographic analyses confirm an only short time of 
evolution from a most recent common ancestor and refine the knowledge of the 
geographical origin of genotype E and the mutation rate of the virus, thus shedding 
light on the genotype E puzzle (Chapter IV, Part 4). 
The burden of chronic liver disease is increased by the co-infection with other viruses, 
especially in highly endemic regions. In sub-Saharan Africa high prevalences of 
hepatitis D virus (HDV), a satellite virus of HBV, have been reported. Of the eight 
genetic HDV clades, four are found in Africa, with clades 5 to 8 having only recently 
been described in West Africa and individuals that migrated to West Europe from this 
region (158, 178, 241). As so far only rare and limited studies have been performed to 
assess the HDV prevalence in HBV chronic carriers (159, 213), we analyse more than 
2000 samples from Burkina Faso, the Central African Republic, Chad and Nigeria. Our 
analyses shed light on the HDV burden in chronic HBV carriers in different cohorts, the 
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distribution of HDV variants and the characteristics of individual HDV clades (Chapter 
IV, Part 5). 
Additional studies are performed in Lao PDR, where about 9% of blood donors are 
chronic carriers of HBV (126) and, like in large parts of Asia, the evolutionary 'older' 
genotypes B, C and I co-circulate(220). Genotypes B and C are often found at 
higher viral loads in the blood than other genotypes and are associated with 
seroconversion at a higher age than genotype E in Africa (48, 167). As a result, 
perinatal transmission of HBV is frequent in Asia, leading to a high proportion of 
chronicity. In highly endemic countries, where different HBV sub-/genotypes co-
circulate, mixed infections (18, 114, 162, 168) and recombinations have been 
described (38, 41, 67, 195, 220, 265, 303, 314). Also, recombination events do not 
seem to be negligible artefacts of HBV co-infections, as recombinant strains have 
become the dominant variant in certain regions. For example, subgenotype Ba, a 
B/C recombinant, prevails in major parts of mainland Asia, and a recombinant 
between genotypes C and D has become the predominant variant in Tibet (67). 
Recently a recombinant variant that circulates in Laos and Vietnam has been 
proposed as a new HBV genotype I (106, 220, 248, 294). Nevertheless, only few 
systematic studies of HBV recombinants have been published from regions with 
intensive co-circulation of several HBV subgenotypes (220, 274, 303). 
In this part of the thesis valuable results of clonal characterization, phylogenetic 
analyses and recombination analyses shed light on the impact of the co-circulation 
of HBV sub-/genotypes on the frequency of recombination events and the 
generation of new viral variants (Chapter IV, Part 6). In Lao PDR blood donations are, 
so far, screened for HBV by only testing for the HBV surface antigen. Thus, HBsAg-
negative and DNA positive, i.e. occult infected, donors are currently not rejected. 
This chapter determines the serological profile of Lao blood donors, the prevalence 
of occult infections and discusses possible implications for the safety of blood 
transfusions in Lao PDR (Chapter IV, Part 7). 
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1 Chemicals and reagents 
Compound Company 
Agarose Lonza 
Ampicillin Sigma 
Dimethylsulfoxide (DMSO) Sigma 
Dithiothreitol (DTT) 0.1 M Invitrogen 
Ethanol 96-100% Merck 
Ethidium bromide Invitrogen 
Ethylendiaminetetraacetic Acid (EDTA) Biorad 
Glycerol Sigma 
Hi-Di™ Formamide Applied Biosystems 
Kanamycin Sigma 
Luria Bertani Broth Base (LB) Invitrogen 
Magnesium Chloride (MgCl2) Invitrogen 
Nucleotides (dNTPs) Invitrogen 
Oligonucleotides/Primers Eurogentec 
Orange G Invitrogen 
PCR Buffer without MgCl2 (10x) Invitrogen 
PicoGreen® 10 000X  Molecular Probes 
Potassium chloride (KCl) Merck 
Random hexamer Invitrogen 
Sodium Acetate Merck 
Sodium chloride (NaCl) Merck 
Sodium hydroxide (NaOH) Merck 
Sucrose Sigma 
SYBR®GreenTM nucleic acid stain (10,000x) Molecular Probes 
SYBR®SafeTM DNA Gel Stain (10,000x) Invitrogen 
Tris(hydroxymethyl)aminomethane (Tris) Sigma 
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2 Buffers and Solutions 
Buffer/solution Reagent Volume/concentration 
DNA loading dye (6x) Orange G 25mg 
 
Sucrose (40%) 4g 
 
ddH2O  fill up to 10ml 
TAE-Buffer (50x) Tris 2M 
 
Sodium Acetate 25mM 
 
EDTA  0.5M 
 
Adjust to pH 7.8 
 
S.O.C. Medium (Invitrogen) Tryptone 2% 
 
Yeast Extract 0.50% 
 
NaCl 10mM 
 
KCl 2.5mM 
 
MgCl2 10mM 
 
MgSO4 10mM 
 
Glucose 20mM 
Phosphate-Buffered-Saline (PBS) NaCl 8g 
 
KCl 0.2g 
 
Na2HPO4 1.44g 
 
KH2HPO4 0.24g 
 
ddH2O fill up to 800ml 
 
Adjust pH to 7.4 with HCl 
 
  ddH2O fill up to 1l 
   
3 Enzymes 
 
Enzyme Company 
Phusion™ High Fidelity DNA polymerase Finnzyme 
Platinum® Taq DNA polymerase Invitrogen 
RNaseOUTTM (Recombinant Ribonuclease 
Inhibitor) 
Invitrogen 
SuperScriptTM III Reverse Transcriptase Invitrogen 
TaqMan Universal PCR master mix Applied Biosystems 
4 DNA marker 
1kb plus DNA ladderTM Life Technologies 
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5 Standard 
2nd WHO International Standard for 
Hepatitis B Virus DNA, NIBSC code 97/750 
NIBSC, Hertfordshire, UK 
6 Bacterial strain 
E. coli One Shot® TOP10 
(Provided with the TOPO TA  
and TOPO BLUNT cloning kits) 
Invitrogen 
7 Bacterial growth medium 
Medium Reagent Volume/concentration 
Luria Bertani Broth (LB) Luria Bertani Broth Base 25 mg 
 ddH2O  fill up to 1l 
 
Autoclave at 121°C for 15 
min 
 
   
To prepare growth plates, 32 mg LB agar were added per 1 l medium. Bacteria were plated 
onto Luria-Bertani-Broth agar plates, in the presence of kanamycin [30 mg/ml] and X-Gal.  
 
8 Vectors 
Vector Company 
pCR® 4-TOPO®  Invitrogen 
pCR®-Blunt II-TOPO®  Invitrogen 
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9 Commercial Kits  
Kit name Company 
AxSYM® HBsAg V2  ABBOTT Diagnostics 
AxSYM® HBe 2.0 ABBOTT Diagnostics 
AxSYM® AUSAB ABBOTT Diagnostics 
AxSYM® CORE ABBOTT Diagnostics 
AxSYM® Anti-HBe 2.0 ABBOTT Diagnostics 
Big Dye® Terminator v3.1 Cycle 
Sequencing Kit 
Applied Biosystems 
ETI-AB-DELTAK-2 Diasorin 
Jet Quick PCR Purification Spin Kit Genomed 
MagMAXTM-96 Total Nucleic Acid Isolation 
Kit 
Ambion 
Murex anti-Delta 
Diasorin (formerly distributed by ABBOTT 
Diagnostics) 
Murex HBsAg Version 3®  
Diasorin (formerly distributed by ABBOTT 
Diagnostics) 
QIAamp Viral RNA Mini Kit Qiagen 
QIAamp® DNA Blood Mini Kit Qiagen 
QIAprep® Spin Mini Kit Qiagen 
QIAquick® Gel Extraction Kit Qiagen 
Smart Check HBsAg Test GlobaleMed 
TOPO TA Cloning® Kit Invitrogen 
Zero Blunt® TOPO® PCR cloning kit  Invitrogen 
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10 PCR primers  
10.1 Hepatitis B virus 
Table 2: Primers and conditions for the amplification and quantification of hepatitis B virus 
  Target 
region 
Primer name 
Primer 
orientation 
Amplification 
round 
5’-3’ Sequence Ref. 
Primer 
[μM] 
MgCl2 
[mM] 
Annealing 
T[°C], t[s] 
Elongation 
T[°C], t[s] 
preS fw2422 forward 
first 
agaactccctcgcctcgcagac (221) 
0.2 1.65 63, 20 72, 60 
 preS-R reverse acaggcggkgtttttcttgttga (221) 
 fw2451 forward 
second 
tcaatcgccgcgtcgcagaa (221) 
0.2 1.5 63, 20 72, 60 
 preS-R reverse acaggcggkgtttttcttgttga (221) 
S P2f forward 
first 
cctgctggtggctccagttc (221) 
0.2 1.65 63, 20 72, 60 
 979 reverse attggaaagtatgtcaaagaattgtgggtcttttg (221) 
 P2f forward 
second 
cctgctggtggctccagttc (221) 
0.2 1.5 60, 20 72, 60 
 Mc2R reverse tggaagttggggatcattgcc (221) 
X 455 forward 
first 
caaggtatgttgcccgtttg (221) 
0.2 1.5 62, 20 72, 60 
 rv1800 reverse agaccaatttatgcctacagcctccta (221) 
 fw696 forward 
second 
tcagtggttcgtagggctttcc (221) 
0.2 1.5 63, 20 72, 60 
 rv1800 reverse agaccaatttatgcctacagcctccta (221) 
C fw1608 forward 
first 
gcatggagaccaccgtgaacg (221) 
0.2 2.0 60, 20 72, 60 
 rv2661 reverse tcatttacagtgagagggcccacaaattg (221) 
 fw1644 forward 
second 
tgcccaaggtcttacataataggactcttg (221) 
0.2 1.8 60, 20 72, 60 
 rv2661 reverse tcatttacagtgagagggcccacaaattg (221) 
Taqman HBV-QTqm-F forward 
- 
actcaccaacctcttgtcct (171) 0.2 
- 95, 15 60, 60  HBV-QTqm-R reverse gacaaacgggcaacatacct (171) 0.2 
 HBV-QTqm-Probe forward FAM-tatcgctggatgtgtctgcggcgt-TAMRA (171) 0.1 
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10.2 Hepatitis D virus 
Table 3: Primers and conditions for the amplification and quantification of hepatitis D virus 
Target 
region (nt) 
Primer name 
Primer 
orientation 
5’-3’ Sequence Ref. 
Phusion 
buffer † 
Primer 
[μM] 
MgCl2 
[mM] 
DMSO 
Annealing 
T[°C], t[s] 
Elongation 
T[°C], t[s] 
307-870 320ds forward ccagagramcccttcarcgaac  (122) * GC 
0.8 1.5 2% 66, 30 72, 35 
307-870 rv900 reverse gtccgacctgggcatccg   
307-870 n320ds forward ccagagramccctctccarcgaac (122) * GC 
0.8 1.5 2% 66, 30 72, 35 
307-870 rv900 reverse gtccgacctgggcatccg   
715-1302 710s forward cgccggctgggcaacatt  GC 
0.8 1.5 2% 66, 30 72, 35 
715-1302 1302das reverse ggnttcaccgacraggagag   
868-483 fw900_2a forward gaccgcgrggaggtggagatg  HF 
0.8 1.5 - 62, 30 72, 50 
868-483 480as reverse ccgggataagcctcactc   
Taqman Delta-F forward gcatggtcccagcctcc (159) 
- 
0.3 
- - 95, 15 60, 60 Taqman Delta-R reverse tcttcgggtcggcatgg (159) 0.3 
Taqman Delta-Probe forward FAM-atgcccaggtcggac-MGB (159) 0.2 
* primer sequence modified; † GC and HF buffers are provided with the Phusion™ High Fidelity DNA polymerase 
 
10.3 M13 cloning verification PCR  
Table 4: Primers and conditions for M13 PCR 
Primer name Primer orientation 5’-3’ Sequence Primer [mM] 
MgCl2 
[mM] 
Annealing T[°C], 
t[s] 
Elongation T[°C], 
t[s] 
M13fw forward gtaaaacgacggccag 
0.8 2.5 58, 30 72, 60 
M13rv reverse caggaaacagctatgac 
 
Materials 
33 
11 Software 
Software Reference 
Adobe Photoshop  Adobe Systems Incorporated 
Adobe Illustrator Adobe Systems Incorporated 
BEAST v.1.6.2  (78) 
BEAUTI v.1.6.2 (78) 
BioEdit v7.0.9.0 http://www.mbio.ncsu.edu/BioEdit 
BLAST http://ncbi.nlm.nih.gov/BLAST 
CFX Manager BioRad 
Clustal W (290) 
Data Collection Software 
v3.0 
Applied Biosystems 
FastPCR v3.7.8 (R. Kalender, University of Helsinki, Finland) 
FigTree v1.3.1  (http://tree.bio.ed.ac.uk/software/figtree) 
Google Earth v6.2.1 Google Inc. 
jPHMM (322) 
LogCombiner v.1.6.2 (78) 
MAFFT v6b http://mafft.cbrc.jp/alignment/software (135, 136) 
MEGA 4.0.2 http://www.megasoftware.net (282) 
MEGA 5.0.5 http://www.megasoftware.net (283) 
Microsoft Office Suite 2003 Microsoft Corporation 
Microsoft Office Suite 2010 Microsoft Corporation 
SigmaPlot Systat Software, Inc. 
SigmaStat Systat Software, Inc. 
Modeltest (234) 
Network v4.610 Fluxus Technology, Germany (20) 
Network Publisher Fluxus Technology, Germany (20) 
Opticon MonitorTM v3.1 BioRad 
RDPv.3.44  (182, 225, 268) 
SeqScape® v2.5 Applied Biosystems 
SimPlot v3.5.1 http://http://sray.med.som.jhmi.edu/SCRoftware/simplot (173) 
SPREAD v1.0.3  (29) 
SPSS 17.0 for Windows SPSS Inc., Chicago, USA 
Topali v2 (192) 
Tracer v.1.6.2 (78) 
TreeAnnotator v.1.6.2 (78) 
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12 Instruments 
Instrument Reference 
Automated analyser AxSYM® system, ABBOTT Diagnostics 
Balance SARTORIUS Precision Balance 
Centrifuges Pico 17, Heraeus®  
Biofuge Stratos, Heraeus® 
UNIVAPO 150H, UniEquip 
Electroporation apparatus Pulse Controller Plus, Capacity Extender Plus, 
Gene Pulser II Plus, Biorad 
Electrophoresis power supply E835, Consort 
Fluorescence reader GENios Plus, Tecan 
Gel Tank and Casting Form Biozyme 
Gel Documentation System InGenius, Syngene 
Heating Block Thermomixer Comfort, Eppendorf 
Incubator HERAcell® 150, Heraeus  
Binder Incubators, Binder 
KingFisher Flex ThermoScientific®, Thermo Fisher Scientific 
NanoDrop ND-1000 Spectrophotometer Isogen 
PCR Machine Mastercycler® Gradient, Eppendorf 
UnoCycler, VWR 
PRO200 Rotor-Stator Homogenizer PRO Scientific Inc. 
Real Time PCR Machines Opticon® 2 DNA Engine, Chromo4TM, CFX, 
MiniOpticon, Biorad 
Safe ImagerTM 2.0 Invitrogen 
Sequencer ABI PRISM® 3130xl Genetic Analyzer, 
Applied Biosystems 
Shaker Multitron 2, INFORS-HT 
UV transilluminator Safe Imager™ 2.0 Blue-Light, 
Transilluminator, Invitrogen 
Vacuum source Vacuum Pump, UNIequip 
Vortex Vortex-Genie® 2, Scientific Industries 
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1 Antigen and antibody detection 
1.1 Enzyme-linked immunosorbent assay (ELISA) 
1.1.1 HBsAg detection  
The detection of the hepatitis B virus surface antigen (HBsAg) in the serum of 
voluntary blood donors and liver patients was performed using the Murex HBsAg kit 
version 3® and following the manufacturer’s protocol. The assay is based on the 
enzyme-linked immunosorbant assay principle (ELISA). Briefly, 25 μl of sample diluent 
were added to the wells of a 96 well microtitre plate, followed by 75 μl of serum 
sample. On each plate, two negative controls and one positive control were 
included (provided with the kit). The plate was then covered by a lid and incubated 
at 37°C for 1 h. After incubation, 50 μl of conjugate were added to each well and 
the plate was incubated again at 37°C for 30 minutes. At the end of the incubation 
time, the plate was washed 5 times with wash fluid using an ELISA washer. 100 μl of 
substrate solution were added to each well. After incubation for 30 minutes at 37°C, 
50 μl of stop solution (0.5 M sulphuric acid) were added to each well. The 
absorbance was measured using an ELISA reader at a wavelength of 450 nm with 
690 nm as a reference wavelength. 
1.1.2 HDV-Ab detection 
The detection of hepatitis D virus antibodies (HDV-Ab) was performed using the 
Murex anti-Delta or ETI-AB-DELTAK-2 ELISA kit, following the manufacturers’ protocols. 
For the Murex anti-Delta kit, 25 μl of sample diluent were added to the wells of a 96 
well microtitre plate followed by 75 μl of serum sample. On each plate, two negative 
controls and one positive control were included (provided with the kit). The plate 
was then covered by a lid and incubated at 37°C for 1 h. After incubation, 50 μl of 
conjugate were added to each well and the plate was incubated again at 37°C for 
60 minutes. At the end of the incubation time, the plate was washed 5 times with 
wash fluid using an ELISA washer and 100 μl of substrate solution were added to each 
well. After incubation for 30 minutes at 37°C, 50 μl of stop solution (0.5 M sulphuric 
acid) were added to each well. The absorbance was measured using an ELISA 
reader at a wavelength of 450 nm with 690 nm as a reference wavelength. 
For analyses with the ETI-AB-DELTAK-2 ELISA kit, 50 μl of sample were added to wells of 
a 96 well microtitre plate. On each plate, three negative controls and two positive 
Methods 
37 
control were included (provided with the kit). In addition, a blank well without 
control/sample and enzyme tracer was included. 100 μl of diluted enzyme tracer 
were added to each well, except for the blank well. The plate was then covered by 
a lid and incubated at 37°C for 3 hours. At the end of the incubation time, the plate 
was washed 5 times with wash fluid using an ELISA washer and 100 μl of substrate 
were added to each well. After incubation at room temperature in the dark for 30 
minutes, 100 μl of blocking reagent were added to each well. The absorbance was 
measured using an ELISA reader at a wavelength of 450 nm and using 630 nm as a 
reference wavelength. 
1.2 Microparticle enzyme immunoassay (MEIA) 
For our study on occult HBV infection in Lao PDR, all assays were performed on an 
automated AxSYM® system in partnering institutions. HBsAg, HBeAg and anti-HBs, 
anti-HBc, anti-HBe antibodies were detected by AxSYM® HBsAg V2, AxSYM® HBe 2.0, 
AxSYM® AUSAB, AxSYM® CORE and AxSYM® Anti-HBe 2.0 assays, respectively. 
Analyses were performed according to manufacturer’s instructions. 
1.3 Rapidtest 
For some samples HBsAg detection was performed in partnering institutions, using the 
Smart Check HBsAg Test, according to manufacturer’s instructions. 
2 DNA extraction 
DNA was extracted from serum samples using the QIAamp® DNA Blood Mini Kit, 
following the manufacturer’s protocol. Briefly, 200 μl serum were added to 20 μl 
ProteinaseK and 200 μl lysis buffer (provided with the kit) in a 1.5 ml centrifugation 
tube. After vortexing, the resulting solution was incubated at 56°C for 10 min. After a 
brief centrifugation, 200 μl ethanol (100%) were added. After vortexing and 
centrifugation, the mixture was applied to a QIAamp® spin column (in a 2ml elution 
tube). The column was centrifuged at 6000g for 1 min. The flow through was 
discarded. The column was then washed in two centrifugation rounds with 500 μl of 
washbuffers AW1 and AW2, respectively. The DNA was eluted into a 1.5 ml tube by 
application of 60 μl elution buffer to the membrane, incubation for 1 min and 
centrifugation at 6000g for 1 min. Eluted DNA was stored at -20°C. 
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3 RNA extraction  
RNA was extracted from serum samples using the QIAamp Viral RNA Mini Kit 
(Qiagen), following the manufacturer´s instructions. 140 μl of serum were added to 
560 μl of AVL buffer (lysis buffer provided with the kit) containing carrier RNA, in a 1.5 
ml cetrifugation tube. After vortexing, the resulting solution was incubated at room 
temperature for 10 min. To this 560 μl ethanol (100%) were added. After vortexing 
and brief centrifugation the mixture was applied to a QIAamp® mini spin column (in 
a 2ml elution tube). The column was centrifuged at 6000g for 1 min. The flow through 
was discarded. The column was then washed in two centrifugation rounds with 500 μl 
of washbuffers AW1 and AW2, respectively. RNA was eluted into a 1.5 ml tube by 
application of 60 μl elution buffer to the membrane, incubation for 1 min and 
centrifugation at 6000g for 1 min. Eluted RNA was stored at -80°C. 
4 Polymerase chain reaction 
The Polymerase chain reaction (PCR) is generally used to amplify double-stranded 
DNA in order to obtain a high amount of DNA for further experiments or to quantify a 
specific DNA fragment. Specific oligonucleotides (primers) are used to amplify a 
specific DNA region. The DNA amplification is facilitated by a DNA dependent DNA 
polymerase during multiple PCR cycles. Each cycle typically consists of a 
denaturation, annealing and elongation step.  
In order to increase the sensitivity and specificity of the analysis, a semi-nested PCR 
setup can be used. In this approach, a product obtained by PCR is subjected to 
another round of amplification, using one first round primer and another primer that 
would bind towards the centre of the first-round product. This approach increases 
the sensitivity of the PCR and reduces the risk of unspecific amplification in the 
second-round PCR.  
Besides template DNA, primers and polymerase, the mixture also contains dNTPs, 
MgCl2 as well an enzyme-specific buffer. Furthermore, SYBR® Green, a fluorescent 
molecule that binds to double-stranded DNA, can be added to the mix for 
quantification in a real-time PCR machine.  
In addition the TaqMan® assay, also known as 5’ nuclease assay, is used for 
quantitative analyses. In addition to the primers, this assay uses an additional 
oligonucleotide (probe). The probe is coupled to a fluorescent molecule and binds 
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to the single DNA strand. The fluorescent molecule is released from the probe during 
elongation by the DNA polymerase and thus emits a fluorescent signal.  
4.1 Amplification of the hepatitis B virus genome 
The HBV genome was amplified in four overlapping PCR fragments, of approximately 
1000 nt of size each, called preS, S, X and C fragments. A semi-nested PCR was used, 
except for the analyses of mixed infections and recombinations in Lao PDR. 5 µl 
extracted DNA or 1 µl first-round product were amplified in the first- and second-
round PCR, respectively. Primers and variable conditions are listed in Table 2. 
Constant PCR parameters are listed in Table 5. 
Table 5: Parameters for PCR using the Platinum® Taq DNA polymerase 
Reagent  End concentration or volume  
PCR Buffer  1x  
MgCl2 See Table 2 and Table 4 
dNTP  200 nM  
Forward primer  0.2 μM 
Reverse primer  0.2 μM 
SYBR® Green (if appropriate) 1x 
Platinum® Taq DNA polymerase 1 unit  
Template  5 μl (1st round) or 1 μl (2nd round) 
RNase/DNase free H2O  Add  up to 25 μl total reaction volume 
 
4.2 Reverse transcription of extracted RNA 
Reverse transcription was carried out to reverse-transcribe RNA into DNA. Briefly, 5 μl 
of extracted RNA were denatured with 45 ng random hexamers and 10 nmol dNTPs 
for 5 min at 72°C. The reaction was then performed for 80 min at 50°C using 200U 
SuperScript III reverse transcriptase and 40U RNAseOUT recombinant Ribonuclease 
Inhibitor. 
4.3 Amplification of hepatitis D virus genome 
The hepatitis D virus genome was amplified in three overlapping fragments, covering 
nts 307-870, 715-1302 and 868-483, respectively. 5 µl of reverse-transcribed DNA were 
amplified. Primers and variable conditions are listed in Table 3. Constant PCR 
parameters are listed in Table 6. 
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Table 6: Parameters for PCR using the Phusion™ High Fidelity DNA polymerase  
Reagent  End concentration or quantity 
Buffer (incl. dNTPs and 1.5mM MgCl2) 1x GC of HF buffer (see Table 3) 
Forward primer  0.8 μM 
Reverse primer  0.8 μM 
SYBR® Green (if appropriate) 1x 
DMSO (100%) See Table 3 
Phusion™ High Fidelity DNA polymerase 1 unit  
Template  5 μl  
RNase/DNase free H2O  Add  up to 25 μl total reaction volume 
 
4.4 Quantification of HBV and HDV by Taqman PCR 
Quantitative PCRs were performed using 5 μl of DNA. Primers and variable conditions 
are listed in Table 2 for HBV and Table 3 for HDV. Constant PCR parameters are listed 
in Table 7. 
Table 7: Parameters for quantitative PCR using the TaqMan Universal PCR master mix 
Reagent  End concentration or quantity 
TaqMan Universal PCR master mix 1x  
Forward primer  See Table 2, Table 3 
Reverse primer  See Table 2, Table 3 
Probe See Table 2, Table 3 
Template  5 μl  
RNase/DNase free H2O  Add  up to 25 μl total reaction volume 
 
5 Agarose gel electrophoresis 
Amplified PCR products were separated by size on an agarose gel. Depending on 
the size of the amplified product, the agarose concentration was varied between 
0.7% and 1.5%, with shorter fragments requiring a higher agarose concentration. For 
a standard gel (approx. 14x12 cm) the appropriate amount of powdered agarose 
was dissolved in 100 ml of 1x TAE buffer, using a microwave oven. For a big gel 
(approx. 25x25 cm) 300 ml TAE buffer was used. Then, 10 µl SYBR® Safe for a standard 
gel or 30 µl for a large gel were added, the warm gel was poured into a casting form 
and combs were inserted. 
After polymerization, the gel was placed in a gel running chamber with sufficient 
1xTAE to cover the whole gel and combs were removed. 5μl of amplified DNA was 
mixed with 1 µl of 5x loading dye and loaded into the resulting pockets. On each gel 
at least one lane of marker was included. The gel was run at 130V for 40 min for a 
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normal gel and 60 min for a large gel. After completion, DNA bands were visualized 
under ultraviolet light (300nm) and pictures were taken with the InGenius Gel 
documentation System.  
6 Agarose gel extraction 
In case of unspecific DNA amplification or for cloning purposes 20 μl to 25 μl of PCR 
product were mixed with 5 μl of 6x Loading Dye and separated on a standard sized 
agarose gel. Bands were visualised using the Safe ImagerTM and excised using a 
clean scalpel. Purification of DNA was performed using the QIAquick® Gel Extraction 
Kit according to manufacturer´s instructions. Briefly, the excised gel slice was placed 
in a 2 ml reaction tube, whose weight had been determined, and weighed. Three 
volumes of QG buffer were added to one volume of gel, with 100 mg corresponding 
to 100 μl. The tubes were incubated in a heating block at 50°C until the gel was 
completely dissolved, (for approximately 10 min). The mixture was vortexed and 
briefly centrifuged to remove droplets from the lid. Then one gel volume of isopropyl 
alcohol was added. After mixing, the solution was transferred to a QIAquick spin 
column (placed in a 2ml collection tube) and centrifuged at 12,000g in a table-top 
centrifuge for 1 min. The flow through was discarded. The column was washed with 
500 μl of GQ buffer and centrifuged at 12,000g for 1 min. Again, the flow through was 
discarded. The column was then washed with 750 μl PE buffer and centrifuged at 
12,000g for 1 min. The flow through was discarded and the column was centrifuged 
dry at 12,000g for 1min. The DNA was eluted into a 1.5 ml tube by application of 30 μl 
EB elution buffer to the membrane, incubation for 1 min and centrifugation at 
12,000g for 1 min. Eluted DNA was stored at -20°C. 
7 PCR Product Purification 
Using the Jetquick PCR product Purification Spin kit, PCR products that were not 
subjected to gel extraction were purified to remove residual primer, non-
incorporated nucleotides and PCR reagents, before subjecting them to downstream 
application such as cloning or sequencing. In short, 20μl of PCR product were mixed 
with 175μl of H1 buffer, transferred to a Jet Quick Spin® column (placed in a 2ml 
collection tube) and centrifuged at 12,000g in a table-top centrifuge for 1min. The 
flow through was discarded. The columns were then washed with 500 μl of H2 buffer 
and centrifuged at 12,000g for 1 min. The flow through was discarded and the 
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column was again centrifuged dry at 12,000g for 1min. The DNA was eluted into a 1.5 
ml tube by application of 30 μl TE elution buffer (heated to 70°C) to the membrane, 
incubation for 1 min and centrifugation at 12,000g for 1 min. Eluted DNA was stored 
at -20°C. 
8 Cloning 
Cloning was used to identify different viral variants, such as different genotypes or 
subgenotypes within an individual sample and to acquire larger DNA quantities for 
downstream applications. Purified PCR products were cloned into a TOPO® vector 
and transformed into TOP10 E. coli electrocompetent cells using the TOPO TA 
Cloning® Kit or the Zero Blunt® TOPO® PCR Cloning kit. 
8.1 TOPO TA Cloning®  
During PCR, the Platinum® Taq DNA polymerase adds 5’ adenosine (A) overhangs to 
every PCR product, irrespective of the sequence of the template. This feature is used 
by the TOPO TA Cloning® kit, which uses a linear pCR®4-TOPO® vector with 3’ 
thymidine (T) overhangs and a covalently bound topoisomerase. Due to the 
complimentary overhangs, the PCR product is included into the vector backbone, 
leading to a circular closed plasmid.  
For cloning, 4 μl of PCR product were mixed with 1 μl of a 1:10 diluted salt solution 
and 1 μl of TOPO TA Cloning® vector (included in the kit). The reaction mix was 
incubated for 5 minutes at room temperature and then put on ice. 
Electrocompetent One Shot® TOP10 E. coli were diluted 1:1 with distilled water. 50 μl 
of diluted bacteria were pipetted in a 0.1 cm electroporation cuvette (on ice). After 
adding 4 μl of the ligated vector, the vector/bacteria mix was electroporated at 2.25 
kV, 200 Ohm and 25 μF. 250 μl of warm S.O.C. ® (37°C) were directly added after the 
electroporation and the solution was transferred into a 2 ml reaction tube and 
incubated at 37°C for 1 hour to allow phenotypic expression of resistance genes. For 
blue and white screening of the colonies, 40μl of X-Gal was spread onto LB plates 
containing 30μg/ml Kanamycin. These plates were also incubated at 37°C for 1 hour. 
After incubation, 50 μl and 150 μl of each cloning reaction were spread on individual 
LBKan plates and incubated at 37°C over night. 
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8.2 Zero Blunt® TOPO® PCR Cloning  
PCR amplification using the Phusion™ High Fidelity DNA polymerase results in blunt-
ended products. Thus, cloning of these PCR products was performed using the Zero 
Blunt® TOPO® PCR Cloning kit. Briefly, 4 μl of PCR product were mixed with 1 μl of a 
1:4 diluted salt solution and 1 μl of Zero Blunt® TOPO® vector. The reaction mix was 
incubated for 5 minutes at room temperature and then put on ice. The downstream 
cloning steps were performed as described in chapter 8.1 TOPO TA Cloning®, p. 42). 
8.3 M13 PCR 
To confirm the cloning of PCR products into plasmids and in order to sequence the 
plasmid inserts, bacterial colonies were subjected to M13 PCR (“colony PCR”). As the 
M13 primer binding sites are located on the plasmid, amplification of the insert is 
independent of its sequence. Single bacterial colonies were picked as a template 
from a LB growth plate, using a sterile tooth pick or pipette tip. PCR was performed 
under the condition described in Table 4. Constant PCR parameters are listed in 
Table 5. 
9 Sequencing 
Sanger sequencing, also called dye terminator sequencing, was performed using the 
BigDye Terminator® v3.1 Cycle Sequencing kit and a mixture of dNTPs and 
fluorescently labelled, chain terminating dideoxynucleotides ddNTPs (Table 8). The 
PCR reaction was denatured at 96°C for 1min, followed by 25 cycles of denaturation 
at 96°C for 10s, annealing at 50°C for 5s and elongation at 60°C for 2min. PCR 
products were purified using 5 μl 125mM EDTA and 10 mM RNase/DNase free H2O. 
After mixing, 60 μl 100% Ethanol was added and the samples were mixed and 
incubated for 15 min at room temperature in the dark. Samples were centrifuged in 
a pre-cooled (4°C) centrifuge for 30 min at 3,000 rpm. The solution was then 
removed. Washing was repeated as described, using 70% of Ethanol. The solution 
was again removed and samples were dried for 15 min in a vacuum centrifuge and 
stored at 4°C until further processing. The sequencing reaction was performed on the 
capillary sequencer ABI PRISM® 3130xl Genetic Analyzer, using 80cm capillaries. For 
this, samples were heated to 95°C for 5min, supplemented with 10μl Hi-Di™ 
Formamide and incubated at 95°C for 5min before loading onto the capillary 
sequencer.  
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Table 8: Sequencing PCR using the BigDye Terminator® v3.1 Cycle Sequencing kit 
 
Reagent Concentration or quantity 
BigDye Terminator® Mix  1x 
TE buffer 1x 
Primer forward 0.5μM 
Primer reverse 0.5μM 
DNA template 10ng (max. 5 μl) 
RNase/DNase free H2O  Add  up to 10 μl total reaction volume 
10 Phylogenetic analysis 
10.1 Electropherogram 
Sequence electropherograms obtained from the capillary sequencer were 
extracted using the SeqScape® software and aligned to a known reference 
sequence. Furthermore, multiple sequences belonging to the same sample were 
assembled to larger fragments or complete genome sequences. The 
electropherograms were visually inspected for inconsistencies. Sequences were then 
imported into the BioEdit sequence for further processing. Multiple ambiguous 
nucleotides in SeqScape® throughout the partial sequences or in sequence overlaps 
indicated mixed infection with multiple HBV variants.  
10.2 Sequence alignment 
Sequences were aligned by genetic similarities, aiming at minimizing nucleotide or 
amino acid discrepancies. Gaps are introduced by the alignment program when 
they increased overall similarity. Pairwise alignments were performed using BioEdit 
with the Clustal W option and MAFFT v6 with the L-INS-i option, with manual 
corrections. 
Consensus-50 analyses were performed using BioEdit. Sequences of individual 
subgenotypes were compressed with a threshold of 50% for inclusion in the 
consensus nucleotide sequence. Consensus-50 subgenotype sequences were used 
to reconstruct genotype consensus-50 sequences in order to exclude a bias of the 
differently sized subgenotype sequence sets available.  
10.3 Recombination analysis 
Recombinant strains can be detected in individual sequences by phylogenetic 
reconstruction of different overlapping sequence fragments or windows to a 
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reference dataset. A recombinant strain is detected, when different fragments of the 
analysed sequence are attributed to different viral variants or (sub)genotypes. 
Recombination analyses were performed using the Bootscan analysis in the Simplot 
v3.5.1 software, jpHMM and the RDP, GENECONV and MaxChi options of RDPv.3.44. 
10.4 Nucleotide distance calculation 
Nucleotide distances between sequences and within or between groups of 
sequences were calculated using the MEGA software and the neighbour-joining 
method of the Kimura 2-parameter model. 
10.5 Phylogenetic and phylogeographic reconstruction 
Phylogenetic trees are inferred based on the analysed sequence alignment. The tree 
can be unrooted or rooted. Sequences are represented on branches that are 
connected by nodes. Sequences clustering on one node are in the same 
phylogenetic group. Phylogenetic groups are, e.g. referred to as genotypes and 
subgenotypes (hepatitis B virus) or clades (hepatitis D virus). In addition to the 
branching pattern, the length of the branches and the horizontal distances between 
sequences are important. Statistical methods are used to determine the branch 
length and genetic relatedness between sequences. To assess the reliability of the 
inferred branching pattern, bootstrap procedures are performed, resampling 
sequence subsets and comparing these with the originally calculated trees. 
Several different methods are available for reconstructing phylogenetic trees. The 
most common construction method is the neighbour-joining method. For analyses, 
the MEGA software was used with the neighbour-joining method of the Kimura 2-
parameter model and with 1,000 bootstrap replicates. 
In the case of more complex phylogenies or for phylogeographic reconstruction 
computationally extensive Bayesian Markov chain Monte Carlo (MCMC) analyses 
are applied. For analyses the BEAST v.1.6.2 software package was used. Briefly, BEAST 
averages phylogenetic trees over tree space to weigh it proportional to its posterior 
probability. Phylogenies are inferred using strict or relaxed molecular clock models to 
infer rooted, time-measured phylogenies. In BEAST analyses parameterized runs were 
repeated to reach an effective sample size greater than 200. The most applicable 
model was selected by calculating Bayes Factors of the different parameterized 
runs.  
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Phylogeographic analyses were performed using BEAST by including geographic 
state parameters. Visualisation was performed using Google Earth v6.2.1 and figures 
were created using Microsoft Office Powerpoint. 
10.6 Median-joining network 
Median-joining networks (MJN) were constructed using Network v4.610 and 
visualized using Network Publisher. Briefly, MJN were constructed starting from 
minimum spanning trees that were combined within a single network. Aiming at 
parsimony, consensus sequences of 3 mutually close sequences were subsequently 
added at a time. These so called median vectors can biologically be interpreted as 
extinct ancestral sequences. This median operation then resulted in the most optimal 
network, reflecting the shortest possible distances between the individual nodes (20). 
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Part 1: Hepatitis B virus: the genotype E puzzle 
 
This manuscript has been published as a Review article: 
 
Andernach IE, Hübschen JM, Muller CP. Hepatitis B virus: the genotype E puzzle. Rev 
Med Virol. 2009 Jul;19(4):231-40. 
 
I.E. Andernach contributed significantly to the design of the experimental part and structure 
of the manuscript and was in charge of literature research, data collection, data analysis 
and writing of the manuscript. 
 
Hepatitis B virus (HBV) is highly endemic throughout sub-Saharan Africa. One of the 
two genotypes A and E dominates in most countries. With several subgenotypes and 
variants, genotype A is more diverse in Africa (4.00%) than in the rest of the world 
(2.96%), suggesting an African origin and a long history on the continent. Despite the 
African slave trade, genotype E has only sporadically been found within the 
Americas, indicating that this genotype was introduced only during the past 200 
years into the general African population. A short history for this genotype in Africa is 
also supported by its conspicuously low genetic diversity (1.75%), which contrasts, 
however, with its excessively high HBsAg prevalence and its extensive spread 
throughout the vast West-African genotype E crescent. We discuss the spread and 
routes of transmission of genotype E and suggest that the distribution and current 
high prevalence levels of HBV (genotype E) in Africa are the result of the extensive 
use of unsafe needles, potentially solving the current African genotype E puzzle and 
shedding new light on the high HBV prevalence in Africa. 
1 Prevalence of hepatitis B virus in Africa 
Despite efficient vaccines, HBV infections continue to be a public health problem. It 
is estimated that more than a third of the world population is or has been infected 
with HBV at some time during their lives (306). More than 350 million people are 
chronic carriers of the virus (309), of which at least 65 million live in Africa (147, 197). 
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Worldwide, HBV infections account for 1 million deaths per year (309), 250 000 in 
Africa alone (147). Acute hepatitis B infection is cleared in more than 90% of adult 
cases (306). During early childhood, acute infection is mild or inapparent, but is 
associated with a risk of chronic disease that can be as high as 90% in infants (82, 
110). Chronic carrier status is relatively low throughout most of Western Europe, 
whereas in South-East Asia, the Indian sub-continent and throughout most of sub-
Saharan Africa the HBsAg prevalence exceeds 10% (156). In high risk populations it 
can be much higher, e.g. 55% in medical students in Mali (197) or more than 90% in 
HIV carriers in Cameroon (197). The prevalence of anti-HBc antibodies is even higher 
and reaches about 85% in Western Africa and 65-85% in East Africa (147), indicating 
that in many sub-Saharan countries most people have at some time been infected 
with HBV.  
2 HBV genotypes 
By accumulating mutations during its natural history, HBV has evolved into at least 
eight recognised genotypes A–H (145, 146, 209-211, 217, 252, 270) plus a potential 
new genotype (tentatively designated genotype I) proposed for strains mainly found 
in Laos (125, 219), but also in Vietnam (106, 294). With the exception of genotypes E, 
G and H, genotypes are divided into subgenotypes with more or less distinct 
geographic distributions (75, 107, 117, 119, 120, 133, 142, 145, 150, 152, 202, 209, 221, 
223, 273, 274). HBV was also found in nonhuman primates, including chimpanzees 
(ChHBV), orangutans (OuHBV) and gibbons (GiHBV) (101, 179, 209, 249), each with its 
own distinct genotype.  
3 Genotype A in Africa 
The majority of non-E genotypes reported from Africa belong to genotype A (Figure 
10, panel 1). Although only relatively few HBV/A sequences are available from 
African countries, except for e.g. South Africa (142, 224), Malawi, Tanzania (109) and 
Somalia (209), it seems that subgenotype A1 is the dominant genotype in countries 
situated along the Eastern coast from South Africa to the Horn of Africa in the North 
and Rwanda in the West (117, 147). In contrast, in West-Africa, HBV/A strains are 
relatively rare and belong to different subgenotypes (Figure 10, panel 2). We have 
found three new variants in West-Africa, tentatively designated subgenotypes A3 
(originally A’’) (197), A4 and A5 (221), and a potential new subgenotype in Rwanda. 
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Subgenotype A3 was originally identified in Cameroon (197), but was also found e.g. 
in The Gambia (107), Gabon (180) and Nigeria (221). A4 has been reported from The 
Gambia and Mali (197) and A5 from Nigeria (221). A2 has rarely been found, but 
mainly in South Africa (224). Nevertheless the genetic diversity of A2 is higher in Africa 
(1.97%) than in Europe (1.38% mean genetic diversity over the complete genome), 
where it is highly prevalent. It has therefore been suggested that this subgenotype 
originated from Southern Africa and was brought to Europe by sailors in the fifteenth 
century (107). As a result of the different subgenotypes, the genetic diversity of 
genotype A is higher in Africa (mean diversity of 4%) than anywhere else in the world 
(2.96%) (Table 9). Hence it has been speculated that genotype A may have initially 
evolved in Africa, from where it has spread to the other continents, giving genotype 
A many centuries of evolutionary history in Africa. 
 
Figure 10: Distribution of HBV genotypes (panel 1) and genotype A subgenotypes 
(panel 2) in Africa.  
Countries with overall less than 10 strains (panel 1) or less than 10 strains of genotype 
A (panel B) available are marked with a coloured dot. Countries with full colour have 
>90% dominance of one (sub-)genotype or a 60-90% predominance of one (sub-
)genotype with minority (sub-) genotypes shown as diamonds. For countries marked 
by asterisks, no sequences were available and shading is modified from reference 
(147). The A subgenotypes in Mozambique are unknown. Sequences obtained from 
GenBank and unpublished data were included. 
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4 Genotype E in Africa 
Genotype E was first described in 1992 (211), but its ubiquitous spread and high 
prevalence throughout the ‘African genotype E crescent’ has only recently been 
recognised. In large studies including hundreds of sequences from The Gambia (79), 
Mali (197), Burkina Faso (197), Ghana (48, 197), Togo (197), Benin (197), Nigeria, 
Central African Republic (28) and Democratic Republic of Congo (197) this 
genotype was found to be by far the most prevalent in these countries (including 
unpublished data). Genotype E also seems to be the main genotype in Senegal 
(301), Ivory Coast (278), Angola and Namibia (147).  
Interestingly, in Cameroon the overall prevalence of genotype A and E is similar, but 
large differences between cohorts have been reported (152, 197, 221). In a large HIV 
cohort, 91.4% were HBsAg positive and 82 and 18% carried genotype A3 and E, 
respectively (197). In children, genotype E prevailed (78%) (197). Bantus and the 
relatively isolated Pygmies showed an equal distribution of genotype A3 and E (152). 
Genotype E strains from this country did not form a separate cluster, but were 
interspersed among sequences from other countries and were as diverse as the 
latter. As genotypes E and A co-circulate in Cameroon, mixed infections are 
frequent (37%) and several A/E recombinations were reported (152, 221). In Europe 
genotype E has been found in sporadic cases, mostly in African immigrants to 
countries of the Mediterranean basin (91, 293).  
 
Table 9: Mean genetic diversity of HBV genotypes A and E, based on complete 
genome and S-fragment sequences, available on GenBank and unpublished data. 
 
  N Mean intra-group diversity (%) 
Genotype  FL (S) Worldwide Africa  
Non-African 
countries Europe  
A 131 (202) 4.00 (2.10) 4.00 (2.09) 2.96 (1.76) / 
A1 55 (89) 2.85 (1.36) 2.74 (1.36) 2.28 (0.97) / 
A2 49 (63) 1.24 (1.25) 1.97 (1.59) 1.17 (1.06) 1.38 (1.41) 
non A1/A2 24 (50) n.a. / (1.85) 3.51 (1.85) / / 
E 69 (610) 1.75 (0.79) 1.75 (0.79) / / 
The genetic diversity of S-fragment sequences is shown in brackets. FL=full length sequence, 
S=S-gene sequence, n.a.=not applicable.  
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Despite its wide geographic spread and high prevalence, genotype E viruses in 
Africa reveal a surprisingly low genetic diversity. When all currently published and 
some unpublished complete genotype E sequences are included (n=69), the mean 
diversity over the whole genome is 1.75%, in comparison to 4% diversity for all African 
genotype A sequences (n=66). The same analysis of S-fragment sequences (n=610) 
shows a lower mean genetic diversity of 0.79%, compared to 2.09% for African HBV/A 
sequences (n=167) (Table 9). Careful analysis of a limited number of complete 
genomes seemed to suggest a higher diversity in the Northern part of the genotype E 
crescent (from Benin to Cameroon) and a separate cluster with a lower genetic 
diversity and a common node in Democratic Republic of Congo, Angola and 
Namibia, the Southern half of the genotype E crescent (115, 147). This may be an 
indication that this genotype emerged in the North before spreading to the South. 
Overall, the low genetic diversity is indicative of a short evolutionary history and a 
more recent introduction of genotype E than genotype A into the general African 
population. It has been suggested that it would take about 200 years to develop the 
current mean diversity of genotype E (197).  
5 HBV genotype E and A in the Americas 
The spread of pathogens is closely linked to their host, e.g. phylogenetic analysis has 
shown that the human T-lymphotropic virus 1 was brought from West-Africa to the 
Americas after the 15th century (296). Similarly, African slaves that were 
forcemigrated to the Americas would have disseminated African HBV strains in the 
New World.  
Nevertheless, HBV/E is only sporadically found in the Americas, despite the forced 
migration of these slaves to the New World between the 16th and 19th centuries. 
Among more than 1600 sequences from 26 studies (and GenBank, December 2008), 
47.4% were of genotype A, 31.8% of genotype F and 12.6% of genotype D. Some 
sequences belonged to genotypes H (2.9%) and C (3.2%) and only sporadic 
sequences to genotypes G (0.8%), B (0.7%) or E (0.2%, Argentina, Brazil)(71, 74, 184-
186, 193, 196, 203, 205, 238, 240, 267, 298).  
In most South-American countries the indigenous genotype F prevails (Figure 11), 
while in Brazil, with the largest community of African descendants (44.7%) in South- 
and Central America (65), a high prevalence of genotype A has been reported (10). 
Even in an isolated Afro-Brazilian community almost all strains were assigned to 
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genotype A1 (196), otherwise found typically in Eastern Africa. This can be explained 
by the transatlantic slave trade, as Brazil was the largest single recipient of slaves 
from West and West Central Africa and later increasingly from East Africa (e.g. 
Mozambique)(132). In Afro-Venezuelans, half showed genotype F and the other half 
genotype A2 (239). All HBV/A sequences from the Americas that could be 
subgenotyped, were exclusively assigned to subgenotypes A1 (Brazil, Argentina) and 
A2 (Venezuelans including Afro-Venezuelans, Brazil, Argentina, Mexico, Nicaragua). 
However, more complete genome sequences from Latin America are required to 
understand their relationship with current African sequences. 
 
Figure 11: Geographic distribution of HBV genotypes in South and Central America.  
Single HBV/E sequences are not visible in the figure. The number of strains is shown in 
brackets together with the country name.   
Results and Discussion 
54 
6 The HBV/E puzzle 
6.1 The role of the slave trade 
The conspicuous absence of a significant number of genotype E strains from the 
Americas and the dominance of HBV/A in Afro-Americans strongly suggest that 
slaves were not carriers of genotype E, indicating that genotype E was rare when 
and where the slaves were rounded up in Africa. Slaves originated mostly from three 
main regions in West-Central Africa: the Bight of Benin, the Bight of Nigeria and the 
Gold Coast in Ghana (194). Thus, genotype E must have been introduced into the 
general West African population only after the slave trade had come to an end, 
which was, throughout most of the Americas, only by the turn of the 18th century 
(194). This would be compatible with the 200 years for the current mean genetic 
diversity of genotype E to develop. Alternative explanations would postulate that 
conditions in the Americas were not conducive to the continued transmission of 
HBV/E, but would fail to explain the distribution of African HBV/A strains in the 
Americas. 
6.2 No known source of genotype E 
Genotype E has been reported to be more closely related to non-human HBV 
isolates than the other genotypes, except genotype F (179). A HBV/E virus (GenBank 
accession AB032431) has been found once in a chimpanzee, but the direction of 
transmission was not established (280). Cross-species transmission from humans to 
baboons (139) and gibbons (19, 258) was shown experimentally, but there is no 
evidence of systematic natural transmission of HBV from non-human primates to 
humans (249).  
An introduction of HBV/E from the closest known non-primate (woodchuck, 53.5% 
mean genetic distance) and primate animal reservoir (chimpanzees, 10.1%) would 
have taken more than a thousand years to cover the mean genetic distance across 
the whole genome (83). Also the evolution of E from the closest known genotype (D), 
or from the African genotype A would have taken many centuries to bridge the 8.11 
or 10.73% mean genetic distance. As the evidence seems to corroborate an 
introduction of genotype E into humans within the last 200 years, it seems unlikely that 
known nonhuman primate genotypes are the source of a recent introduction of 
HBV/E into the general population, although primates would be the most probable 
source of such a putative ancestor strain. 
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6.3 Cross-protection between genotype A and E 
The much higher genetic diversity of HBV/A than of HBV/E suggests that genotype A 
was widespread in Africa long before genotype E was introduced. If natural routes of 
transmission were as effective for HBV/A as for HBV/E, genotype E had to overcome 
widespread pre-existing immunity to HBV/A viruses. Antibodies against important 
epitopes of the HBsAg are critical for protection and are mainly directed against the 
major antigenic determinant ‘a’ (amino acid 124–147) (330). Both genotypes E and 
A show consistent amino acid differences in the a-determinant (Table 10), which 
may reduce cross-protection between genotype E and A strains, although amino 
acid position 145, which is often associated with vaccine escape mutations against 
genotype A based HBsAg vaccines (14, 330), is not one of them. A potential 
displacement of HBV/A by genotype E seems therefore not plausible.  
 
 
Table 10: Characteristic amino acid changes in genotype E and A strains found 
across the major “a” determinant present in HBV vaccines. 
 
 Amino acid position in HBsAg 
Genotype N 122   127  131   140   143   159 
E (679) 598 R  L  T  S  S  G 
             
A1 (70) 40 K  P  N  T  T  A 
 21 R  .  .  .  .  . 
             
A2 (30) 22 K  P  N  T  T  A 
 7 R  .  .  .  .  . 
             
non A1/A2 (42) 28 R  P  N  T  T  A 
 8 K  .  .  .  .  . 
Sequences harbouring mutations with a prevalence < 10% per genotype are not shown. Total 
numbers of sequences of each genotype or subgenotype are shown in brackets. Position 122 
co-determines the serotype.  
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6.4 Vertical transmission 
HBV infections tend to be mild or asymptomatic in children, but 90% of infants and 
30–50% of toddlers become chronic carriers, in contrast to 5–10% of adults (306). Thus 
the age of infection is critical for the spread of HBV, but, in contrast to Asia, perinatal 
infection or infection in early infancy is estimated to be as low as 1–8% in sub-Saharan 
Africa (48, 140, 246). Nevertheless, early childhood transmission is thought to be the 
most important infectious route with most children being infected by the age of 5 
years (48). The capacity to produce HBeAg and seroconversion to anti-HBe antibody 
is thought to play an important role in the transmission and outcome of perinatally 
acquired HBV infections (48, 140). The risk of perinatal infection increases if the 
mother is HBeAg positive and 80% of their infants become chronic carriers (140). 
Seroconversion to anti-HBe in Ghana and Benin, where HBV/E is predominant, occurs 
much earlier in life (<16 years of age) than in Asia (48, 88) and thus women of child-
bearing age are less likely to infect their children. The prevalence of anti-HBe seems 
to be similar for genotypes E and A (91). Thus, vertical and early horizontal household 
transmission alone could hardly account for the high seroprevalence that would 
have developed throughout the HBV genotype E crescent within the estimated last 
200 years.  
6.5 Horizontal transmission 
The recent introduction of HBV/E seems difficult to reconcile with the excessive HBV 
prevalence throughout the genotype E crescent, unless a very efficient transmission 
mechanism has caused its explosive spread. 
During the last 200 years, numerous injection mass-campaigns were performed, e.g. 
in French and Belgian colonies, where nowadays genotype E largely prevails, against 
yaws in the 1920s (77, 266) or sleeping sickness, where, for instance, from 1917 to 1919 
only six syringes were used to treat 90 000 individuals (89). Also smallpox campaigns in 
West Africa, e.g. in the French colonies where at least 35 000 immunisations were 
documented between 1893 and 1910 (111) and the pervasive use of injectable 
antibiotics have resulted in frequent and unsafe inoculations (77). In Egypt, the 
widespread and efficient transmission of hepatitis C virus HCV was recently linked to 
unsafe injections during mass-treatment of schistosomiasis until the 1980s (87). The 
more stable HBV is estimated to be 10 and 20 times more transmissible via unsafe 
injections than HCV and HIV, respectively (87, 266). According to some studies at 
least 13 million HBV infections per year may be caused by unsafe injections in the 
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developing world (266). In addition to virus transmission as a result of poor iatrogenic 
practices, permissive sexual behaviour and traditional tribal practices during 
adulthood also contribute to the horizontal spread of HBV. However, conversion to 
chronic carrier status would be infrequent. In this context, insect vectors of infection 
should also be revisited using modern sensitive detection techniques. So far mainly 
bedbugs and kissing bugs have been implicated in the spread of HBV, as the 
persistence of HBsAg and DNA in these organisms and their excrements was shown 
(31, 264). Also mosquitoes could potentially be infective, but only when changing 
hosts after an interrupted blood-meal (32). Interestingly, the geographical distribution 
of HBV/E matches largely that of the tsetse fly which has been considered a 
potential vector of HCV (237). Whether a combination of once-in-a-generation early-
life vertical infection associated with a high risk of chronicity and rampant infections 
during adult-life with a lower risk of chronicity could explain the explosive spread of 
HBV/E, requires sophisticated modelling combined with demographic and 
epidemiological assumptions.  
6.6 Conclusions 
The genetic diversity of HBV/A suggests that this genotype has a longer evolutionary 
history in Africa than genotype E. This is also confirmed by observations that HBV/A is 
the most important genotype in Afro-Americans. The absence of genotype E in the 
descendants of the African slaves and the low genetic diversity suggest that this 
genotype was introduced during the past 200 years, after the slave trade had come 
to an end. Although the ancestor of HBV/E is not known, evidence points towards a 
secluded tribe or non-human primates as a historical reservoir in Western Africa. The 
excessively high prevalence of HBV/E throughout the genotype E crescent can only 
be explained by an explosive spread of the virus. Thus, routes of transmission need to 
be revisited. Although a competitive advantage of HBV/E in comparison to HBV/A 
cannot be fully excluded, there is no direct evidence that genotype E is more 
infectious. If routes of transmission had been the same for both genotypes, it could 
have been expected that, before the introduction of HBV/E, genotype A would be 
as prevalent throughout Africa as genotype E is today. In this case genotypes E and 
A would have had co-circulated for many years before genotype E had overcome 
widespread pre-existing immunity against HBV/A to eventually replace it. As this is not 
very likely within the short time frame, two of the above assumptions must be revised: 
(i) The prevalence of genotype A and thus of HBV was traditionally much lower in 
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Africa than the HBV prevalence is today and HBV/A only occurred in relatively 
secluded areas. This is supported by the low prevalence of genotype A in the HBV/E 
crescent; the rare recombinations between genotypes A and E also suggest that the 
clash between the two genotypes historically never occurred. (ii) The explosive 
spread of HBV/E must have been the result of a new route of transmission, 
‘revolutionary’ at that time. Much evidence points towards historical mass-
campaigns with unsafe injection needles as the main culprits of the current high 
prevalence levels of HBV and in particular genotype E throughout most of sub- 
Saharan Africa. This seems to be the one and most obvious way to reconcile all 
genotype E contradictions and to explain the current African genotype E puzzle. It 
also sheds new light on the high HBV prevalence that is seen today in Africa.  
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Part 2: Hepatitis B virus genotype E variability in Africa 
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Despite the availability of efficient vaccines, hepatitis B virus (HBV) is estimated to 
cause chronic infections in more than 350 million people worldwide and death in 
one million per year (309). Nearly 20% of the chronic carriers live in Africa with 
excessively high prevalence rates reported especially from the sub-Saharan regions 
(147, 152, 180, 231). In Africa, the spread and evolution of HBV genotypes are still 
poorly understood. While genotype D seems to be the most prevalent genotype in 
the northern part (147), the highly diverse genotype A is the dominant genotype in 
the southern and eastern regions of the African continent (107, 142, 147, 150, 275). 
Genotype E predominates throughout a vast crescent spanning some 6000 km from 
Senegal to Namibia (147, 177, 197) and extending to the Central African Republic in 
the East (27, 197). With about 70–140 million chronic carriers in this region, genotype E 
may well be the most important genotype worldwide (197). Here we review our 
current understanding of this genotype reanalysing all currently available sequences 
including many unpublished sequences. 
1 Geographical distribution of genotype E 
After sequence analysis of more than 400 HBV strains, we found that genotype E was 
by far the most prevalent genotype in Mali, Burkina Faso, Nigeria, Togo, Benin, 
Central African Republic and The Democratic Republic of the Congo (27, 197, 215, 
221). In Cameroon, either genotype A or E were described to be the most frequent, 
depending on the cohorts studied (152, 197, 221). As a result of the co-circulation of 
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these two genotypes, recombinations and a high number of mixed infections were 
detected (221). Genotype E was also reported from other West African countries like 
Senegal (301), Ivory Coast (278), Ghana (50), The Gambia (80), Angola and Namibia 
(147). In addition, a few strains were found further east like in Mozambique (68) and 
Madagascar (149) and Tunisia (16) in the North. Genotype E has not been found 
outside of Africa, except for a few rare cases mostly in individuals with an African 
background. In Europe, sporadic genotype E strains were reported from, e.g. France 
(91, 105), Italy (226), Spain (293), Belgium (170) and The Netherlands (297) and in the 
Americas from Argentina (184), Brazil (267) and the US (59, 134).  
2 Phylogenetic analysis of African HBV genotype E strains  
Despite the wide geographic distribution in Africa and the high prevalence 
throughout large parts of Africa, genotype E has a very low genetic diversity (147, 
197, 221). For the purpose of this review all currently available sequences covering 
the S gene and the complete genome were aligned in order to identify potential 
genetic clusters that may help to understand the spread of genotype E strains. For 
the analysis of the S gene, 596 strains including 163 unpublished sequences from 16 
countries were available (Table 11). The complete genome analysis was based on 68 
sequences (all published) from nine different countries (Table 11). The phylogenetic 
tree based on the S gene (Figure 12) showed that except for a few very small groups 
of identical or very similar strains, no clearly distinct clusters of sequences could be 
detected. The complete genome analysis, however, revealed that the sequences of 
the Democratic Republic of the Congo (DRC) form an own cluster, supported by a 
bootstrap value of 99, together with sequences from Angola and Namibia 
(bootstrap value 93, Figure 13). The majority of the strains from the Central African 
Republic form a cluster of their own which is however not supported by a high 
bootstrap value (below 50). The rest of the Central African sequences group with a 
strain from Cameroon (AB194948). The strains from Ghana form several clusters most 
of which are not supported by high bootstrap values (Figure 13). Thus, except for the 
strains from DRC, Angola and Namibia, it seems difficult to recognize geographical 
clusters of HBV genotype E in Africa. 
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Table 11: HBV genotype E strains available for phylogenetic analysis 
 
Country 
S fragment 
sequences 
Complete genome 
sequences 
Genotype E/other 
genotypes 
Mean 
(maximal) 
genetic 
distance 
Angola 8 2 100% (8/8) 0.85% 
Benin 17 4 100% (30/30) 1.64% (2.12%) 
Burkina Faso 41 0 76% (47/62)  
Cameroon 29 2 64% (74/116) 2.34% 
Central African 
Republic 
55 28 94% (62/66) 1.37% (2.73%) 
Democratic 
Republic of the 
Congo 
7 4 64% (7/11) 0.18% (0.25%) 
Equatorial Guinea 3 0 21% (3/14)  
Ghana 160 14 96% (307/319 1.92% (3.18%) 
Ivory Coast 10 2 92% (12/13) 1.35% 
Madagascar 2 1 100% (2/2)  
Mali 20 0 88% (37/42)  
Namibia 6 6 100% (6/6) 0.82% (1.13%) 
Nigeria 142 0 96% (251/262)  
Sierra Leone 2 0 100% (2/2)  
The Gambia 70 0 90% (192/214)  
Togo 22 0 100% (22/22)  
Unattributed 2 5   
∑=16 ∑=596 ∑=68  1.71% (3.54%) 
Genetic distances are calculated over the complete genome sequences within each 
country. 
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Figure 12: Subdivided genotype E cluster of the phylogenetic tree based on 681 nt of 
the S gene using all genotype E strains available on GenBank and some unpublished 
sequences. 
Alignments were generated with SeqScape® v2.5 and BioEdit. Phylogenetic analysis 
was performed using MEGA version 3.1. Only one example of strains from the same 
country on the same branch is displayed and groups comprising strains from the 
same country are compressed to reduce the size of the figure. Only bootstrap values 
above 49 are shown.  
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Figure 13: Phylogenetic analysis of complete genome sequences of HBV genotype E 
using the neighbor-joining method. 
Strains from the same country are coded with the same colour. Only bootstrap values 
above 49 are shown. 
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3 Genetic distances among HBV genotype E strains 
A low mean genetic diversity of about 1.5% for the preS/S and preC/C regions and of 
1.73% intragenotype nucleotide divergence over the complete genome of HBV 
genotype E strains was reported in earlier studies (147, 197, 221). The mean genetic 
diversity among all currently available genotype E sequences of the S gene and the 
complete genome was now calculated to be 0.73% and 1.71%, respectively (Kimura 
2-parameter method of MEGA version 3.1) (151). The two most distant strains 
(AB106564 from Ghana and AB194948 from Cameroon or rca026 from the Central 
African Republic) are separated by a genetic distance of 3.54% over the complete 
genome. The maximum and mean genetic distances for the different countries are 
shown in Table 11. The sequences from DRC show a relatively low diversity, indicating 
that they may have developed only recently from a common ancestor. The situation 
in Namibia and Angola is similar. The sequences from Benin and Ghana on the other 
hand show a comparatively high diversity suggesting that genotype E has been 
endemic in these countries for longer than in the more Southern countries. The 
sequences from the Central African Republic seem to have a somewhat 
intermediate diversity. These conclusions need to be verified on a larger number of 
complete genome sequences, as currently only rare sequences from mostly single 
studies are available for these countries (Table 11). 
4 Recombinations and mixed infections 
Except for our own studies, few studies on HBV genotypes in Africa were designed to 
detect mixed infections or recombinants. As a result of the co-circulation of 
genotype A and E strains, both recombinations and mixed infections were mainly 
reported from Cameroon. Mixed infections with genotypes A and E have been 
detected in more than one third of patients (15/41) from Cameroon and in 4 out of 
49 patients (8%) from Nigeria (221). One or possibly two genotype A/E recombinants 
were described from Cameroon (152, 197, 221); in addition another A/E (or possibly 
A/D) recombination with a small genotype G insert was reported in a strain from 
Nigeria (221) and a D/E recombinant from the Central African Republic (27). The first 
recombinant was a genotype A strain with about 200 nucleotides from the 
polymerase gene of genotype E (152), the possible A/E recombinant from 
Cameroon exhibited genotype A in the preS/S part, but genotype E in the preC/C 
region (197, 221). The Central African Republic recombinant was a genotype E strain 
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except for a genotype D signature in the C gene (27); the A/E recombination in a 
strain from Nigeria occurred in the preC/C region (221). For the purpose of this review 
we checked all published S gene and complete genome sequences of genotypes A 
and E from Cameroon and all complete genome sequences of genotype E strains 
for recombinations (SimPlot v3.5.1) (173), but no additional A/E recombinants were 
found.  
5 Discussion and conclusions  
Phylogenetic analysis of the nearly 600 S gene sequences revealed no clearly distinct 
geographic or genetic clusters of strains. However, the phylogenetic tree generated 
with complete genome sequences showed that the sequences from the Southern 
end of the genotype E crescent (South-West Africa and DRC) cluster together, as 
observed before (147), and may be derived from a common source or ancestor. In 
the North, the West African strains, especially the ones from Ghana and Benin 
revealed a relatively high diversity and several smaller lineages, indicating that 
genotype E has a longer natural history in this region. Together, the higher diversity in 
the North and the lower diversity in the South, suggest that the virus may have 
emerged in the Northern part of the genotype E crescent before spreading to the 
South. Our analysis confirmed the South-West/Central African cluster (147), and 
showed that the 28 new sequences from the Central African Republic (27) included 
here did not fall into this cluster, but formed at least two distinct lineages, one 
clustering separately, the other one with a strain from Cameroon. 
As genotype E is essentially absent from the Americas despite the Afro-American 
slave trade until the 19th century, these strains must have been relatively rare when 
the slaves were rounded up in West Africa. Thus, genotype E strains may have been 
introduced into the general African population only within the past 200 years. This 
would be compatible with the conspicuously low genetic diversity of genotype E 
viruses. However, the origin of these viruses remains obscure. Even the closest known 
HBV viruses either in humans or non-human primates could not bridge the genetic 
distance within 200 years. Moreover, how the virus may have spread throughout the 
vast expanses of the genotype E crescent cannot be explained without revisiting 
transmission routes. A thorough investigation of possible ways of transmission and 
spread of genotype E in Africa is warranted to prevent its further dissemination. 
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Part 3: Slave Trade and Hepatitis B Virus Genotypes and 
Subgenotypes in Haiti and Africa 
 
This manuscript has been published as: 
 
Andernach IE, Nolte C, Pape JW, Muller CP. Slave Trade and Hepatitis B Virus 
Genotypes and Subgenotypes in Haiti and Africa. Emerg Infect Dis. 2009;15(8):1222-8. 
 
I.E. Andernach contributed significantly to the study design and experimental work and was 
in charge of experimental setup, training of the visiting scientist, data analysis and writing of 
the manuscript. 
 
In sub-Saharan Africa, genotypes E and A predominate. East of the E/A divide (117), 
subgenotype A1 is dominant in countries along the eastern coast from South Africa 
to the Horn of Africa (148). Although genotype A has been found on every 
continent, its genetic diversity is higher in Africa (4% over the complete genome) 
than in the rest of the world (3%). Therefore, some researchers have suggested that 
genotype A has emerged in Africa (107) and, after a long evolution, has been 
introduced to other continents. However, despite the high genetic diversity of HBV/A 
in West Africa, this genotype is rare there. In contrast, genotype E is found almost 
exclusively throughout the vast expanses of a crescent from Senegal in the west 
(301) to the Central African Republic in the east (28) and Namibia in the south (147). 
In comparison to HBV/A, the conspicuously low genetic diversity of HBV/E suggests its 
short natural history in Africa (197) and relatively recent introduction into the general 
population there (197). However, the recent presence of HBV/E in Africa contrasts 
sharply with its current high prevalence and extensive geographic distribution there. 
The wide spread of genotype E also seems difficult to reconcile with a long natural 
history of genotype A in Africa (197). 
In Haiti, where >90% of the population descends directly from African slaves (64), we 
investigated the phylogeny of HBV to learn which genotypes may have been 
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prevalent in Africa several centuries ago. The conspicuous absence of genotype E in 
Haiti suggests recent and rapid spread of genotype E in Africa during the past 200 
years, probably as the result of public health interventions. 
1 Clinical Samples 
Serum samples were collected in 2006 after informed consent as part of a national 
survey to evaluate prevalences of human immunodeficiency virus infection, hepatitis 
B, and serologic syphilis among pregnant women at their first prenatal medical visit in 
19 clinics throughout Haiti. Women were tested for hepatitis B surface antigen 
(HBsAg) by using the Murex HBsAg Kit. DNA was extracted from HBsAg–positive 
samples by using the DNA Blood Mini kit. The complete HBV genome was amplified in 
4 overlapping fragments (preS, S, X, and C) and phylogenetic analysis and distance 
calculations were performed by using MEGA v.4. Genotyping was performed by 
analyzing the complete genome or at least 1 of the 3 fragments of preS, S, or C 
genes. Subgenotyping was done on the full-length genome or on at least 2 
complete fragments preS, S, or C. Sequences were submitted to 
EMBL/GenBank/DDBJ under accession nos. FJ692502–FJ692553 (Haiti S-fragment 
sequences), FJ692557–FJ692613 (Haiti complete genome sequences), and FJ692554–
FJ692556 (Nigeria complete A5 sequences). 
2 Results 
2.1 Genotypes and subgenotypes 
In 7,147 blood samples of pregnant Haitian women, HBsAg prevalence was 5%, 
ranging from 1.0% to 8.5%, depending on the sampling clinic. Of 320 HBsAg–positive 
samples available, 247 (77.2%) were positive for at least 1 of the 4 overlapping PCR 
fragments (Table 12). Interpretable sequences from at least 1 of the 4 PCR fragments 
were obtained from 213 viruses. A total of 179 of these strains could be clearly 
assigned to a genotype by analyzing the complete genome or at least 1 of the 3 
fragments of preS, S, or C genes. Of the 213 strains, 31 showed signs of mixed 
infection or recombination, and 3 strains were considered outliers because they 
could not be genotyped. 
Phylogenetic analysis of the above 179 genotypeable strains (excluding mixed, 
recombinant, and untypeable strains) showed that 128 (71.5%) viruses belonged to 
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genotype A; 40 (22.4%), to genotype D; and 11 (6.1%), to genotype E (Table 13). 
Genotype A strains were attributable to subgenotypes A1 (n=77 [43.0%]) and A5 
(n=35 [19.6%]). Genotype D strains belonged to D4 (16.2%) and D3 (3.9%). Fifteen 
viruses of genotype A and 4 of genotype D could not be further subgenotyped 
(Table 13) because only partial gene sequences or single preS, S, or C fragments 
were obtained. In all of the above strains, genotypes of the different fragments 
agreed with each other. In addition, 31 viruses were suspected mixed genotype 
infections or recombinants; they were not included in the above analysis and are 
discussed later. 
 
Table 12: Number of serum samples investigated, including suspected mixed and 
recombinant strains of HBV, Haiti 
 
Sequence or gene No. samples 
No. sera (HBsAg pos) available 320 
No. sera PCR pos 247 
No. of sera of which sequences were obtained* 182 
  Full length genome 68 
  Full preS fragment 57 (37) 
  Full S fragment 67 (19) 
  Full X fragment 67 (20) 
  Full C fragment 20 (34) 
No. sera of suspected mixed strains 25 
  Full length genome 10 
  Full preS fragment 8 (3) 
  Full S fragment 12 (2) 
  Full X fragment 10 (2) 
  Full C fragment 3 (3) 
No. sera of suspected recombinant strains 6 
  preS fragment 3 
  S fragment - 
  X fragment 3 
  C fragment - 
*No. serum samples includes 3 outliers and excludes mixed or recombinant strains. 
  
Results and Discussion Part 3 
69 
Table 13: Prevalence of HBV genotypes and subgenotypes, excluding mixed or 
recombinant strains and untypeables, Haiti 
 
Genotype or 
subgenotype 
No. (complete genomes; partial 
strains) of genotypeable or 
subgenotypeable strains 
Genotypeable or 
subgenotypeable strains, % 
A 128 (63; 65) 71.51 
  A1 77 (36; 41) 43.02 
  A2 1 (1; 0) 0.56 
  A5 35 (21; 14) 19.55 
D 40 (5; 35) 22.35 
  D3 7 (2; 5) 3.91 
  D4 29 (3; 26) 16.2 
E 11 (1; 10) 6.15 
Total 179 (69; 110) 100 
 
2.2 Phylogenetic analysis 
2.2.1 Subgenotype A1 
Phylogenetic analysis of A1 complete genome sequences showed that Haiti strains 
form several clusters (not necessarily supported by bootstrap values) within available 
full-length A1 strains (Figure 14) from South Africa and other eastern African countries, 
as well as from the Philippines. Haiti’s complete genome A1 strains showed a mean 
genetic diversity of 1.45% (maximum diversity of 3.86%) that rose to a mean genetic 
diversity of 2.49% (maximum 6.61% between FJ692589 and U87742) when all 
available A1 strains (mean 2.87%, maximum 7.64% between AY161140 and U87742) 
were included. 
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Figure 14: Phylogenetic analysis of selected sequences clustering with subgenotype 
A1, based on the complete genome.  
Diamonds indicate Haiti sequences. All complete A1 sequences available in 
GenBank are included.  
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2.2.2 Subgenotype A5 
A5 originally was proposed on the basis of the preS and preC/C gene fragments of 3 
Nigerian strains (221) We present here the full-length sequences of the latter strains 
(accession nos. FJ692554–FJ692556) and compare them with all full-length A 
sequences from Haiti. Twenty-one sequences clustered with the only available A5 
sequences from Nigeria. The overall mean intrasubgenotype diversity of A5 is 1.42% 
(maximum genetic diversity 2.89%). The mean intersubgenotype distance of the 
proposed A5 subgenotype was above the approximately 4% proposed for a new 
subgenotype (145, 217) for subgenotypes A1 (4.1%), A2 (4.8%), and A3 (5.1%); it was 
3.8% when compared with the previously proposed subgenotype A4 (221). 
Nevertheless, A5 strains from Haiti and Nigeria form 2 distinct phylogenetic subgroups 
within A5, supported by high bootstrap values (99%; Figure 15). These subgroups are 
separated by a mean, minimal, and maximum genetic distance of 2.28%, 1.71%, and 
2.89%, respectively. 
Figure 15: Phylogenetic analysis of selected sequences clustering with subgenotype 
A5, based on the complete genome.  
Diamonds indicate Haiti sequences; squares indicate Nigeria A5 strains. All complete 
A5 sequences available in GenBank are included. Scale bar indicates nucleotide 
substitutions per site.  
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2.2.3 Genotype D 
Because of low numbers of complete genome sequences available for genotype D 
in Haiti, we analyzed this genotype on the S fragment. In Haiti, most D strains 
belonged to D4 (29/179 [16.2%]). Besides a small cluster of D4 sequences from 
Australia and Papua New Guinea, a few D4 sequences from Rwanda (accession 
nos. FM200194, FM200212, and FM200213) (117) and single D4 sequences from Spain 
and France are available in GenBank. D4 sequences from Haiti were closely related 
to those from the latter 3 countries and somewhat separate from the Australian 
cluster (Figure 16). Despite the relatively high prevalence of D4 throughout most of 
Haiti, the mean genetic diversity of D4 S fragment sequences was only 0.39% 
(maximum diversity of 2.18%). 
D3 (7/179, 3.9%) was less frequently found in Haiti than D4. Sequences seemed to 
form small geographic and genetic clusters, 1 of which most closely resembled 
strains from Rwanda (GenBank accession nos. FM200190, FM200191, FM200197, and 
FM200205)(117) but all D3 strains in Haiti were interspersed among strains from Brazil 
(Figure 16). Haiti D3 S fragment sequences showed a mean genetic diversity of 0.74% 
(maximum diversity of 1.44%). 
2.2.4 Genotype E 
The prevalence of genotype E sequences was surprisingly low, with only 11 (6.1%) of 
the 179 subtypeable strains being classified as this genotype. Available S-fragment 
sequences clustered with African HBV/E strains and were interspersed as individual 
strains among those HBV/E strains (Figure 17). The mean and maximum genetic 
diversity of the Haiti S fragments were 0.76% and 1.93%, compared with 0.74% and 
4.66% of all African genotype E strains.  
2.2.5 Mixed Infections and Recombinations 
We suspected mixed infections in 25 samples either because of at least 5 divergent 
nucleotides corresponding to discrepant (sub)genotypes in at least 1 overlapping 
region of the PCR fragments or because of divergent nucleotides within the 
fragments after additional PCR analyses. Mixed infections included all genotypes in 
Haiti, as well as 1 B4 (S-fragment) and 1 C (X-fragment) sequence. Six other strains 
showed possible recombinations within the preS fragment or the X fragment. PreS-
fragment recombinants were based on HBV/E and HBV/A, whereas those in the X 
fragment emanated from HBV/G in recombination with genotypes D or A. One of 
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these strains also showed signs of mixed infection. Although sequences were 
relatively short, recombination breakpoints seemed to be located around nucleotide 
800 on the X gene; the location varied in the preS gene (nucleotide 330, 640, or 870). 
Figure 16: Phylogenetic analysis of selected sequences clustering with subgenotype 
D4 (A) or D3 (B), based on the S fragment. 
Diamonds indicate Haiti sequences; squares squares indicate Rwanda strains. 
Asterisks indicate potential mixed or recombinant strains. Scale bar indicates 
nucleotide substitutions per site.  
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Figure 17: Phylogenetic analysis of selected sequences clustering with genotype E, 
based on the S fragment.  
Diamonds indicate Haiti sequences. Asterisks indicate potential mixed or 
recombinant strains.  
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3 Discussion  
More than 90% of today’s Haitian population is descended directly from African 
slaves (64) exported from the late 17th century through the early 19th century (194). 
Because vertical transmission and household transmission during early childhood are 
important routes of infection and are associated with excess risk for chronic disease, 
HBV is transmitted between generations (48, 306). Thus, HBV strains in Haiti may to 
some extent reflect strains that were prevalent in Africa several centuries ago. 
3.1 Subgenotype A1 
Forty-three percent of African HBV sequences belong to subgenotype A1, the main 
African A subgenotype. This subgenotype was found in most eastern African 
countries (147) and dominated in this region for which larger sets of HBV strains have 
been characterized, including Somalia, Kenya (147), Rwanda (117) and South Africa 
(147). Subgenotype A1 is essentially absent from West Africa (i.e., west of the African 
E/A1 genotype divide) (117) and from other continents. During the peak of Haiti’s 
slave importation during the late 18th century, almost 60% of captives came from 
southeastern and central Africa (92, 93) (Figure 18). Complete Haitian A1 strains 
(36/77 A1 strains) formed several small clusters within A1, at least the largest of which 
is supported by a bootstrap value of 95%. Thus, the phylogeny is highly suggestive of 
multiple early introductions into Haiti of distinct A1 strains from eastern Africa that 
continued to spread in Haiti’s population. 
3.2 A5, a new subgenotype 
One third of HBV/A strains clustered with a group of rare strains that have been found 
only in southwestern Nigeria (221). Because only preS and preC/C sequences had 
been available, these strains had only provisionally been assigned to a new 
subgenotype, A5, until full-length sequences would become available. Complete A5 
genome sequences from Haiti (n=21) and Nigeria (n=3) presented in this study 
showed a mean intrasubgenotype diversity of 1.42%. The mean intersubgenotype 
distances of A5 are above the approximately 4% of the definition of a subgenotype 
(3) for subgenotypes A1 (4.1%), A2 (4.8%), and A3 (5.1%). Compared with the 
proposed subgenotype A4 (3.8%), the mean intersubgenotype diversity is only slightly 
<4%. Thus, together with high bootstrap support (99%), these strains fulfil the formal 
definition, proposed by Kramvis et al. (147), of a new subgenotype A5.  
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A5 has been found only in southwestern Nigeria, the former Bight of Benin, where the 
first wave of slaves brought to Haiti originated (92). Interestingly, all A5 sequences 
from Haiti clustered together, but somewhat separately (bootstrap support of 99%) 
from those from Nigeria, suggesting early evolutionary separation of the 2 clusters. 
This distinct clustering further corroborates early introduction of these strains to Haiti 
during the slave trade. A5 strains in Haiti were considerably more homogenous than 
A1 strains, possibly reflecting their geographic confinement to and homogeneity in 
Africa. 
Compared with subgenotype A5, A1 showed only a slightly higher mean genetic 
distance between African and Haitian strains (2.62% for A1; 2.28% for A5). However, 
when each Haitian A1 group is considered as a separate and independent 
introduction, the mean genetic diversity of these groups is only 0.8%–1.6% (for the 
different groups), indicating more recent introduction of these strains into Haiti. 
 
 
 
Figure 18: Distribution of hepatitis B virus A subgenotypes and D4 (only in Rwanda) in 
Africa and their potential routes of spread toward Haiti.  
Colored dots indicate African countries with <10 A strains available; full color 
indicates countries with >90% dominance of 1 subgenotype; or a 60%–90% 
predominance of 1 subgenotype, with minority subgenotypes shown as diamonds. 
Subgenotypes other than A1 and D4 are not shown for Rwanda. Sequences included 
were obtained from GenBank and unpublished data.  
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3.3 Genotype E 
We have extensively investigated HBV genotypes in Nigeria (197, 221) (and 
unpublished data). Of almost 300 sequences from both southern and northern 
Nigeria, 95% belong to genotype E and 4% to subgenotype A3. Thus, in Nigeria, the 
only location where HBV/A5 has been found, almost all HBV carriers are infected by 
genotype E, and the most prevalent none-E strains belong to subgenotype A3. In 
contrast, genotype A5 is rare and confined to Nigeria. Historical records (92) and the 
prevalence of A5 confirm that ancestors of the Haitian population came from the 
Bight of Benin, one of the most important slave trading posts. Nevertheless, only ≈6% 
of strains in Haiti belonged to genotype E. Single sequences were interspersed 
among current HBV/E sequences from Africa, with little genetic distance between 
them, suggesting that these HBV/E strains were introduced only recently into Haiti. 
The recent establishment HBV/E into Haiti strongly indicates that genotype E was 
essentially absent from West Africa when and where slaves were assembled for 
transport. Recent introduction of genotype E into the general West African 
population, as we have suggested previously (197, 221), also would explain the low 
genetic diversity of this genotype. 
3.4 Subgenotype A3 
A3, the minority subgenotype in West Africa, was virtually absent from Haiti, 
suggesting that this subgenotype also arrived later in the Bight of Benin. Interestingly, 
Cameroon is the only country where genotypes E and A3 cocirculate at similarly high 
prevalences (152, 197), suggesting that both E and A3 may cooriginate from this 
region. 
3.5 Genotype D 
More than 20% of sequences analyzed from Haiti belonged to genotype D (D3, D4). 
Subgenotype D4 strains are rare in the world, but we found a surprising 17% 
prevalence in Haiti. Interestingly, some of the D3 and the D4 strains were closely 
related to recent strains from Rwanda (117). With prevalences of 15.6% of D3 and 
6.7% of D4 (117) Rwanda is also the only country where sizeable percentages of 
these 2 subgenotypes were found, further corroborating an origin of these strains 
from that part of Africa. During the second half of the 18th century, slaves were, to a 
large extent, collected in west-central Africa and shipped either from the western 
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coast (194) or the eastern coast (92, 194) to the Caribbean. Thus, an African origin of 
the D strains seems likely (Figure 18).  
3.6 Time of evolution 
Our results seem to agree with the time frame of the transatlantic slave trade. 
According to the simplest evolutionary model with a mutation rate of 4.2 x 10-5 (83), 
separation between Haitian and African A5 strains, with a mean genetic distance of 
2.28%, would have occurred ≈270 years ago. When each Haitian A1 group is 
considered as a separate and independent introduction, the mean genetic diversity 
of 0.8%–1.6% corresponds to at least 100–190 years of evolution of each of the A1 
groups in Haiti. These estimates for A1 and A5 seem to agree with the historical 
records that slaves (putatively infected with A5) from West Africa were introduced to 
Haiti ≈270 years ago, i.e., during the early phase (from the 1730s on) of the slave 
trade (92) and slaves (putatively infected with A1) from eastern Africa were exported 
to Haiti around the turn of the 18th century (92, 93).  
The apparent absence of old genotype E strains in Haiti indicates that it was rare in 
West Africa at the time of the slave trade and emerged in the general African 
population by the beginning of the 19th century, after the majority of the slave trade 
was suspended. Indeed, the mean genetic diversity (1.74%) would evolve over the 
complete genome in only ≈200 years, even from a single virus. 
Given the recent introduction of genotype E, the excessively high prevalence of this 
genotype throughout the genotype E crescent is difficult to understand. If HBV 
antibody prevalence was as high at the time of the emergence of HBV/E as it is 
today, why did genotype E spread so much more efficiently than genotype A 
(subtype A3 or A5) in West Africa? No evidence exists to indicate that immunity to 
genotype A (e.g., through vaccines) does not protect against genotype E. The rare 
A/E recombinants do not suggest a long cocirculation of both genotypes at a high 
prevalence. A more likely scenario is that HBV was relatively rare in Africa until 
genotype E was massively spread by a new route of transmission. Much evidence 
points toward mass injection campaigns performed in the Belgian and French 
colonies at the turn of the 19th century. Treatment campaigns against yaws during 
the 1920s–1950s (77, 266) and chemoprophylactic campaigns against sleeping 
sickness (89) were widespread and entailed sometimes reusing only a few syringes to 
treat, for example, 90,000 persons (89). Later, the extensive use of injectable 
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antibiotics, vaccines, and other drugs (e.g., against syphilis) with unsafe needles 
further promoted HBV transmission (77, 266). In Egypt, widespread transmission of 
hepatitis C virus has been linked to unsafe mass injection campaigns against 
schistosomiasis until the 1980s (87). Because HBV is estimated to be 10 times more 
transmissible than hepatitis C virus (87, 266), injection with unsafe needles is a possible 
route of transmission of HBV (genotype E). In addition, early potentially contaminated 
vaccine preparations, as well as insect vectors, might be culpable in the spread of 
HBV infection. 
The high prevalence of genotype A5 in Haiti strongly indicates that predecessors of 
the Haitian population came from the Bight of Benin. However, subgenotype A3 and 
genotype E, highly prevalent today in this part of Africa, are essentially absent in 
Haiti. This lack strongly indicates that HBV/E emerged only later in the general African 
population. The high prevalence of HBV/E in large parts of Africa further suggests 
that HBV hyperendemicity is a recent phenomenon and probably the result of the 
extensive use of unsafe needles. 
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Part 4: Bayesian inference of the evolution of HBV/E 
 
This manuscript has been submitted for publication as: 
 
Andernach IE, Hunewald OE, Muller CP. Bayesian inference of the evolution of 
HBV/E. 
 
I.E. Andernach contributed significantly to the study design and computational analyses and 
was in charge of data analysis and writing of the manuscript. 
 
Except for Cameroon, where genotype A is dominant, genotype E is highly endemic 
in most of sub-Saharan Africa. Despite its high prevalence and wide geographic 
spread throughout large parts of Africa, HBV/E has a surprisingly low mean genetic 
diversity of only 1.75% over the full-length genome, in contrast to 4% diversity for the 
African HBV/A strains (6). It has been suggested that it would take only about 200 
years for the genetic diversity of HBV/E to develop (8, 197), while recent studies 
indicate an even earlier emergence of HBV/E (5, 85). To understand the evolution of 
the virus, a number of studies have been performed to assess the nucleotide 
substitution rate of HBV. However, because of differences in the computational 
approach as well as the dataset, large differences of nucleotide substitution rates 
were observed, ranging from ~10-4 to 10-5 substitutions per site and year (s/s/y) (83, 
141, 216, 222, 223, 320). As most of these studies were based on repeated sampling in 
the same chronic carriers of the virus or on viral strains collected from mother child 
pairs, the observed substitution rates are largely indicative of short evolutionary rates 
and may not necessarily reflect general longer term evolutionary rates. A recent 
study estimating HBV mutation rates on a selected dataset used Bayesian Markov 
chain Monte Carlo (MCMC) analyses and revealed a relatively high substitution rate 
of 3.7x10-4 to 7.7x10-4 s/s/y on the full-length genome (327). A substitution rate of 
3.2x10-4 was furthermore reported for a small HBV/E dataset (5). All of these studies 
indicate an only recent introduction and a short time of evolution of HBV/E in the 
general population of sub-Saharan Africa. 
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Recently, a study investigated the long-term evolution of HBV worldwide on a 
selected HBV S-gene dataset, including all genotypes and subgenotypes (229). The 
authors linked the global spread of HBV to human migratory patterns to estimate a 
global evolution during the past 34,000 years and found a long-term substitution rate 
of 2.2x10-6 s/s/y on the S-gene which is almost 100 times slower than previous 
estimates. Based on this mutation rate, the tMRCA of genotype E was estimated to 
be 6000 years.  
In our study, we address these apparent discrepancies and provide evidence that 
HBV/E has indeed only recently been introduced into the general West-African 
population. We performed phylogeographic analyses, including Bayesian MCMC 
modeling on extensive HBV/E full-length genome and S-gene datasets, in order to 
infer the timescale and dynamics of evolution of HBV/E. Our results confirm an only 
recent emergence of HBV/E, most likely within the last 130 years, and rapid 
expansion of HBV/E in sub-Saharan Africa most probably due to dramatic changes in 
routes of viral transmission. 
1 Sequences 
Non-recombinant sequences of HBV genotype E for which the country and year of 
sampling was available were obtained from NCBI (accessed December 2011). 
Recombinant strains were excluded using jpHMM and the RDP, GENECONV and 
MaxChi options of RDPv.3.44(182, 225, 268). The dataset included 167 full-length 
genome sequences and a total of 454 S-gene sequences with the accession 
numbers AB194947, AB194948, AB205188-AB205192, AM494689-AM494715, AM494717, 
AY738147, FN545821-FN545824, FN545827, FN545841, FN545842, GQ161755-
GQ161766, GQ161768-GQ161774, GQ161776-GQ161787, GQ161789-GQ161805, 
GQ161807-GQ161845, GQ161847-GQ161812, GQ161814-GQ161836, HM363565-
HM363611 (full-length) and AB194954, AB194955, AB205323-AB205329, AF323617-
AF323619, AF323620, AF323621-AF323636, AJ604932-AJ605031, AM494719-AM494723, 
AM494725, AM494727, AM494730-AM494734, AM494737-AM494741, AM494743-
AM494748, AM494751-AM494753, AM494832, FJ692540, FJ692544-FJ692548, FJ692550-
FJ692553, FN547192-FN547199, FN547202-FN547205, FN547207, FN547209-FN547215, 
FN547217, FN547218, FN547220, FN547221, FN547225-FN547227, FN547229, FN547230, 
FN547232, FN547234, FN547236, FN547237, FN547239, FN547240, FN547248, FN547251-
FN547253, FN547255-FN547257, FN547259, FN547261, FN547263-FN547272, FN547274-
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FN547277, FN547279, FN547282-FN547288, FN547292-FN547294, FN547297-FN547299, 
FN547304, FN547310, FN547333, FN547339, FN547347, FN547356, FN547358, FN547359, 
FN547362, GQ161775, GQ161806, GQ161839, GQ161842, GQ161844, GQ161846, 
HM195104-HM195106, HM195108-HM195113, HQ385227, HQ385235, HQ385236, 
HQ385238, HQ385239, HQ385241, HQ385242, HQ385245, HQ385246, HQ385248-
HQ385257, HQ385260-HQ385265, HQ385267 (S-gene only). Origins and sampling 
dates of the analyzed HBV sequences are summarized in Table 14. 
The full-length and S-gene sequence sets were aligned using MAFFT v6 for Windows 
with the L-INS-i option. 
2 Phylogenetic and phylogeographic analyses 
Model estimation was performed for both the HBV/E full-length and S-gene datasets, 
using Topali v2 (192). Based on the Akaike information criteria obtained the general 
time-reversible model with four gamma categories and invariant sites (GTR+G+I) was 
selected for each dataset. In addition, the less complex symmetrical (SYM) and 
transversion (TVM) models were tested on the S-gene alignment. The analyses were 
carried out using the BEAST v.1.6.2 software package. Parameter settings were 
defined using BEAUTi v.1.6.2 with subsequent manual adjustments and analyses were 
performed with BEAST. Sequence sets were analyzed with a strict or relaxed 
molecular clock, using constant size, exponential and expansion growth tree priors. 
Additionally, geographical information was included as a “state” location parameter 
for a subset of parameterized runs. For each run all states before convergence and 
at least 10% of states, were discarded as burn-in. Each parameterized run was 
repeated to reach effective sample sizes (ESS) greater than 200. Runs were assessed 
using Tracer and merged using LogCombiner v.1.6.2. The most applicable 
parameterized merged runs were selected based on the highest Bayes Factors, as 
calculated by Tracer. 
Tree calculation of the resulting output files was performed with TreeAnnotator v.1.6.2  
and visualization with FigTree v1.3.1. Visualization of the geographic spread of HBV/E 
was performed on S-gene tree files including geographical information using SPREAD 
v1.0.3. Longitude and latitude data of the individual country midpoints were 
included in the analyses as geographical coordinates. Bayesian skyline analyses 
were performed in BEAST, using the Bayesian skyline coalescent of BEAUTi. 
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Table 14: Origin and sampling date of analyzed HBV genotype E full-length and S-
gene sequences. 
 
  No. analyzed sequences 
Country Year Full length S-gene 
Angola 2007 / 9 
Benin 2001 / 13 
Burkina Faso 2001 / 10 
Cameroon 2007 2 11 
 2006 1 1 
 2005 / 3 
 2002 / 19 
 1994 2 4 
Central African Republic 2004 28 55 
Congo DRC 2001 / 3 
 1998 1 1 
Ghana 2000 5 15 
Guinea 2006 77 79 
Haiti 2006 / 10 
Mali 2002 / 18 
Nigeria 2007 47 47 
 2006 4 40 
 2005 / 33 
 2001 / 15 
 1998 / 8 
 1997 / 9 
 1996 / 3 
Sudan 2009 / 26 
Togo 2001 / 22 
Total   167 454 
 
3 Median-joining network (MJN) 
A median-joining network of the 454 S-gene strains was constructed using Network 
v4.610 and visualized using Network Publisher. Briefly, MJN were constructed starting 
from minimum spanning trees that were combined within a single network. Aiming at 
parsimony, consensus sequences of 3 mutually close sequences were subsequently 
added at a time. These so called median vectors can biologically be interpreted as 
extinct ancestral sequences. This median operation then resulted in the most optimal 
network, reflecting the shortest possible distances between the individual nodes. 
Results and Discussion Part 4 
 
84 
4 Results 
4.1 Substitution rates and tMRCA 
To estimate the time of evolution from a most recent common ancestor (tMRCA) 
and assess the nucleotide substitution rates, we performed Bayesian coalescent 
analyses on 167 HBV/E full-length and 454 S-gene strains. For both sequence sets the 
Bayes Factors (BF) significantly favored a Relaxed Molecular Clock model, with the 
Uncorrelated Exponential Clock having a higher BF than the Uncorrelated Lognormal 
Clock. Furthermore the Expansion Growth Coalescent with a UPGMA generated 
starting tree was favored. 
Based on these parameters the substitution rate of the full-length HBV/E was 
estimated to be 1.86x10-4 substitutions per site and year (s/s/y), with a median tMRCA 
of 130 years (mean tMRCA of 174 years; 95% highest posterior density (95% HPD): 36-
441 years). When including the geographic “state” parameter as a discrete 
phylogeographic inference, the substitution rate changed to 2.23x10-4 s/s/y and a 
median tMRCA of 116 years (mean 145 years; 95% HPD: 37-336 years), indicating an 
influence of the geographic “state” parameter in the analysis. While inclusion of this 
parameter is a prerequisite for visualization of the phylogeographic data, the 
resulting time estimations would have to be considered with caution. Since today’s 
geographic boundaries were not present at the time of the supposed spread, one 
would expect the tMRCA without the geographic parameter to be more reliable 
with respect to time of evolution of HBV/E. Furthermore, calculations were performed 
using median values, as this would reduce the influence of rare outliers in the 
analyses. 
Analyzing the S-gene sequences, the mutation rate of 1.9x10-4 s/s/y, as calculated for 
the full-length genome, would correspond to a median tMRCA of 71 years (mean 73 
years; 95% HPD: 54-97) and 52 years (mean 53 years; 95% HPD: 39-71 years) when 
including the geographic “state” parameter. Based on a tMRCA of 130 years, as 
calculated for the full-length genome the mutation rate for the S-gene strains would 
correspond to about 7x10-5 s/s/y, (126 years tMRCA), while inclusion of the 
geographic parameter would increase the timeframe to about 156 years tMRCA. 
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4.2 Geographic distribution of HBV/E 
Phylogeographic analyses of both the S-gene and full-length dataset showed that 
HBV/E strains formed several clusters. Interestingly, strains from individual countries did 
not necessarily cluster together, while strains sampled within one country at different 
time points could be found in the same, but also in different clusters (Figure 19, Figure 
20). The analysis furthermore revealed a putative origin of HBV/E in the area of 
Nigeria. This is supported by spatial phylogenetic reconstruction, that revealed a 
clustering of HBV/E primarily in the region of Nigeria and a putative spread along the 
West African coast and to Angola, Congo DRC and the Sudan (Figure 21). 
4.3 HBV/E population growth 
The low genetic diversity and wide spread of HBV/E variants in sub-Saharan Africa 
suggests a rapid and recent increase in the number of HBV/E infections. Indeed, 
Bayesian skyline analyses of S-gene strains show a rapid population expansion over 
time. Based on a mutation rate of 7x10-5 s/s/y, corresponding to approximately 130 
years of evolution from a MRCA, the most significant expansion of HBV/E infections 
would have occurred from the 1880s until the 1930s (Figure 22). This rapid expansion is 
furthermore supported by the star-like topology of the median-joining network (MJN) 
analysis (Figure 23). The central clustering of strains originating most prominently from 
Nigeria and Guinea, countries that are several thousand kilometers apart, indicate a 
recent and rapid spread of HBV/E. Haiti, in contrast, does not show a central 
clustering but rather monophyletic clades with a tMRCA of 62,4 and 55,9 years.  
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Figure 19: Phylogenetic analyses of all available HBV/E S-gene sequences, using the 
GTR+G+I model with geographic information. 
Branching and roots of strains from individual countries are indicated by colors. 
Clusters with strains sampled in the same country and during the same year are 
collapsed.  
Results and Discussion Part 4 
 
87 
 
Figure 20: Phylogenetic analyses of all available HBV/E full-length sequences, using 
the GTR+G+I model with geographic information.  
Branching and roots of strains from individual countries are indicated by colors. 
Clusters with strains sampled in the same country and during the same year are 
collapsed. 
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Figure 21: Schematic representation of the phylogeographic spread of HBV/E. 
Geographic and temporal spread of HBV/E strains for which the S-gene sequence is 
available, using a mutation rate of 7x10-5 s/s/y with the GTR+G+I model with 
geographic information.  
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5 Discussion 
We performed extensive phylogenetic as well as phylogeographic analyses to 
characterize the origin and evolution of HBV/E. Such studies have obvious limitations 
due to sampling bias, since sampling is necessarily fragmented and incomplete. 
Nevertheless, under these assumptions, and including all available HBV/E strains, our 
analyses suggest a putative origin of HBV/E in what is today Nigeria, irrespective of 
whether the S-gene or the full-length dataset was analyzed. This finding is robust 
even when the oldest sequences from Nigeria are removed (data not shown). From 
this region the virus seems to have spread along the West African coast in the region 
from Guinea to the Central African Republic and subsequently towards Eastern and 
Southern countries, such as Sudan, Angola and the Democratic Republic of the 
Congo (Figure 19, Figure 20).  
Median-joining network (MJN) analysis of this pool of genetically similar or even 
identical viral variants, which circulate all over sub-Saharan Africa, reveals a star-like 
topology, indicating a centralized origin of HBV/E (Figure 23). While the MJN analysis 
cannot give information on the temporal spread of HBV in Africa, the tight clustering 
of strains from distant countries several thousand kilometers apart, with sequences 
from Nigeria and Guinea dominating in the center of the MJN, further support a 
recent and rapid spread in countries along the West African coast. Indeed, Bayesian 
analyses revealed a median time of evolution from a most recent common ancestor 
(tMRCA) of 130 years, with a substitution rate of 1.9x10-4 substitutions per site and year 
(s/s/y). 
In contrast to most other studies these values were based on an approach with 
limited priors to avoid unnecessary biases. In particular, we did not assume a specific 
time of evolution or mutation rate. This, together with the limited sampling period (13 
years), would explain to a large extend the high confidence interval (36-441 years) of 
the 130 years tMRCA. 
The uncertainty introduced by the high confidence interval is difficult to overcome 
by computational methods without the possibility of a deeper calibration with older 
viral strains. However, since HBV is transmitted by chronic carriers from generation to 
generation, our earlier HBV study from Haiti with its large population of descendants 
of African slaves provides additional independent clues. While the prevalence of 
HBV/E was conspicuously low in Haiti (6.1%) (8), the 10 S-genes of HBV/E strains were 
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interspersed within the African strains clustering with strains from Nigeria and Mali. 
They seemed to be the result of multiple introductions only after the HBV/E spread 
along the West African coast (Figure 19), with an observed tMRCA of the 
monophyletic Haitian clades of 62.4 and 55.9 years based on the above substitution 
rate of 1.9x10-4 s/s/y. These recent introductions are supported by the low variability in 
the different HBV/E cluster from Haiti in the phylogenetic tree. In contrast to strains 
from Africa that form regional clusters, strains from Haiti do not cluster together, but 
seem to originate from different African cluster and even from different countries, 
supporting the conclusion that individual HBV/E strains would have been introduced 
to Haiti only recently. This, as well as the only rare strains of HBV/E detected in the 
Americas (6), indicates that HBV/E was introduced and also spread in the general 
West-African population only recently and after the end of the transatlantic slave 
trade.  
The only recent introduction of HBV/E into the general West-African population is 
furthermore supported by Bayesian skyline analyses that indicate an extensive 
increase in effective numbers of HBV/E infections (Figure 22) and is indicative of a 
recent and rapid spread of the virus explaining today’s hyperendemicity in this 
region. 
 
Figure 22: Bayesian skyline plot showing the epidemic history of the HBV/E S-gene 
dataset.  
The plot indicates the median estimate of the effective population size, with the 95% 
highest posterior density indicated in blue. The applied timeframe ranges between 
the most recent sampling date and the calculated 130 years of evolution from the 
most recent common ancestor, as calculated in the HBV/E full-length analysis.  
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Figure 23: Median-joining Network of HBV/E S-gene sequences.  
Pie charts represent sequence variants at the nodes, with colors indicating the 
country of sampling of individual sequences, the sizes reflecting the frequencies of 
the corresponding variants.  
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Previous studies estimated substitution rates of 7.72x10-4 s/s/y for HBV in general (327) 
and 3.2x10-4 to 4.3x10-4 s/s/y when analyzing individual HBV genotypes (5, 327). The 
latter substitution rates are comparable with those observed for HBV/E in our study. 
However, a recent study by Paraskevis et al. linked the evolution of HBV worldwide to 
human migratory patterns (229). The authors suggest that HBV co-expanded and co-
migrated with human populations within the last 34,000 years and estimated a long-
term substitution rate of 2.2x10-6 s/s/y for HBV in general and a tMRCA for HBV/E in 
Africa to be 6000 years (95% HPD: 3200 – 9400 years).  
When applying their substitution rate to our HBV/E S-gene dataset, we found a 
tMRCA of 3717 years. This is, however, nowhere close to the 130 years of evolution 
observed in our study and is also incompatible with the absence of HBV/E in other 
parts of the world.  
While methodological differences, such as the use of the S-gene or the full-length 
genome or differences in datasets may explain some of this discrepancy, biological 
considerations are equally important. Paraskevis et al. base their analyses on a 
limited dataset of selected S-genes of all HBV sub-/genotypes in order to infer a long-
term substitution rate. In order to minimize mutational saturation, a conserved region 
may be appropriate for the study of long-term evolution, but not for HBV/E in Africa 
and for the estimation of (short-term) substitution rates. Because of the observed low 
genetic variability of HBV/E and because the S-gene does not fully represent the HBV 
variability (e.g. HBV genotypes and subgenotypes are defined on the basis of the 
full-length genome (147, 148)), our analyses on the full-length genome more closely 
reflect the time of evolution of HBV/E. Nevertheless, our results could at least be 
partially reconciled with those of Paraskevis et al. assuming that since its separation 
from the most closely related genotype D, HBV/E was confined for thousands of 
years to an isolated population from where it would have spread to the general West 
African population only 100 to 200 years ago.  
In fact, based on a tMRCA of 130 years, the most prominent increase of HBV/E 
infections would have occurred approximately until the 1930s (Figure 22). As HBV is 
transmitted not only sexually, but also through percutaneous or parenteral contact 
with infected blood and body fluids (306), mass injection campaigns that became 
popular at the time provided a new route of transmission that may have 
disseminated the virus with unprecedented efficiency in the late 19th century and 
Results and Discussion Part 4 
 
93 
well into the 20th century. Indeed, the above timeframe coincides largely with unsafe 
mass public health campaigns that were performed in sub-Saharan Africa at that 
time, such as smallpox vaccinations (111), treatment campaigns, e.g. against yaws 
and leishmaniasis (77, 266) and prophylactic injection campaigns against sleeping 
sickness (89). Even later the extensive use of injectable antibiotics, vaccines (e.g. 
against smallpox), and other drugs (e.g. against syphilis) with unsafe needles may 
have further promoted the transmission of HBV (77, 84, 232, 266).  
The medical health campaigns, some even lasting into the second half of the 20th 
century, seem to be in contradiction with a saturation of the HBV/E population 
growth after the 1930s, as estimated in the skyline analysis. However, while an 
extensive spread in a (largely) HBV-naive region would lead to a rapid expansion of 
the overall viral population, the increasing prevalence of acute and chronic HBV 
carriers would subsequently result in a reduction of HBV-susceptible hosts which 
would, at least partially, explain a stabilization of the viral population despite 
continuing (local) transmissions.  
Efficient horizontal transmission would accelerate viral replication and contribute to 
the high substitution rate observed. While the rapid spread of HBV/E can be 
explained by efficient horizontal transmission whether sexually, by unsafe mass 
injection campaigns or other practices, the current high contemporary prevalence 
of chronic carriers would be indicative of a high infection rate during early 
childhood. 
While our study cannot provide a clear origin of HBV/E in Western Africa, Bayesian 
MCMC analyses corroborate a massive transmission and rapid expansion of HBV/E in 
the last 130 years. This is supported by MJN and skyline analyses, which showed a 
rapid increase of HBV/E infections, approximately until the 1930s. These results are in 
line with the low genetic diversity, the high prevalence of HBV/E in Africa and its 
absence in other parts of the world, indicating that the hyperendemicity of HBV in 
Western Africa is a recent phenomenon and likely due to dramatic changes in the 
routes of transmission in a relatively recent past. 
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Part 5: Characterization of Hepatitis Delta Virus in Sub-Saharan 
Africa 
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Hepatitis D virus (HDV), a negative-strand RNA virus of 1.7kb size, is associated with 
hepatitis B virus (HBV) infection. Worldwide, about 15 million HBsAg carriers are 
estimated to be also infected with HDV (285). The co-infection with these two viruses 
results in fulminant hepatitis more frequently than HBV infection alone, whereas 
super-infection of HBV with HDV is associated with chronicity of HDV in up to 80% of 
carriers (310). 
Of the eight distinct HDV clades (158, 241), clade 1 is the most prevalent clade 
worldwide and prevails in Africa, the Mediterranean basin, the Middle East as well as 
in Central and Northern Asia (73, 86, 118, 157). Clades 2 and 4 have so far been 
described in East and North-East Asia, with Clade 2 also present in the Yakutia region 
in Russia (121, 122, 312). Clade 3 has only been detected in South America (53). 
Clades 5 to 8 on the other hand have recently been described in West Africa and 
individuals that migrated to West Europe from this region (158, 178, 241). In this region 
HBV is highly endemic (6, 104, 147, 178, 197) and early childhood transmission is 
thought to be the most important route of infection (48). While this results in a high 
proportion of chronic HBV carriers, high rates of subsequent HDV super-infections 
add considerably to the burden of chronic liver disease (307). 
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Here, we analysed samples from Burkina Faso, the Central African Republic, Chad 
and Nigeria, where so far only rare and limited studies had been performed to assess 
HDV prevalence in HBV chronic carriers (159, 213). We analysed more than 2000 sera 
from these countries to determine the seroprevalence of HBV and HDV infection 
among different cohorts and analysed the genetic diversity and spread of HBV and 
HDV variants. 
1 Clinical samples 
Serum samples were obtained from apparently healthy individuals (Burkina Faso, 
Chad, Central African Republic), patients with symptomatic liver disease (Nigeria, 
Central African Republic) and HIV-positive individuals (Nigeria) between 1998 and 
2010. These were stored at -80°C. The characteristics of the donors are shown in 
Table 15. All analyses have been approved by the competent ethical committees in 
each of the participating countries. 
2 Serology 
Hepatitis B surface antigen (HBsAg) was tested using either the Murex HBsAg Ver3 
ELISA (samples from Burkina Faso, Nigeria, Central African Republic) or the Smart 
Check HBsAg Test) (Nigeria). Hepatitis D virus antibodies (HDV-Ab) status was 
determined using the Murex anti-Delta or the ETI-AB-DELTAK-2 ELISA. Equivocal 
samples were, if possible, retested and the result of the second test was accepted.  
3 RNA and DNA isolation, RT-PCR, PCR and sequencing 
RNA was extracted using the QIAamp Viral RNA Mini Kit. RNA was reverse transcribed 
into DNA and the complete genome was amplified in three overlapping fragments, 
covering nucleotides 307-870, 715-1302 and 868-483, respectively.  
HDV quantification was performed, using 5μl of cDNA template material and the 
TaqMan PCR product of sample 36286 was cloned, using the TOPO-TA cloning kit. 
Concentrations were measured using the ND-1000 spectrophotometer and copy 
numbers were calculated. A 10fold dilution series of the plasmid, ranging from 107 to 
10 copies, was used as a standard in the quantification reaction. In all reactions, 
correlation coefficient of the standard series was above 0.998.  
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HBV DNA was extracted from HDV TaqMan PCR positive sera of sufficient volume, 
using the QIAamp DNA Blood Mini Kit. HBV genotyping was performed on at least 
one of the HBV preS, S, X and C-gene regions. Quantitative real-time PCR was 
performed on 5μl of the extracted DNA and compared to a 10fold dilution series of 
WHO International standard 97/750.  
4 Phylogenetic Analysis 
Raw sequences were edited using SeqScape®, aligned with the L-INS-i option of 
MAFFT v6 and manually corrected. Neighbor-Joining trees and genetic distances 
were calculated using the MEGA 5 software. Statistical tests were performed using 
SigmaStat v3.11. All HDV full-length strains available on NCBI GenBank (accessed in 
June 2012) were included in the analysis.  
Sequences were submitted to EMBL/GenBank/DDGJ under accession numbers 
JX888098-JX888135. 
5 Results 
5.1 Hepatitis B surface antigen serology 
Of 2,273 leftover serum samples from apparently healthy adults (Burkina Faso, 
Tchad), children (Burkina Faso, Central African Republic), patients with symptomatic 
liver disease (Nigeria, Central African Republic) and HIV-positive individuals (Nigeria), 
2,145 samples were tested for HBsAg, while for the remaining 128 there was not 
sufficient serum available for this test. 743 of the 2,145 were HBsAg positive, while 3 
were equivocal and excluded from prevalence calculations.  
The observed HBsAg seroprevalence rates ranged from 12.2% in children from 
Burkina Faso up to 81.7% in a liver patient cohort from Nigeria (Table 15). While the 
HBsAg prevalence was similar in healthy adults from Burkina Faso (14.5%, cohort size 
n=337 and 16.2%, n=370) and HIV-positive donors from Nigeria (14.6%, n=308 and 
15.9%, n=69), it was different in children from Burkina Faso (12.2%, n=424) and the 
Central African Republic (44.3%, n=79). Interestingly, the latter was similar to the 
prevalence observed in liver patients from the same country (48.3%, n=29), while 
even higher prevalences were found in liver patients from Nigeria (62.9%, n=70 and 
81.7%, n=126) (Table 15). 
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Table 15: Prevalences of hepatitis B surface antigen (HBsAg), hepatitis D antibodies (HDV-Ab) and hepatitis D RNA in cohorts from 
different West and Central African countries. 
 
    
HBV/HDV prevalence (no. positive/total. (%)) 
Country Sampling location (year) Cohort 
Cohort 
size (no.) HBsAg HDV-Ab* HDV RNA** 
Burkina Faso Bobo-Dioulasso (2001) Mothers 370 60/370 (16.2%) 1/40 (2.5%) 0/1 (0%) 
 
Bobo-Dioulasso (2001) Children 424 52/424 (12.2%) 9/44 (20.5%) 0/9 (0%) 
 
Bobo-Dioulasso, Houndé (2007) Pregnant women 337 49/337 (14.5%) 0/49 (0%) - 
Nigeria Ibadan (1998) HIV+ 106 11/69 (15.9%) 3/11 (27.3%) 0/3 (0%) 
 
Lagos (2004) HIV+ 319 45/308 (14.6%) 3/45 (6.7%) 2/3 (66.7%) 
 
Ibadan (2003) Liver patients 93 44/70 (62.9%) 3/44 (6.8%) 0/3 (0%) 
 
Ibadan (2006) Liver patients 126 103/126 (81.7%) 1/78 (1.3%) 1/1 (100%) 
 
Abuja, Nasarawa state (2006) HBsAg+ 330 - 40/326 (12.3%) 15/40 (37.5%) 
Chad Military camp (2007) Military personnel 50 14/50 (28%)*** - 3/14 (21.4%)*** 
Central 
African 
Republic Bangui (2007) Children 81 35/79 (44.3%) 1/35 (2.9%) 0/1 (0%) 
 
Bangui (2009) Liver patients 37 14/29 (48.3%) 7/14 (50%) 5/7 (71.4%) 
* Prevalence among HBsAg-positive samples, excluding equivocal samples. 
** Prevalence among HBsAg-positive, HDV-Ab positive samples. 
*** Prevalence calculations based on HBV and HDV TaqMan PCR. Samples positive for at least one assay were considered HBV positive. 
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One-hundred-twenty-eight sera were not tested with HBsAg ELISA but the burden of 
infection was assessed using the results from the HDV-Ab ELISA and the quantitative 
HBV and HDV PCRs. In particular, none of the 50 sera from Chadian military personnel 
were tested for HBsAg. 
Among these 50 sera from the Chad, 13 were found to be HBV DNA positive while 
one HBV DNA negative sample was HDV RNA positive, resulting in an overall HBV 
prevalence of 28% (14/50) in the Chad (Table 15). 
5.2 HDV-Ab serology 
HDV-Ab ELISA was performed on 695 of the 743 HBsAg positive sera and 98 of the 128 
sera that had not been tested for HBsAg. The remaining 48 and 30 sera could not be 
screened with HDV-Ab ELISA due to low sample volume. 68 of the 695 HBsAg positive 
and 3 of the 98 sera of unknown HBsAg status were HDV-Ab positive, while 9 and 1, 
respectively, were equivocal and excluded from prevalence calculations.  
The HDV-Ab prevalences among HBsAg-positive sera from the different cohorts 
varied substantially (Table 15). They ranged from 0% in pregnant women (n=49) from 
Burkina Faso to 50% in liver patients (n=14) from the Central African Republic (Table 
10). In Burkina Faso, the HDV-Ab prevalence in healthy adults (n=49 and 60) was 
generally low (0% and 2.5%), while a surprising 20.5% of children (n=44) were found to 
be positive. In the Central African Republic in contrast, the HDV-Ab prevalence was 
low in children (2.9%, n=35), while 50% of HBsAg-positive liver patients (n=14) (plus one 
of unknown HBsAg status) had antibodies against HDV (Table 10). 
Also in Nigeria, HDV-Ab prevalences varied between the different cohorts (Table 15). 
In HIV-positive/HBsAg-positive donors from Lagos (n=45) and Ibadan (n=11) 6.7% and 
27.3% were HDV-Ab positive, while in liver patients from Ibadan (n=78 and n=44) 
HDV-Ab were only found in 1.3% (plus one HBsAg-negative patient) and 6.8% of 
patients. A HDV-Ab prevalence of 12.3% was furthermore found in HBsAg positive 
sera from Abuja and Nasarawa state. 
Of 50 sera from the Chad, none of which was analysed for HBsAg, 31 were screened 
for HDV-Ab, while the remaining 19 were directly subjected to RNA extraction. 2 of 
the 31 unselected samples (6.5%) were found to be HDV-Ab positive. All HDV-Ab 
positive samples and 30 untested samples underwent RNA extraction. 
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5.3 HDV quantification and genotyping 
HDV quantification of 88 samples with complete HBsAg and HDV serology and 40 
samples with incomplete or missing serology revealed 24 and 4 samples to be 
positive for HDV RNA. The viral load (detection limit: 1x103 copies/ml serum) of the 28 
HDV TaqMan positive samples ranged from 8.36×103 to 1.63×109 copies/ml without 
notable geographic differences in RNA titers. 
22 of the HDV TaqMan positive samples, as well as 2 that were repeatedly TaqMan 
negative, were PCR positive for at least one HDV fragment. Fragment 307-870 was 
obtained for 19 samples (and partially for 3 samples), fragment 715-1302 for 21 
samples and fragment 868-483 for 18 samples (plus 3 partial fragments). Taken 
together, the region 907-1265, commonly used for genotyping, was obtained for 22 
samples and for 19 of these the complete L-HDAg ORF (nucleotide 954-1598) was 
available (and partially for 1 sample lacking 21nt). For a total of 16 samples, the full 
HDV genome was obtained. All 24 strains could be genotyped and revealed a 
predominance of clade 1 (17/24, 71%) and the presence of clades 5 (5/24, 21%) and 
6 (2/24, 8%) in this study.  
Clade 1 strains were found in sera from Nigeria (8/15, 53%), the Central African 
Republic (6/6, 100%) and Chad (3/3, 100%), while clades 5 (5/15, 33%) and 6 (2/15, 13 
%) were exclusively found in Nigeria.  
5.3.1 Phylogenetic analysis of HDV 
Phylogenetic analyses of all available 87 HDV-1 full-length genome sequences from 
public databases (including the 12 strains from this study) revealed that HDV-1 
formed multiple clusters in the phylogenetic tree (Figure 24). Interestingly, one cluster 
consisted of strains from all over the world, while 2 smaller clusters contained 
predominantly African strains, including our analysed strains (Figure 24). This apparent 
segregation of clade 1 could however not be clearly reproduced when analysing 
only the region nt 907-1265, typically used for HDV genotyping (Figure 25). 
Furthermore, the genetic variability of the “African” clusters (12.7% and 14% mean 
genetic diversity; 18.1% and 18.8% maximum genetic distance) was similar to the one 
observed among the other HDV-1 strains (12.8% mean; 21.3% maximum). The overall 
HDV-1 mean genetic diversity was 15.2% (23.4% maximum genetic distance). 
Clade 5 was found in 33% of genotyped strains, but exclusively in samples from 
Nigeria. These formed a separate cluster apart from the other West African clade 5 
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strains (Figure 24 ,Figure 25). The overall mean intra-clade diversity of the full-length 
strains was 13% (16.9% maximum genetic distance). The intra-group diversity of the 
subgroups varied and was 3.9% (4.6% maximum genetic distance) in the Nigerian 
cluster and 12.8% (16.9% maximum genetic distance) in the remaining strains. 
Also our two clade 6 strains from Nigeria clustered with a Nigerian (Figure 24 ,Figure 
25). Analysing all HDV-6 sequences, we found a mean genetic diversity of 11.9% 
(14.6% maximum genetic distance). 
 
Figure 24: Phylogenetic clustering of all available HDV full-length strains.  
Strains from this study are indicated by diamonds. Scale bar indicates nucleotide 
substitutions per site.  
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Figure 25: Phylogenetic analysis of the HDV genotyping region 907-1265 with 
reference sequences for which the full-length genome was available. 
Diamonds indicate strains obtained in this study. Strains from this study for which the 
full-length sequence is available are indicated by solid diamonds. Scale bar 
indicates nucleotide substitutions per site.  
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5.4 Hepatitis B Virus quantification and genotyping 
HBV quantification was performed in 23 samples with a known HDV genotype. In 11 
of these (47.8%) HBV was undetectable, while in the remaining 12 samples 2.51x103 to 
5.32x109 HBV copies/ml were detected. In 4 of these, the HBV load was even higher 
than that of HDV. 
In 58.8% (10/17) of the HDV-1 positive sera, HBV was detectable, while in only 20% 
(1/5) of HDV-5 positive sera HBV DNA was found. HDV-1 positive sera seemed to have 
a higher HBV load (mean 4.79x108 copies/ml; median 2.92x103 copies/ml) than HDV-5 
sera (mean 2.48x103 copies/ml; median 0 copies/ml), although not statistically 
significant (p=0.311, Fisher’s Exact Test). Furthermore, one HDV-6 sample was found to 
have 4.12x103 HBV copies/ml. 
Although HBV genotyping proved difficult due to the low viral load, seven HDV 
sequences were correlated to HBV genotypes. HBV-E and HDV-1 were found in 4 of 
the 7, while HBV-A/HDV-1, HBV-D/HDV-1 and HBV-E/HDV-6 were observed in one 
sample each. 
5.5 Hepatitis Delta Antigen 
Nineteen samples, for which the full HDAg ORF was obtained, were further 
characterized on the amino acid (AA) level. For 17 of these, the large HDAg was 214 
AA long, while one sample each harboured an insertion (59045) or a deletion (36036) 
of one amino acid. For none of the strains a change in the reading frame was 
observed.  
Clade 1 had been previously described to have higher virus assembly efficiency than 
other clades (160, 262). Indeed, all our clade-1 strains harboured proline 205, while in 
strains of the other clades arginine was found in this position. Similarly, the clathrin 
box, thought to be important for virion packaging (112, 113), varied between clade 
1 (LFPSD) and our strains of the other clades (LPLLE). Furthermore, the isoprenylation 
signal, important for virion maturation (113), was CRPQ in clade 1 and CTPQ in our 
non-HDV-1 strains. 
In addition AA 202 had been proposed as a marker to characterize the geographic 
origin of HDV-1 and was shown to largely vary between strains with African (serine 
202) or Eurasian (arginine 202) origin (157). Indeed, our clade 1 strains revealed a 
serine at this position, except one strain from the Chad that had a proline 202. 
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6 Discussion 
In the present study we characterized samples from Burkina Faso, the CAR and the 
Chad, from where no HDV data are available, as well as from Nigeria and 
characterized, for the first time, HDV strains from these countries. As only 34 HDV full 
length strains from Africa are publicly available, our 16 full-genome sequences 
considerably enlarge the genotype information from this continent.  
In all our analysed cohorts HBsAg was highly endemic., but its prevalence varied 
widely, ranging from 12.2% in apparently healthy to 81.7% in symptomatic liver 
patients. Although it is difficult to compare the different cohorts, the HBsAg 
prevalence was similar in healthy adults and HIV carrier from Burkina Faso and 
Nigeria (14.5%-16.2%), while differences were substantial between children from 
Burkina Faso (12.2%) and the Central African Republic (44.3%). Although the cohort 
from the Central African Republic included children with a higher age (2-15 years) 
than in Burkina Faso (2-6 years), HBsAg prevalences in children from the Central 
African Republic were relatively constant and higher than 40%, irrespective of the 
age group analysed (2-5, 6-10 or >10 years of age), indicating a high burden and an 
increased early transmission of HBV in children from the Central African Republic. This 
high prevalence is however surprising, as HBsAg prevalences had previously been 
found to be 14% and 15.5% in young adults and high school students in the Central 
African Republic (144, 230). Furthermore, the observed HBV prevalence in the 
children was almost as high as in liver patients from the same country (48.3%), 
indicating an unusual route of transmission for the investigated group of children. 
Also in military personnel from the Republic of Chad a high HBV prevalence of 28% 
was observed. As the HBV burden in the Chadian cohort was estimated based on 
HBV DNA and HDV RNA positivity, the HBV prevalence may even be underestimated 
in this group. Although generally military personnel seem to have higher HBV 
infection rates than unselected populations (181), HBV seems to be highly endemic 
in the Chad. 
The rare recent studies that had been performed to assess the prevalence of HDV 
antibodies in the West African population, revealed varying HDV infection rates. 
While HDV-Ab prevalence in HBsAg carriers had been found to be below 20% in 
Cameroon and Mauretania (86, 181), it was found to reach up to about 70% in 
Gabon (178). Interestingly, also the HDV-Ab prevalences observed in our study varied 
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widely and ranged from 0% to 27.3% in asymptomatic carriers and 1.3% to 50% in liver 
patients. Surprisingly, 20.5% of HBsAg-positive children from Burkina Faso (12.2% HBsAg 
prevalence) were also HDV-Ab positive, a prevalence almost 10-times higher than 
the one observed in the mothers. These children are at high risk to develop severe 
fulminant or chronic hepatitis. Vast HDV-Ab differences were furthermore observed in 
liver patients from Nigeria and the Central African Republic. While in Nigeria a large 
proportion of liver patients were HBsAg positive, only 1.3% and 6.8% of these were 
HDV-Ab positive, with prevalences similar or lower than those observed in the other 
Nigerian cohorts (6.7%-27.3% HDV-Ab prevalence). On the other hand, 50% of liver 
patients from the Central African Republic were HDV-Ab positive, indicating that in 
the Central African Republic, in contrast to Nigeria, HDV super-infection might be the 
cause of chronic hepatitis with frequent severe liver conditions. 
The HDV viral load varied widely in the analysed samples ranging from 103 to 109 
copies/ml. As infection with HDV suppresses HBV replication, HBV was undetectable 
in almost 50% (11/23) of HDV RNA positive donors. This would however not necessarily 
be the result of a more efficient HDV replication, as these samples had an only 
slightly higher HDV load (mean 3.68x108 copies/ml, median 3.18x107 copies/ml) than 
the HBV DNA positive ones (12/23; mean 1.54x108 copies/ml, median 1.06x107 
copies/ml). While on average a higher HDV load was observed in clade 1 strains 
(mean 2.5x108 copies/ml, median 1.3x107 copies/ml) than in clade 5 (mean 4.19x107 
copies/ml, median 8.98x106 copies/ml) or clade 6 strains (mean and median 5.9x106 
copies/ml), the low numbers of clade 5 and 6 strains may not be representative 
enough. In fact, 71% (n=17/24) of the genotyped strains were assigned to clade 1, 
with strains originating from Nigeria, the Central African Republic and the Chad. 
Furthermore, 21% and 8% of our strains belonged to clade 5 (n=5/24) and clade 6 
(n=2/24), respectively, all of these strains originating from Nigeria. 
Phylogenetic analysis of HDV-1 strains revealed several clusters, although not 
necessarily with high bootstrap support, with strains from this study largely clustering 
together with other African strains (Figure 24). While previous studies indicated an 
ancestral origin of clade 1 strains in Africa (324), the genetic diversity of HDV-1 was 
similar in the African clusters (12.7% and 14% mean genetic diversity; 18.1% and 18.8% 
maximum genetic distance) as well as among the other (non-African) HDV-1 strains 
(12.8% mean; 21.3% maximum). A recent study identified an amino acid on the 
HDAg to distinguish between isolates of African (serine 202) and Eurasian (alanine 
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202) origin(159). Indeed, almost all our clade 1 strains revealed a serine 202 in the 
HDAg, supporting the hypothesis that at least the majority of African HDV-1 isolates 
might represent an ancient subgroup that originated from this continent. Together 
with the recently characterized HDV clades 5 to 8 (158, 241), HDV sequences are 
overall more divergent in Africa than anywhere else in the world (113), indicating 
that, similar to hepatitis B virus, HDV might have originated in Africa (241, 286). 
Nevertheless, the origin and emergence of HDV remains unclear. While it has been 
discussed that HDV might have co-originated with the most simple hepatitis B virus in 
ducks (DHBV), HDV has so far not been found to naturally occur in ducks or in 
mammals beside humans (112), indicating that HDV might have originated in 
ancestral humans, potentially from Africa.  
All studies on HDV in sub-Saharan Africa revealed a predominance of HDV-1 in a 
region where HBV genotype E (and to a lower extent the African HBV/A 
subgenotypes 3 to 7) prevails. However, a close co-evolution of HDV-1 and HBV/E 
seems unlikely, since HDV-1 can be found worldwide whereas HBV/E is largely 
confined to Africa. A recent study in Turkey found that all HDV-1 variants were 
associated with HBV genotype D (157). More than 50% of these belonged to the 
putative African group (serine-202), while the remaining strains harboured alanine-
202 and clustered in the Eurasian group (157). The high prevalence of HDV-1 might 
however be explained by a more efficient spread of this clade. Indeed, HDV-1 
displays some unique nucleotide and amino acid features in the large HDAg when 
compared with the other HDV clades, potentially leading to more efficient viral 
reproduction (262). However, this is speculative and requires additional detailed 
studies.  
In conclusion, our study revealed high prevalences of both HBV and HDV in multiple 
countries and cohorts from sub-Saharan Africa. Although the prevalences varied in 
the different cohorts, HDV superinfection was excessively high in cohorts with severe 
chronic hepatitis, while others were virtually free of HDV. The high variability between 
individual cohorts and countries indicates that HDV evolution is very complex. While 
especially clade 1 seems to originate from Africa, a co-evolution with the 
predominant HBV genotype E in this region is unlikely. Nevertheless, in a large 
proportion of cohorts analysed here, HDV represent a serious public healthcare 
problem, calling for an increased screening for HDV antibodies and extensive 
vaccination against HBV in this region. 
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Part 6: A High Variability of Mixed Infections and Recent 
Recombinations of Hepatitis B Virus in Laos 
 
This manuscript has been published as: 
 
Andernach IE, Jutavijittum P, Samountry B, Yousukh A, Thammavong T, Hübschen J, 
Muller CP. A High Variability of Mixed Infections and Recent Recombinations of 
Hepatitis B Virus in Laos. PloS One. 2012;7(2):e30245. 
 
I.E. Andernach contributed significantly to the study design and was in charge of the 
experimental setup, experimental work, data analysis and writing of the manuscript. 
 
In highly endemic countries, particularly in Asia where hepatitis B virus (HBV) 
genotypes B, C and I and their subgenotypes co-circulate, mixed infections (18, 114, 
162, 168) and recombinations have been described (38, 41, 67, 195, 220, 265, 303, 
314). For instance, in China almost 50% of infections are mixed (114) and mixed 
infections have also been reported from Thailand (124). 
Recombination events do not seem to be negligible artefacts of HBV co-infections, 
as recombinant strains have become the dominant variant in certain regions. For 
example subgenotype Ba, a B/C recombinant, prevails in major parts of mainland 
Asia, and a recombinant between genotypes C and D has become the 
predominant variant in Tibet (67). Furthermore, recently a recombinant variant that 
circulates in Laos and Vietnam has been proposed as a new HBV genotype I (106, 
220, 248, 294). Nevertheless, only few systematic studies of HBV recombinants have 
been published from regions with intensive co-circulation of several HBV 
subgenotypes (220, 274, 303). 
In Laos, with 8.7% of chronic carriers (126), multiple HBV sub-/genotypes co-circulate 
(220) and were shown to belong to genotype C (55.4%), with subgenotypes C1 
(93.1% of genotype C strains), C5 (6.4%) and C3 (0.5%), genotype B (42.2%), with 
subgenotypes B4 (78.5% of genotype B strains), B2 (11%), B5 (9.8%) and B3 (0.6%) and 
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the suggested genotype I (2.4%), with subgenotypes I1 and I2 (220). As a result of the 
high prevalence of chronic HBV carriers and the co-circulation of multiple genotypes 
and subgenotypes, Laos is prone to generate recombinant viruses. Here, we 
systematically analysed mixed infections and recombinations in 42 HBV strains from 
HBsAg positive first time blood donors. Our study revealed an unusual cauldron of 
mixed infections as a breeding ground of multiple and highly variable recombination 
events that so far have not led to new dominant strains. 
1 Clinical samples 
DNA was extracted using the QIAGEN DNA Blood Mini Kit, from sera of 40 HBsAg 
positive, but otherwise healthy, rejected first time blood donors from Vientiane City 
and Central provinces of Laos (collected in 2004/2005) and of 2 donors from the 
North of Laos (2006). 
2 Amplification and cloning 
The HBV S gene was amplified, using forward primer P2f  and reverse primer 979. PCR 
products were cloned, using the TOPO TA cloning kit. Bacteria were plated onto 
Luria-Bertani-Broth agar plates, in the presence of kanamycin and X-Gal. White 
colonies were picked and inserts were amplified by colony-PCR using M13fw  and 
M13rv primers. 
3 Sequencing and phylogenetic analysis 
The M13 PCR products, with 10 to 31 clones per donor, were purified and sequenced 
as described before (221) with above primers. Phylogenetic analysis and distance 
calculations were performed, using the MEGA v.4 with the neighbour-joining method 
of the Kimura 2-parameter model and a  value of 0.6, with 1,000 bootstrap 
replicates. Sequences were submitted to EMBL/GenBank/DDBJ under accession 
numbers: HE652134 - HE652863. 
4 Recombination analysis 
Bootscan analyses were performed using SimPlot v.3.5.1 with a window size of 200 bp 
and a step size of 20 bp. Recombination breakpoints were confirmed by comparing 
each recombinant sequence with consensus sequences with a threshold of 50% for 
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inclusion in the consensus nucleotide sequence (consensus-50) (265) of 
subgenotypes B1-B8, C1-C7 and I1, I2. Of these, the subgenotype B6 consensus-50 
harboured one ambiguous nucleotide. Additionally, consensus-50 sequences of 
genotypes B, C and I were included in the analysis, reconstructed from the 
associated consensus-50 sequences of the above subgenotypes to exclude a bias of 
the differently sized sequence sets available. The individual fragments of the 
potential recombinant strains were confirmed by phylogenetic analyses. 
5 Results 
5.1 Genotypes and subgenotypes 
In 9157 blood donors in Vientiane city and central provinces from 2004 and 2005 the 
HBsAg prevalence was 8.8%. Of the 498 available samples of HBsAg positive blood 
donors, 453 were found to be PCR positive, 446 of them at least for the S gene. 
Sequence analyses of these donors revealed at least 5 ambiguous nucleotides within 
the amplified S gene of 40 donors, indicative of infections with several HBV variants. 
In addition, 2 donors from Luang Prabang in the North of Laos were suspected to be 
mixed infected and included in the analyses. The S gene PCR products from these 42 
donors were further characterized by extensive cloning. Phylogenetic analyses 
revealed that among the 730 clones of these 42 donors, 16 donors had only clones 
of the same subgenotype (Table 16). Of these 16 non-mixed/non-recombined 
samples, strains from 12 donors belonged to subgenotypes B4 and one each to C1, 
and I1. Genotype B strains of the remaining 2 donors could not further be 
subgenotyped (Table 17; nomenclature according to Huy et al. (119)). The Asian 
recombinants, assigned to subgenotype B2-B4 (former Ba), and the proposed 
genotype I are not considered recombinants for the purpose of this study. 
5.1.1 Mixed, non recombinant 
The other 26 donors, or 5.8% of the 446 donors that were PCR positive for the S gene, 
were mixed infected with different variants. For 9 of these donors (14 to 30 clones) all 
clones were clearly assigned to a sub-/genotype, whereas the remaining 17 donors 
(3.8% of the 446 S gene PCR positive donors) had at least one (and up to 27 clones of 
the 10 to 31 clones generated) with signs of a recombination within the S fragment 
(Table 16). In addition, recombination events were detected in 2 strains from Laos 
Results and Discussion Part 6 
109 
already published on NCBI (accession nos. FJ023979, FJ023832) which were included 
in the analyses. 
In the above 9 donors with mixed, non-recombined variants, at least one clone of 7 
of the donors was assigned to genotype C1, while the second sub-/genotype varied 
and belonged to subgenotypes B4 (n=1 donor), C5 (n=1 donor), I2 (n=1 donor), and 
non-subgenotypable genotype B clones (n=2 donors), while for one donor each B1 
and B4, or C5 and B4 was found in addition to C1. For two donors no clone was 
assigned to genotype C and clones were attributed to genotypes B2 and B4 as well 
as B4 and non-subgenotypable B clones (Table 17). 
5.1.2 Mixed, recombinant 
In the other 17 donors with mixed-infections at least one clone showed signs of 
recombinations, and at least one clone showed no such evidence. 16 of these 
donors had non-recombined clones, that were assigned to genotype C, 15 to 
genotype B and 1 to genotype I, with subgenotypes C1 (n=16), C5 (n=1), B4 (n=14) 
and I1 (n=1) (Table 17). Strains of one donor were attributed to genotype C, but 
clustered separately from all HBV/C subgenotypes. Additionally, genotype B clones 
from 3 donors could not be subgenotyped, as the reference strains for genotype B 
subgenotypes B3, B5, B7 and B8 clustered interspersed with each other and the 
investigated strains (Figure 26). 
5.1.3 Deletions and insertions 
The S gene of the 730 clones was 681nt long, except for 7 clones, consisting of 
genotypes C1, B4 and B which contained single nt deletions (3 clones in donors with 
mixed infected, non-recombinant clones and 4 clones in donors with recombinant 
strains). For another 6 clones, consisting of genotypes B4 and B, the S gene sequence 
could not be fully recovered. 
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Table 16: Number of donors suspected to be mixed infected with at least 2 sub-
/genotypes of HBV, Lao PDR. 
Samples  No. donors 
Detection-PCR positive  453 
S-gene PCR positive  446 
Total analyzed/suspected mixed infection  42 
  Non-mixed, non-recombinant  16 
Total mixed  26 
  Mixed, non-recombinant  9 
  Mixed, recombinant 17 
 
Table 17: Sub-/genotypes in HBV mixed infections in Lao PDR. 
Category  Sub-/genotype(s)  No. donors 
Donors suspected/analyzed  n.a.  42 
Non-mixed, non-recombinant donors (n=16) B  2 
  B4  12 
  C1  1 
  I1  1 
Clones in mixed, non-recombinant donors (n=9) B4, B  1 
  B4, B2  1 
  B4, C1  1 
  C1, B  2 
  C1, C5  1 
  C1, I2  1 
  B1, B4, C1  1 
  B4, C1, C5  1 
Clones in mixed, recombinant donors (n=17) B  1 
  B4, B, C1  2 
  C1, C5, B4  1 
  B4, C1  11 
  C1, C  1 
  C1, I1  1 
n.a.=not applicable 
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Figure 26: Phylogenetic clustering of selected HBV/B subgenotype B3, B5, B7 and B8 
strains from GenBank and selected genotype B strains from Laos.  
Non-subgenotypable clones are indicated by red diamonds. Scale bar indicates 
nucleotide substitutions per site.  
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5.2 Control experiments 
Considering the large proportion of recombinant strains detected in this study, we 
performed extensive tests to exclude that there may be recombinants due to PCR or 
other artefacts. Therefore, M13 products of cloned, characterized HBV/B and HBV/C 
strains were mixed in various ratios (1:25, 1:5, 1:1, 5:1 and 25:1) and concentrations (1 
ng and 100 ng total DNA) and amplified using different elongation times (1 min 
elongation as in the study protocol and a reduced elongation time of 20 sec). PCR 
products were cloned by TOPO TA, amplified by M13 PCR and sequenced. In the 1 
min elongation PCR only rare recombinants (<2%, 2/107 clones) were found (Table 
18). Only when the elongation time was reduced to 20 sec the rate of 
recombinations increased to an overall 16% (18/111 clones). At 1 ng final 
concentration and 20 sec elongation 6.4% of clones showed recombinations. This 
increased to 39.4% when using 100 ng template DNA and the short elongation time 
(Table 18). Thus recombinant artefacts seem to depend on high template 
concentrations and short elongation times. 
After PCR amplification of our clinical samples the highest final concentration of PCR 
product before cloning was 154 ng/ul, corresponding to a template starting 
concentration considerably lower than the nanomolar concentrations of DNA 
analysed in the above control experiments. Although we cannot exclude that some 
recombinants may have developed only when the concentration of template 
increased during the later amplification cycles, these recombinants would be 
relatively rare and unlikely to be picked up during the cloning. This confirms that 
under our experimental conditions only very few recombinants (of the observed 9.9% 
of recombinant clones) would be the result of PCR artefacts. We also excluded that 
recombinations may have occurred during cloning. Thus, the observed high 
prevalence of recombinant clones in 65.4% of mixed infected donors is essentially 
free of PCR dependent or other artefacts. 
 
Table 18: Number of PCR-induced recombinant clones in control experiments. 
 Template concentration 
Elongation time 1 ng 100 ng 
20 s 6.41% (5/78 clones)* 39.39 (13/33 clones) 
60 s 2.53% (2/79 clones) 0% (0/28 clones) 
*Clones for each condition originate from HBV/B and HBV/C strains mixed for amplification in 
ratios 1:25, 1:5, 1:1, 5:1 and 25:1.   
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5.3 Distance calculations of non-mixed, non-recombined samples 
Distance calculations were performed in clearly subgenotypable clones of individual 
donors, with at least 5 clones of the respective subgenotype, including only clones 
for which the full S-gene could be recovered. These clones formed quasispecies 
within individual donors and revealed relatively low mean intra-group diversities for 
subgenotypes B2 (0.47%; n=1 donor) and B4 (0.08–0.47%; n=24), subgenotypes C1 
(0.05–0.82%; n=11) and C5 (0.04%; n=1), as well as subgenotypes I1 (0.34%; n=1) and 
I2 (0.25%; n=1). 
5.4 Amino acid analysis of clearly genotypable strains 
The comparison of 651 clearly genotypable strains (excluding the 7 clones with 
nucleotide insertions that were not considered for analyses on the amino acid level) 
with consensus-50 sequences of genotypes B, C and I as well as their subgenotypes 
revealed multiple and variable amino acid (AA) changes over the S protein. 
5.4.1 HBV/B clones 
In 469 HBV/B clones, including the 6 clones of which the S gene sequence could not 
be fully recovered, AA substitutions occurred in 120 of 227 AA positions. In 7 of these 
positions substitution occurred in >5 clones: T27A/I/V (n=7 clones of d=5 donors), 
S61L/A (n=6, d=6), P62L (n=6, d=5), C76Y/R (n=8, d=6), P120S/T/L (n=20, d=14), M133I 
(n=31, d=2), T140I (n=8, d=6). Furthermore, a total of 6 internal stop codons (*) were 
detected. 
5.4.2 HBV/C clones 
In 154 genotype C clones we found AA substitutions in 56/227 positions, with 2 
occurring in >5 clones: I92T (n=11, d=1), T118M/P (n=51, d=15). In the genotype C 
strains, a total of 4 internal stop codons were detected. 
5.4.3 HBV/I clones 
In the 28 genotype I clones, 19/227 AA positions were found to harbour substitutions. 
Due to a lower sample size of HBV/I strains, only 2 AA positions with >1 substitutions 
per site were further characterized. The investigated strains were found to harbour 
P111L/Q (n=2, d=2), I226N (n=12, d=1). In the genotype I strains, a total of 2 internal 
stop codons were detected. 
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5.4.4 Vaccine or treatment associated mutations 
Despite the frequent amino acid substitutions only rare mutants had been described 
previously as vaccine or treatment associated mutations (172, 261, 315), including 
P120T (n=5, d=4), G145R (n=1), W172* (n=2, d=2), W182* (n=2, d=2), L192F (n=1), 
W196* (n=1), M198I (n=18, d=2) and W199* (n=1). 
5.4.5 HBsAg subtypes 
All 4 major HBsAg subtypes, that have been described previously in genotype B and 
C strains from Asia (209), were found among the analysed clones. In the 469 
analysed genotype B strains HBsAg subtype ayw1 predominated (n=444 clones, d=35 
donors), while 18 clones (d=3) were attributed to adw2 and one (d=1) to ayw2. Three 
clones (d=3) harboured 127S and were attributed to ayw. For three additional clones 
no HBsAg subtyping could be performed, as two clones harboured AA substitutions 
122G or 160E and for one clone the HBsAg sequence could not be fully recovered. 
The 154 genotype C strains belonged primarily to subtype adr (n=122, d=25), but also 
to adw2 (n=30, d=4), ayr (n=1, d=1) and ayw1 (n=1, d=1). 
In the 28 genotype I strains on the other hand both adw2 (n=16, d=2) and ayw1 
(n=12, d=1) prevailed. 
5.5 Description of recombinant clones 
A total of 72 recombinant clones were detected in the 42 analysed donors, from 
which 730 clones were generated. In 17 donors at least one recombinant clone was 
detected. All of the 72 recombinant clones exhibited one or two recombination 
site(s) within the S gene and revealed recombinations between genotypes B and C 
(Figure 27). Of the 185 genotypable fragments 72 were assigned to genotype B and 
113 to genotype C. 
In none of the analysed recombinant strains the recombination breakpoint could be 
exactly defined because homologous stretches of at least 17 nt length separated 
the recombined fragments (Figure 27). Interestingly, recombinations occurred all 
over the S-gene: nt 1–170 with 10 recombinant sites, nt 171–510 with 58 recombinant 
sites and nt 511–681 with 45 recombinant sites (Figure 27). For each of the individual 
185 fragments of the 72 cloned recombinants the most similar strains were identified 
by phylogenetic analyses and pairwise comparison with a carefully selected dataset 
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that was composed of all available, clearly subgenotypable full-length genome 
strains from NCBI (accessed 08/2011) and all non-recombinant strains from this study.  
Based on the simplest evolutionary model with a mutation rate of 4.2×10−5 mutations 
per site and year (83), the time of evolution from a hypothetical most recent 
common ancestor (tMRCA) was calculated. For 127 of the 185 fragments a non-
recombinant strain of the same genotype was detected in the same donor. Two of 
the 127 fragments were most closely related (Kimura-2-parameter, pair wise genetic 
distances) to strains of the same donor (0% and 0.5%), with minimum genetic 
distances corresponding to 0 and 60 years of evolution from a hypothetical MRCA, 
while 58 fragments (of the 127) were genetically equidistant to clones found within 
the same donor and to strains from other origins (0–0.7%, 0–83 years to a MRCA). In 13 
of the latter 2 and 58 fragments, the tMRCA was lower than or equal to the age of 
the donor. The remaining 67 of the above 127 fragments were most closely related to 
strains from another source (0–7.6%, 0–905 years to a MRCA). 
58 of the above 185 fragments of recombinant strains, however, originated from 
donors that were not coinfected with a strain of the genotype found in the 
recombinant fragments. Of the latter 58 fragments 1 fragment was found to be most 
similar to a strain from Laos (0%, 0 years to a MRCA), and 56 fragments were 
equidistant to strains within and outside Laos (0–7.6%, 0–905 years to a MRCA). 1 
fragment was most similar to strains outside of Laos (3.2%, 381 years to a MRCA). 
In addition, recombination events were detected in the previously published strains 
FJ023979 and FJ023832 and the individual fragments (n=5) of these two recombinant 
strains were attributed to genotype B and C. For 1 of these fragments the most 
closely related strain was found within Laos (1%, 119 years to a MRCA), while 3 
fragments were equidistant to strains within and outside Laos (0–7.6%, 0–905 years to 
a MRCA) and 1 fragment was most closely related to strains outside of Laos (0%, 0 
years to a MRCA).  
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Figure 27: Phylogenetic clustering and recombination patterns of HBV recombinant 
strains.  
Colour codes indicate genotypes B and C (red and yellow) involved in the 
recombination and regions homologous between at least 2 genotypes (grey). 
Recombinant strains from this study (red) or detected in previously published strains 
(green) are indicated by diamonds. 
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5.6 Amino acid sequence analysis of recombinant clones 
Comparison of the 74 recombinant clones (including FJ023979, FJ023832) with the 
consensus-50 alignment revealed several consistent amino acid (AA) substitutions 
over the HBsAg. In these clones AA substitutions occurred in 47 of 227 AA positions. In 
10 of these positions substitution occurred in >5 clones: P11H (n=44 clones of d=3 
donors and FJ023832), T/A45P (n=43, d=3 and FJ023832), P/L49R (n=43, d=3 and 
FJ023832), C76F/S (n=43, d=3 and FJ023832), T118A/M (n=17, d=5 and FJ023832), 
F134I (n=42, d=3 and FJ023832), V190A (n=27, d=2), I218L (n=41, d=3 and FJ023832), 
F219S (n=41, d=3 and FJ023832), C221F (n=41, d=3 and FJ023832). Furthermore, 3 
recombinant clones revealed internal stop codons. Of the observed amino acid 
substitutions only W182* had been described as vaccine or treatment induced 
mutation (172, 261, 315). 
Similarly to the clear genotypable strains, the 4 major HBsAg subtypes were found 
within the recombinant clones. For 16 clones as well as FJ023832 and FJ023832 the 
end or the beginning of a recombinant fragment fell within the ‘a’-determinant. For 
these clones the HBsAg subtypes were found to be ayw1 (n=14, incl. FJ023832), 
adw1/2 (n=3) and adr (FJ023979). The remaining clones were attributed to ayw1 
(n=52) and adr (n=4). 
6 Discussion 
6.1 Genotypes 
The 42 HBsAg positive donors from which clones were derived, were infected with a 
large variety of subgenotypes (B1, B2, B4, C1, C5, I1, I2) (Table 17) similar to the one 
observed in our earlier study (220). Both genotypes B and C seemed to circulate with 
high prevalences in the investigated cohort and were found in 85.7% and 57.1% of 
investigated donors, with subgenotypes B4 (73.8% of all donors) and C1 (57.1%) 
dominating. Subgenotyping of a number of genotype B clones was, however, 
hampered by the mis-assignment of subgenotypes B3, B5, B7 and B8 strains currently 
available on GenBank (Figure 26). The low phylogenetic support and genetic 
distances, sometimes below 3% (between B3 and B7) (212), may require a later 
reclassification of genotype B strains. 
The proposed genotype I, reported from several locations in Laos and from Vietnam 
(106, 220, 248, 294) shows evidence of recombinations between genotypes C, G and 
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perhaps A (by SimPlot analyses), but is for the purpose of this study not considered a 
recombination. While genotype I had been proposed on the basis of at least 7.8% 
mean genetic distance to established genotypes (220), its classification as a 
genotype remains an open but academic debate (153) until more detailed 
guidelines for nomenclature and the definition of recombinants are established. 
As a result of the co-circulation of HBV subgenotypes in Laos, 5.8% (n=26) of the 446 
analysable HBsAg positive blood donors, were mixed infected with multiple HBV 
variants (Table 16). 17 of these (3.8% of the 446 donors or 65.4% of the 26 mixed 
infected donors) revealed at least one recombinant strain, all originating from 
genotypes B and C (subgenotype C1). 
The proposed genotype I, however, was relatively rare (3/42 donors). The most 
prominent Asian recombinants with B and C parent sequences (subgenotypes B2-B4, 
formerly Ba) were found in Laos in 31/42 donors, while the C/D recombinant 
predominant in Tibet (67) was absent. These latter widespread recombinant strains 
(B2-B4, I1, I2) seem to have long evolutionary histories in Asia, originating from either 
single or multiple very similar recombination events in a distant past, and are here no 
longer considered recombinants. However, these subgenotypes of B recombined 
further in Laos with HBV/C, most often C1, strains, to form the relatively recent 
recombinants described in this study. 
6.2 Recombinations 
A surprisingly large number of 72 recombinants was found in 64.5% of mixed infected 
donors, representing 9.9% of all cloned strains. These strains largely reflect 
recombinant strains circulating in Laos and cannot be explained by PCR artefacts, 
as confirmed by our control experiments. 
127 of the genotypable 185 fragments belonged to the same genotype as the co-
infecting, non-recombinant strains. For 60 of these, the most closely related known 
virus was found, although not necessarily exclusively, in the same donor. Using a 
published mutation rate of 4.2×10−5 mutations per site and year (83), the observed 
minimum genetic distances of 0–0.7% between parent strain and recombinant 
fragment would correspond to 0–83 years of evolution from a MRCA. For 13 of these 
fragments (all originating from different cloned recombinants) even a lower or the 
same time of evolution than the age of the donor was calculated. Although, some 
donors with recombinant strains were not co-infected with similar (non-recombinant) 
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parent strains, the above observations are suggestive of recent recombination 
events and even within the individual donors. These putative recent recombination 
events would explain the very limited spread of each of the recombinants and that 
the recombinant virus strains are largely distinct from each other (Figure 27). Only the 
proposed genotype I and subgenotypes B2 and B4 represent older recombinants in 
this region. The large number of apparently independent recent recombination 
events is also reflected in an unexpected diversity in recombination breakpoints 
(Figure 27), the locations of which were highly variable throughout the S gene. This 
variability in recombination sites was surprising, since earlier studies (38, 41, 195, 265) 
reported recombination breakpoints mostly near gene boundaries. Interestingly, all 
recombined fragments, independently of their breakpoints within the S gene, were 
separated by homologous stretches of at least 17 nucleotides, suggesting that this 
may be conducive to recombinations. The breakpoint diversity in these 
recombinants also seems to be in contrast to the dominant recombinants found in 
the rest of mainland Asia (51, 67, 209, 220). 
When comparing the breakpoints of individual recombinant clones more closely, 
clones with different recombination patterns were not only found in different donors, 
but also within the same donor (e.g. donor M05-1173) and in similar or different strains 
from different donors (Figure 27). The relatively rare recombinations with identical 
recombination patterns of the same genotypes in different donors seem to further 
suggest their recent emergence, probably within the last century. Thus, several of the 
above lines of evidence, as well as our control experiments, suggest that many of the 
recombinants described here have occurred in the same donor. 
Surprisingly, amino acid substitutions were found in a large proportion of investigated 
clones. However, these were largely free of vaccine or treatment induced mutations. 
They furthermore agreed largely with the HBsAg subtypes that had been described 
previously in genotype B and C strains from Asia (209), indicating that recombination 
between genotypes B and C is not adding to the diversity of HBsAg subtypes in HBV 
strains circulating in Laos. 
Perinatal transmission is considered by some authors the most common route of 
infection in Asia (95). Furthermore, superinfections are considered to be rare and the 
ongoing immune response and the replicative space may limit superinfections and 
acceleration of chronic HBV even in regions of high endemicity (129). Since 
furthermore quasispecies found within the individual donors are unlikely to all be 
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transmitted independently, one could argue that all quasispecies would emerge 
from the initial pool of viruses infecting at birth. Assuming further, that all quasispecies 
develop from a single virus, we calculated the mutation rate, required for the most 
distant quasispecies (of the same subgenotype) to develop since birth of the donors. 
The median mutation rate was found to be 1.58×10−4 mutations per site and year, 
irrespective of whether samples were included for which at least 5 or 10 clones were 
available. This is well within the range of published short-term mutation rates (range 
1.4×10−5 to 7.9×10−4) (327). These estimates of short-term evolutionary rates of HBV 
are, however, distinct from the much slower mutation rates (~10−9) recently observed 
during co-evolution of HBV genomes in birds over several millions of years (96). The 
dramatic differences between long and short-term mutation rates reflect the 
different evolutionary constraints during co-evolution with the host species and rapid 
adaption under the pressure of the host immune system. In addition, mutational 
saturation could be limiting and high mutation rates would not be reflected in the 
long-term evolution of a virus. 
On the basis of the mutation rate 1.58×10−4 mutations per site and year, calculated 
above, the tMRCA would be reduced by a factor of 3.8, largely corresponding to 
about 0–22 years of evolution for those recombinant fragments for which the most 
closely related known virus was found within the same donor, further suggesting that 
these recombinations occurred during the lifetime of the donor. Even under the 
more likely assumption that more than a single virus quasispecies was infectious at 
birth, the above contention seems to suggest that the number of quasispecies 
transmitted vertically is limited. 
In conclusion, in Laos, multiple HBV sub-/genotypes co-circulate, generating highly 
variable recent recombinants with unique breakpoints, few of which seem to have 
spread within the population. About 65% of mixed infected donors showed recent 
recombinations in the S-gene alone, strongly suggesting that, at least in Laos, mixed 
infections invariably lead to recombinations. 
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Part 7: Occult hepatitis B infections among blood donors in Lao 
PDR 
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In Asia, where hepatitis B virus (HBV) is highly endemic, chronically infected 
individuals with detectable HBV surface antigen (HBsAg) represent a significant risk of 
virus transmission by blood donation. The Asian genotypes B and C are often found 
at higher viral loads in the blood (>107-108 copies/ml) (167), whereas other 
genotypes, such as genotype E in Africa, are associated with HBeAg seroconversion 
before the age of 15 or 16 and lower viral loads (48, 167). An additional risk for 
transfusion transmitted infections (TTI) results from occult HBV infections (OBI), defined 
as the presence of HBV DNA in the blood or liver without detectable HBsAg. The 
patho-physiological basis of OBI is still poorly understood but is probably due to an 
incomplete immune control of the infection. Most individuals with OBI have 
antibodies against HBV core antigen (anti-HBc) possibly reflecting an ongoing 
chronic infection with HBsAg below detection limits. This is particularly common in 
endemic countries where individuals are infected during early childhood. OBI with 
antibodies against HBV surface antigen (anti-HBs), with or without anti-HBc 
antibodies, sometimes occurs during the recovery phase of the infection. Rare 
seronegative cases of OBI occur in individuals with no markers of HBV infection other 
than HBV DNA. Individuals with chronic hepatitis who have mutated HBsAg that is not 
detected by diagnostic assays also contribute to OBI. Whilst OBI infections are 
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generally characterized by very low levels of HBV DNA in the blood (usually <1000 
copies/ml or <200 IU/ml (242)), they nevertheless are a concern for recipients of 
blood donations (2, 169, 214). 
In Western countries with a low prevalence of HBV infections, anti-HBc antibody 
testing is included in the screening of blood donations for TTI to exclude individuals 
with past exposure to HBV (including the vast majority of OBI). However, in highly 
endemic countries, this approach would exclude a large proportion of healthy 
donors that have cleared HBV infections, severely undermining the blood supply (47, 
218). In these settings, screening for TTI commonly includes HBsAg testing (169, 218). 
However, this strategy does not detect OBI or acute infections during the initial 
infection period. Thus, nucleic acid testing (NAT) has been proposed and tested as a 
highly sensitive technique for HBV DNA detection in OBI blood donors. However, in 
low income-countries NAT may not be possible due to limited resources (47, 169, 218, 
233). 
In Lao PDR, HBsAg is highly endemic, with a prevalence of 8.7% in Lao blood donors 
(126). As in its neighboring countries Cambodia and Vietnam (218), blood donations 
in Lao PDR are screened for HBsAg only, with the risk of TTI by HBsAg-negative blood 
donors with OBI. In this study, we determined the serological profile of Lao blood 
donors and the prevalence of OBI. We discuss possible implications for the safety of 
Lao blood donations. 
1 Study group 
A total of 906 first-time blood donors, including 296 females, were randomly recruited 
between March and June 2006. In Lao PDR, all blood donors are routinely asked for 
sexual and medical risk factors related to TTI including clinical hepatitis in an 
interview and by questionnaire. Donors with previous hepatitis B, C, HIV and syphilis 
were excluded. Donors are not routinely asked whether they are vaccinated against 
HBV and sera are not routinely tested for ALT. The mean age of the donors was 23.8  
7.4 years (range 16-53 years), with about 80% of donors being less than 30 years old. 
Serum samples were obtained from Vientiane municipality, Vientiane province and 
Bolikhamsay province, either at the National Blood Transfusion Centre of the Lao Red 
Cross in Vientiane or by mobile collecting units and were stored at -20°C until further 
testing.  
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2 Serological analyses 
All assays were performed on an automated AxSYM® system. HBsAg, HBeAg and 
anti-HBs, anti-HBc, anti-HBe antibodies were detected by AxSYM® HBsAg V2, AxSYM® 
HBe 2.0, AxSYM® AUSAB, AxSYM® CORE and AxSYM® Anti-HBe 2.0 assays, 
respectively.  
3 Molecular and phylogenetic analyses 
DNA was extracted using the DNA Blood Mini Kit and the HBV genome was amplified 
as 4 overlapping fragments (preS, S, X, and C). The sensitivity of the PCR reactions for 
preS, S, X and C were 1424, 1009, 2240 and 950 copies per reaction, respectively. 
Phylogenetic analyses were performed using MEGA v.5. Genotyping was performed 
by analyzing at least one of the four fragments. For detection of OBI, DNA was 
extracted from HBsAg negative, anti-HBc and/or anti-HBs positive donors. HBV DNA 
was quantified by TaqMan PCR and compared to a HBV plasmid dilution series 
ranging from 18.5 to 1.85x1010 copies in the PCR corresponding to 1110 to 111x1010 
copies/ml serum. Although viral DNA can be detected below the linear range, they 
were not quantifiable. Therefore, values below this linear range (CT values above 34) 
are expressed as ”less than 1110 copies/ml”. The estimated limit of detection using 
our in-house plasmid was about 110 copies/ml or approximately 20 IU/ml. Samples 
with CT values above 37 were considered negative. Negative controls were included 
in all extractions and PCR experiments.  
4 Statistical analyses 
A computerized data sheet was used for record keeping; all data were evaluated 
with SPSS 17.0 for Windows statistic software package or SigmaPlot 12.0. Parameters 
were compared by chi-square test or Fisher’s exact test where appropriate. 
5 Ethical statement 
This study was approved by the competent Research Ethics Committee of the 
Faculty of Medicine of Chiang Mai University, Thailand, and the Ethics Committee of 
the Faculty of Medical Sciences, National University of Laos, Lao PDR. 
Results and Discussion Part 7 
124 
6 Results 
HBsAg, anti-HBs and anti-HBc antibodies. In the 906 blood donors the overall HBsAg 
prevalence was 9.6% (87/906), while anti-HBc and anti-HBs antibodies were detected 
in 43.7% (396/906) and 27.7% (251/906) of donors, respectively. Anti-HBc and anti-HBs 
antibody prevalence increased with age with significantly higher percentages in the 
oldest compared to the youngest age group (p<0.005 and p<0.05, respectively), 
while HBsAg was less frequent in the older age groups, with a peak prevalence of 
11.6% at 20-29 years of age (Figure 28, Table 19). Overall, males were more frequently 
infected with HBV than females (48.7% and 38.9%, respectively; p<0.05). 86 out of the 
87 HBsAg-positive donors were also positive for anti-HBc, while one (a 22 year old 
male) was repeatedly negative for both anti-HBc and anti-HBs, suggestive of recent 
infection. One of the HBsAg-positive samples was also positive for anti-HBs (Table 19). 
494 of the 819 HBsAg-negative sera were negative for all serum markers, while the 
remaining 325 sera were positive for either anti-HBc antibodies (n=75; 9.2% of HBsAg-
negative sera), anti-HBs antibodies (n=15; 1.8%) or both (n=235; 28.7%) (Table 19).  
HBeAg and anti-HBe antibodies. 85 HBsAg-positive carriers, excluding two samples 
with insufficient serum volumes, were further screened for HBeAg and anti-HBe 
antibodies. HBeAg and anti-HBe antibodies were mutually exclusive and were found 
in 44.7% (38/85) and 55.3% (47/85) of HBsAg-positive donors, respectively (Table 20). 
At a younger age (<30 years), approximately half of the carriers were positive for 
either HBeAg or anti-HBe. In contrast all 10 donors older than 30 years were positive 
for anti-HBe (Table 20). 
6.1 Occult infections 
To determine the prevalence of OBI, 320 of the 325 HBsAg-negative, anti-HBc and/or 
anti-HBs positive sera were screened with a highly sensitive in-house TaqMan PCR. In 
35 of the 320 samples (10.9%) HBV DNA was detected, with 32 of these having less 
than 1110 copies/ml. All 35 TaqMan positive samples were found to be anti-HBc 
positive, with 23 of these also positive for anti-HBs (Table 21). HBV viral load ranged 
from below 1110 to 17,550 copies/ml, with the highest concentration observed in 
anti-HBc positive/anti-HBs negative.  
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Figure 28: Percentage of HBsAg, anti-HBs and anti-HBc positives among age groups. 
Prevalence of HBV serum markers according to age group. Prevalences for HBsAg 
(blue), anti-HBc (red) and anti-HBs (green) are calculated based on the whole study 
group (906 individuals). 
 
 
Table 19: Seroprevalence of HBsAg, anti-HBc, and anti-HBs according to age groups. 
Serological markers  No. samples (% of age group)  
HBsAg Anti-HBc Anti-HBs  16-19 20-29 30-39 40-53 Total 
+ - -  0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 
+ + +  1 (0.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.1%) 
+ + -  31 (9.0%) 44 (11.4%) 6 (4.7%) 4 (8.0%) 85 (9.4%) 
- + -  17 (5.0%) 29 (7.5%) 20 (15.8%) 9 (18.0%) 75 (8.3%) 
- + +  75 (21.9%) 101 (26.1%) 42 (33.1%) 17 (34.0%) 235 (25.9%) 
- - +  5 (1.5%) 3 (0.8%) 5 (3.9%) 2 (4.0%) 15 (1.7%) 
- - -  213 (62.3%) 209 (54.0%) 54 (42.5%) 18 (36.0%) 494 (54.5%) 
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Table 20: Seroprevalence of HBeAg and anti-HBe in HBsAg positive sera according to 
age groups. 
Serological markers  No. samples (% of age group)  
HBeAg Anti-HBe  16-19 20-29 30-39 40-53 Total 
+ -  16 (51.6%) 22 (50.0%) 0 (0%) 0 (0%) 38 (44.7%) 
- +  15 (48.4%) 22 (50.0%) 6 (100%) 4 (100%) 47 (55.3%) 
 
Table 21: DNA positivity among HBsAg negative, anti-HBc and/or anti-HBs positive 
donors.  
  
Serological markers 
 
No. samples (% of age group) 
 
DNA 
 
Anti-HBc Anti-HBs 
 
16-19 20-29 30-39 40-53 Total 
+ 
 
+ - 
 
3 (3.2%) 3 (2.3%) 5 (7.4%) 1 (3.6%) 12 (3.8%) 
+ 
 
+ + 
 
10 (10.8%) 8 (6.1%) 2 (2.9%) 3 (10.7%) 23 (7.2%) 
+ 
 
- + 
 
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
- 
 
+ - 
 
12 (12.9%) 28 (21.4%) 16 (23.5%) 8 (28.6%) 64 (20.0%) 
- 
 
+ + 
 
63 (67.7%) 89 (67.9%) 40 (58.8%) 14 (50%) 206 (64.4%) 
- 
 
- + 
 
5 (5.4%) 3 (2.3%) 5 (7.4%) 2 (7.1%) 15 (4.7%) 
 
Table 22: Prevalence of HBV genotypes B and C according to age groups and 
HBeAg/anti-HBe status in HBsAg positive sera. 
  
Serological markers 
 
No. samples (% of age group) 
 
Genotype 
 
HBeAg Anti-HBe 
 
16-19 20-29 30-39 40-53 Total 
B 
 
+ - 
 
5 (29.4%) 10 (41.7%) 0 (0%) 0 (0%) 15 (34.9%) 
  
- + 
 
3 (17.6%) 0 (0%) 1 (50%) 0 (0%) 4 (9.3%) 
C 
 
+ - 
 
7 (41.2%) 10 (41.7%) 0 (0%) 0 (0%) 17 (39.5%) 
  
- + 
 
2 (11.8%) 1 (4.2%) 1 (50%) 0 (0%) 4 (9.3%) 
I 
 
+ - 
 
0 (0%) 1 (4.2%) 0 (0%) 0 (0%) 1 (2.3%) 
  
- + 
 
0 (0%) 2 (8.3%) 0 (0%) 0 (0%) 2 (4.7%) 
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6.2 HBV genotypes  
Of the 85 HBsAg positive sera that were screened for HBeAg and anti-HBe, 43 were 
PCR positive on at least one of the four HBV genotyping fragments. Most HBeAg 
positive sera (33/38) could be genotyped but as a result of reduced viral load after 
seroconversion only few anti-HBe positive samples (10/47) were PCR positive and 
could be genotyped. Phylogenetic analyses revealed that strains belonged to 
genotypes B (19/43), C (21/43) and I (3/43), with similar rates of genotypes B and C 
throughout the different age groups (Table 22). 
Additionally, the 35 TaqMan PCR positive OBI sera were subjected to preS and S-
gene genotyping PCRs. 11 of these, with viral copies ranging from less than 1110 to 
17,550 per ml, were found to be positive in at least one of the PCRs. Phylogenetic 
analyses revealed a predominance of HBV genotype C (8/11), while one strain each 
was attributed to genotypes B and I. Another strain was suspected to be mixed 
infected with multiple genotypes and was not further analyzed. While the proportion 
of genotype C infections in the occult group was significantly higher than in the 
HBsAg positive group (p<0.05), this is likely to be a selection bias, since HBV/C 
infections tend to have higher viral loads than HBV/B infections. Thus, OBI with HBV/B 
variants is more likely to remain undetected.  
7 Discussion 
In healthy first-time blood donors we found a high prevalence of HBV serum markers. 
We determined that 45.5% of the blood donors were positive for any of the HBV 
markers, suggesting that almost half of the Lao population has been in contact with 
HBV at one point during their lives. 9.6% of the donors were HBsAg positive. This is 
consistent with the 8.7% HBsAg prevalence reported before from Lao PDR (126) as 
well as from neighboring countries such as Cambodia (7.7% HBsAg and 58.6% anti-
HBc prevalence) and Vietnam (11.4% HBsAg and 51.7% anti-HBc) (218). 
The presence of anti-HBc and also anti-HBs antibodies in the investigated cohort 
increased with age and was significantly higher in the oldest age group, while 
HBsAg-positivity had a tendency to decrease in the higher age groups. This is likely to 
represent spontaneous HBsAg seroclearance during late stages of HBV infections 
and is consistent with clearance rates of up to 45% observed in endemic regions (60). 
In Lao PDR, a country with a high prevalence of chronic HBV carriers, most infections 
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are acquired during early life, perpetuating chronic infections. Anti-HBs antibodies 
were found in 27.7% of all donors and only 6.1% of these were anti-HBc negative and 
therefore potentially vaccinated. This is in accordance with the low HBV vaccine 
coverage in adults in Lao PDR where HBV vaccine was only introduced in 2001 for 
infants. Furthermore, 8.3% of donors were anti-HBc-positive but negative for HBsAg 
and anti-HBs, indicating high numbers of later stage chronic HBV infections with loss 
or reduced levels of HBsAg, or resolved infections (HBV DNA negative) with anti-HBs 
antibodies below the detection limit (Figure 28, Table 19). 
Interestingly, one sample was repeatedly positive for HBsAg as well as for anti-HBc 
and anti-HBs antibodies. Whilst this may be a case of exposure to heterologous 
HBsAg serotypes, we have no further basis for such speculations (7). This serological 
profile may also be indicative of acute HBV infection or the case of a chronic carrier 
with severe liver disease, although the latter is unlikely as blood donors are normally 
healthy volunteers. 
More than 40% (38/85) of HBsAg carriers in this study were HBeAg positive. 
Interestingly, while about half of the carriers below 30 years of age were positive for 
either HBeAg or anti-HBe, all 10 donors older than 30 years were positive for anti-HBe 
but not HBeAg (Table 20). This suggests that seroconversion from HBeAg to anti-HBe, 
an indicator of sustained remission, occurs at around 30 years of age in Lao PDR. 
Although previous studies indicated earlier HBeAg seroconversion in patients 
infected with HBV genotype B than for those infected with HBV genotype C (130, 
319), we could not observe a difference in the prevalence of HBV B and C 
genotypes in the different age groups (Table 22). 
In our study, 10.9% (35/320) of HBsAg negative, anti-HBV antibody positive donors 
were HBV DNA positive in a highly sensitive real-time PCR. Thus, at least 3.9% of all 906 
investigated donors were occult infected with HBV (OBI). When a less sensitive 
commercial assay was used, only four samples, including the three with the highest 
DNA levels, were DNA positive (data not shown). This would correspond to an OBI 
prevalence of 1.3% of HBsAg negative, anti-HBV antibody positive donors and 0.4% 
of all donors. It is possible that the individuals detected with the commercial assay 
represent the greatest risk of onwards HBV transmission. This apparent difference in 
prevalence highlights the difficulty of comparing OBI prevalence data from studies 
using different detection techniques. Previous studies in highly endemic regions also 
showed high prevalences of OBI. In Indonesia, where 9.4% of the population is 
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chronically infected, a study using nested PCR found 8.1% of blood donors to be 
occult infected (288). Similarly, in a highly endemic population in India, an in-house 
PCR detected OBI in 30% of anti-HBc antibody positive donors (228). This is in contrast 
to data from regions where HBV is not endemic, such as the USA, where OBI can be 
as low as 3.7% of anti-HBc antibody positive donors (143). While the prevalence of 
OBI is dependent on epidemiological aspects such as the route of infection, the 
clinical evolution of the disease and interventions, the infectivity of OBI blood as well 
as the determinants of this infectivity still remain unclear.  
The majority of OBIs that could be genotyped in the current study were attributed to 
genotype C (8/11). Significantly fewer HBV genotype B infections were observed in 
the OBI group (1/11) than in HBsAg carriers (19/43), where equal proportions of HBV 
genotype C and B were observed. One study of OBI in individuals from south-east 
China, where genotype B is dominant, also showed that the prevalence of genotype 
C was significantly higher in OBI than in HBsAg positive individuals (318), whilst others 
have not seen this difference (49). Studies on larger cohorts are needed to further 
determine the significance of a genotype bias in OBI. 
All OBI donors were anti-HBc positive while the prevalence of OBI was somewhat 
lower in anti-HBs/HBc antibody double positive (23/229; 10%) than in anti-HBc single 
positive samples (12/76; 15.8%; not statistically significant). In other studies, OBI 
prevalences were also higher in individuals with anti-HBc antibodies only and lower in 
double positive or anti-HBs antibody only donors (292). In general, high levels of anti-
HBs antibodies in donated blood forestall HBV infections of recipients (reviewed in 
(47)). Thus, recipient infection may not be prevented in the presence of low levels of 
anti-HBs antibodies (less than 100 IU/ml), in particular when levels of HBV DNA are 
high or when the recipients are immuno-compromised (47). In our cohort, OBI sera 
had a range of anti-HBs levels from 0 to 768 IU/ml. Importantly, the three donors with 
highest DNA levels (1790, 12800 and 17550 copies per ml) had undetectable anti-HBs 
antibodies, re-emphasizing the higher risk of TTI from these donors. Rare seronegative 
cases of OBI occur in individuals with no markers of HBV infection other than HBV 
DNA. For example, in Thai blood donors about one in 3,000 had HBV DNA and were 
antibody and HBsAg negative. Approximately 20% of these were window period 
cases (58, 174). Since we only investigated HBV DNA in antibody positive cases, our 
study would have missed DNA positive (antibody-negative) window cases. 
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The significance of OBI for the donor and the recipient is poorly understood. In 
particular, there are very few studies investigating the infectivity of transfusion with 
OBI blood. The few available studies seem to agree that only subsets of recipients of 
OBI blood become infected. For example, one study in Taiwan showed that two out 
of 11 recipients of OBI blood became subsequently infected (302). In another study 
from the Japanese Red Cross, OBI blood was infectious in 19% of recipients (251). 
Recently, it was suggested that the 50% infectious dose of OBI blood products would 
be about 1000 HBV DNA copies (3). However, the relationship between viral DNA 
concentration or serology of the donor and infection of the recipient was not 
determined in these studies. Thus, certainly a large proportion of the OBIs observed in 
the current study, and especially the “anti-HBc only” donors with higher serum DNA 
levels, represent a considerable risk of TTI.  
To eliminate the risk of HBV transmission by blood transfusion, additional analyses 
besides HBsAg are required in Lao PDR. While anti-HBc antibody screening would 
largely exclude the HBsAg negative/DNA positive sera, it would also unnecessarily 
exclude anti-HBc antibody positive blood with undetectable HBV DNA i.e. 
approximately 30% of all donors. In Thailand, a country with an emerging economy, 
blood banks systematically screen for HBV, hepatitis C virus and HIV-1/2 by nucleic 
acid testing (NAT) since 2006. Together with a broad hepatitis B vaccination strategy, 
this has led to a reduction in the incidence of new HBV infections in that country (58). 
Whilst this triple NAT screening may be cost effective in Thailand due to its high 
prevalence of HIV-1 infections, its cost-benefit in resource poor Lao PDR requires 
careful evaluation.  
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Hepatitis B virus (HBV) is a major public health concern. Worldwide, more than 2 
billion people are or have been infected with hepatitis B virus at some time during 
their lives, accounting for approximately 600,000 deaths per year, most of which 
occur in the developing world. 350 to 400 million people are chronically infected and 
are at risk of liver cirrhosis and death due to liver failure. Especially in areas of high 
HBV prevalence, concurrent infections, e.g. with hepatitis D virus (HDV) complicate 
the course of disease, generally resulting in more severe and progressive liver disease 
than HBV infection alone.  
The first parts of the current dissertation on HBV in sub-Saharan Africa confirm that 
one of the two genotypes A and E dominates in most countries. We demonstrate 
that genotype A is more diverse in Africa (4.00% mean genetic diversity) than in the 
rest of the world (2.96%), suggesting an African origin and a long history on the 
continent. Genotype E, on the other hand, revealed a conspicuously low genetic 
diversity (1.75%), indicating a short history of this genotype in Africa. This, however, 
seems to be in contrast with its excessively high prevalence and its extensive spread 
throughout the vast West African genotype E crescent. As the spread of pathogens is 
closely linked to their host, African slaves that were force-migrated to the Americas 
from the 17th to the early 19th century during the transatlantic slave trade would 
have disseminated African HBV strains present at that time in the New World. 
Nevertheless, analysing more than 1600 sequences, we show that genotype E is only 
sporadically found in the Americas, corroborating an only recent emergence of this 
genotype.  
We furthermore demonstrate that in Haiti, where >90% of the population are 
descendants of African slaves, more than 40% of HBV infections were caused by 
genotype A1, which today is found mainly in Eastern Africa. Another 20% belong to a 
rare subgenotype, A5, which has been found only in the former Bight of Benin, a 
primary slave trading post. Haitian A subgenotypes appear to have separated early 
from the African subgenotypes, while the most prevalent genotype and 
subgenotype in West Africa today (E and A3, respectively) are rare in Haiti. These 
results provide evidence that the dominant (sub-)genotypes in Africa emerged in the 
general population only after the end of the transatlantic slave trade, within the last 
100 to 200 years, and explain the low genetic diversity of genotype E.  
In addition, our analyses show that the prevalence of genotype A and thus HBV in 
general must have traditionally been much lower in West-Africa than it is today. This is 
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supported by the current low prevalence of genotype A in the genotype E crescent. 
In addition, the rare and recent recombination events between genotypes E and A 
indicate, that the clash between genotypes never occurred in this region. These 
results, together with today’s high prevalence of genotype E in much of Africa, 
suggest that the high HBV endemicity is a recent phenomenon, probably resulting 
from well-intended injection mass campaigns of the French and Belgian colonial 
powers with unsafe needles.  
Our phylogenetic analyses also provide evidence, that genotype E emerged in the 
Northern part of the genotype E crescent before spreading to the South. This is 
confirmed by phylogeographic analyses, suggesting that genotype E originated 
from the area of Nigeria, before rapidly spreading throughout sub-Saharan Africa. 
Furthermore, we estimate a substitution rate of 1.9x10-4 substitutions per site and year 
and demonstrate that genotype E emerged only recently, most likely within the last 
130 years. Interestingly, viral strains found in Haiti seem to be the result of multiple 
introductions only in the second half of the 20th century, corroborating the absence 
of a significant number of genotype E strains in West Africa several centuries ago. 
Together with the strong increase in the effective number of genotype E infections 
over time, as revealed by Bayesian skyline plot analyses, our results strongly indicate 
the recent introduction of HBV/E into the general West-African population after the 
transatlantic slave-trade had come to an end.  
Taken together, the hyperendemicity of genotype E and of HBV in general in Africa is 
likely the result of dramatic changes in the routes of viral transmission in a relatively 
recent past. The analyses are however limited by the availability of genotype E full 
genome sequences and sampling is necessarily fragmented and incomplete. As 
HBV/E strains have a low genetic variability, an increased number of sequences 
would likely add to the robustness of analyses in future studies. It is thus important to 
characterize HBV strains from additional countries to further understand the genetic 
history of genotype E in sub-Saharan Africa. As furthermore all available HBV/E 
sequences were sampled within the last 13 years, a deeper calibration using ‘older’ 
HBV strains would be desirable. This is however hampered by the lack of older 
samples, as, unlike for HIV, no older paraffinated tissues are available. Although there 
is no evidence that genotype E is more infectious than genotype A, a competitive 
advantage of HBV/E cannot be excluded. Thus, a phenotypic characterisation of 
genotypes E and A would be desirable and analyses of differences in HBV replication 
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and virus release as well as in HBsAg production should shed light on differences or 
similarities in infectivity of these genotypes. 
The complexity of HBV infection in sub-Saharan Africa is further increased by 
concurrent infection with hepatitis D virus (HDV), a satellite virus of HBV. Analysing 
more than 2000 samples from Burkina Faso, the Central African Republic, Chad and 
Nigeria, we demonstrate that this virus is an important cause of chronic hepatitis. The 
prevalences vary widely between countries and cohorts, ranging from 0% to 27.3% in 
asymptomatic carriers and from 1.3% to 50% in liver patients. Surprisingly, 20.5% of 
HBsAg-positive children from Burkina Faso were HDV-Ab positive, a prevalence 
almost 10-times higher than the one observed in the mothers. These children are at 
high risk to develop severe fulminant or chronic hepatitis.  
Vast HDV-Ab differences were furthermore observed in liver patients from Nigeria 
and the Central African Republic. While in Nigeria a large proportion of liver patients 
were HBsAg positive, only 1.3% and 6.8% of these were HDV-Ab positive, while 50% of 
liver patients from the Central African Republic were HDV-Ab positive, indicating that 
in the Central African Republic, in contrast to Nigeria, HDV super-infection might be 
the cause of chronic hepatitis with frequent severe liver conditions. 
In our study we observed the African clades 5 and 6 solely in Nigeria. However, clade 
1 predominated in the analysed cohorts, as more than 70% of strains were assigned 
to HDV-1, originating from Nigeria, the Central African Republic and the Chad. Our 
analyses indicate that HDV-1 strains originate from Africa, where largely HBV 
genotype E prevails. Indeed, more than 50% of genotypable HDV and HBV pairs 
revealed HDV-1 and HBV/E. Nevertheless, a close co-evolution of hepatitis D virus 
clade 1 and hepatitis B virus genotype E seems unlikely, since HDV-1 can be found 
worldwide, while HBV genotype E is largely confined to Africa. 
As so far only rare studies have been performed on HDV in sub-Saharan Africa, 
further analyses are warranted to understand the origin and evolution of hepatitis D 
virus clades and the association with the different HBV genotypes. However, the 
analysis of HBV genotypes at concurrent HDV infection is complicated by reduced 
HBV DNA loads. The characterization of these samples would benefit from high 
throughput next generation sequencing analyses. 
In Lao PDR, about 9% of the population are chronic carriers of HBsAg and multiple 
subgenotypes of genotypes B, C and I co-circulate. We show that almost 6% of 
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HBsAg positive rejected blood donors are infected with multiple sub-/genotypes. We 
furthermore provide evidence, that about 65% of the mixed infected donors showed 
recombinations in the surface gene alone. These had surprisingly diverse 
recombination breakpoints and involved the predominant genotypes B and C. Our 
analyses revealed that recombinant virus strains are largely distinct and vary 
between and within individual donors. 
As perinatal transmission is the most important route of transmission in Asia and 
superinfection of different HBV variants is considered to be rare, quasispecies found 
in the individual donors are likely to have developed since birth. Assuming further, 
that all quasispecies have developed from a single virus, we calculated the 
substitution rate for the most distant quasispecies and observed 1.58x10-4 substitutions 
per site and year. This is well within published short-term mutation rates and close to 
the 1.9x10-4 substitutions per site and year we observed in our study on genotype E in 
Africa.  
Taken together, our results provide evidence that, at least in Laos, hepatitis B virus 
mixed infections lead to frequent recombinations, largely within individual donors, 
that so far have not led to new dominant strains in the population.  
As our study was focussed on the HBV surface gene, future studies warrant the 
analysis of larger regions of the genome. This is, however, complicated by 
experimental challenges. As full-length genome PCRs seem to have a lower 
sensitivity than the fragmented surface gene PCRs, such a study would not be 
performed easily by conventional PCRs. Although next generation sequencing would 
have the same limitations as other PCR based approaches, the high sequencing 
throughput, combined with good genome coverage should be considered for 
further analyses. 
Aiming to have a further understanding of the serologic and phylogenetic 
characteristics of HBV in blood donors from Lao PDR, we show that 45.5% of the 
blood donors were positive for at least one of the hepatitis B virus markers. Thus, in the 
absence of vaccination against HBV, our results suggest that almost half of the 
Laotian population has been in contact with this virus at one point during their lives. 
We furthermore provide evidence, that blood screening procedures in Lao PDR 
need to be reconsidered. We show that the screening of donated blood solely for 
HBsAg leaves a sizable risk of hepatitis B virus transmission by HBsAg-negative occult 
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infected donors in at least 3.9% of blood donations. These would potentially be 
infective for hepatitis B. However, screening for other viral markers such as antibodies 
against the HBV core protein (anti-HBc), as performed in western countries, would 
exclude about 30% of healthy donors that have cleared HBV infections, thus severely 
undermining the blood supply in Lao PDR.  
Nevertheless, additional analyses besides HBsAg are required in Lao PDR to eliminate 
the risk of HBV transmission by blood transfusion. Additional studies are necessary to 
evaluate different screening methods, such as nucleic acid testing. However, the 
cost-benefit of these screening methods in resource poor Lao PDR requires careful 
evaluation. 
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